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The development of novel imidazopyridines, which includes both 
tetrahydroimidazo[1,5-a]pyridine (rIMP) and imidazo[1,5-a]pyridine (IMP) was 
investigated using conventional and microwave induced procedures that afforded 
compounds at high yield of 88-96%. rIMP was synthesized using a two-step procedure 
that involved the microwave synthesis of IMP, then the reduction of the pyridine moiety 
of the fused imidazopyridine rings using 10% Pd/C and hydrazine monohydrate. The 
microwave synthesis of imidazopyridines involved the one pot reaction of 2-
benzoylpyridine, substituted benzaldehyde and ammonium formate in acetic acid under 
open vessel microwave conditions, which resulted in products within 40 minutes. Novel 
PEG-IMP development, involved the synthesis of ethylene glycol tethered benzaldehydes 
and IMPs using traditional Williamson etherification synthesis, which afforded products 
at a high yield of 92-95%. We have then shown IMP and rIMP roles in its 
 
ii 
antiproliferative property towards PCa cells, specificity in inhibiting PI3K isoforms, and 
structural motif’s interaction with different residues in the kinase binding domain of the 
class I PI3K isoforms. The antiproliferative property towards PC3 cells shows increased 
activity with compounds containing pyridyl group on carbon 3 of the imidazo [1,5-
a]pyridine parent moiety with signs of toxicity to PC3 within 24 hours of incubation and 
at 1 μM of the parent compound. Furthermore, the IMPs were tested against five prostate 
cellular lines: PC3, RWPE1, D145, LNCaP and LNCaP C81. IMPs showed little activity 
towards RWPE1 and increased activity towards PC3 cells. We determined that 
functionalizing the phenyl group at position 1 increased the efficacy of rIMP compared to 
the IMP. After showing increased toxicity to PC3 cells, it was important to investigate the 
mechanism in which IMP pose toxicity towards PC3 cells. The biochemical assay 
showed that rIMP was more effective in inhibiting PI3Kα isoform compared to both pan 
inhibitor wortmannin and IMP. Both IMP and rIMP inhibited more than 60% of PI3Kγ 
isoform activity at nanomolar concentrations. After showing IMPs affinity to PI3K 
isoforms, we investigated the binding interactions rIMP and IMP towards the PI3K 
isoforms using MOE molecular modeling software.  
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RxN reaction 
rIMP  tetrahydroimidazo[1,5-a]pyridine 
rt reaction time 
RDB Ras binding domain 
RTK receptor tyrosine kinase 
ROS reactive oxygen species 
s  singlet 
srIMP  single reduced imidazopyridine 
t  triplet 
TBS tert-Butyldimethylsilyl 
TBAB tetra-Butylammonium bromide 
t-Bu  tert-Butyl 
TLC thin liquid chromatography 
THF  tetrahydrofuran 
TMS  tetramethylsilane 
δ  NMR chemical shift in parts per million 








1.1  General Introduction 
 
 In general, heterocyclic compounds play a major role in clinical applications 
where they serve an active part in anti-bacterial, anti-viral, anti-fungal, anti-
inflammatory, and anti-tumor drugs.1-6 Currently, 73% of the heterocyclic 
chemotherapeutic drugs are nitrogen-containing with a small percentage containing 
nitrogen and other elements such as oxygen and/or sulfur.6 Imidazole is a nitrogen-
containing compound that has been gaining attraction as active biological scaffolds. The 
properties of imidazole include hydrogen bond donor-acceptor capability, π-π stacking 
interactions, coordination bonds with metals and other intermolecular forces such as van 
der Waals, polarization, and hydrophobicity. Those properties are accountable for the 
reactivity and affinity for a series of biomolecules including enzymes and receptors. As a 
derivative of imidazole, fused imidazole-pyridine, imidazo[1,5-a]pyridine and its closely 
related isomers extends the popularity of the imidazole group for its use in medicinal 
therapy. The isomers benzimidazole, imidazopyrazine, imidazopyrimidine, 
pyrazolopyridine, and pyrazolopyrimidine have demonstrated antiviral, antiulcer and 




Recently, Gaba et al.7 reported the recent advances and future direction of 
benzimidazole and imidazole scaffolds for a variety of drug uses.  In 2015, Bagdi et al.8 
reviewed the synthesis of imidazo[1,2-a]pyridine over the past ten years starting in 2005, 
which thoroughly described the advances of its synthetic approaches. The growth of 
those biologically active scaffolds rises to the importance for the review of structurally 
related scaffold imidazo[1,5-a]pyridine.  
The role imidazo[1, 5-a] pyridine (IMP) in the last decade has grown from novel 
OLED to a novel CRPC therapeutic. The synthesis and development of IMP are now 
critical for its biological therapeutics and photophysical applications. Those applications 
have influence continuous efforts to develop an efficient and environmentally friendly 









 Cancer is the second leading cause of death in Americans, which is gaining 
rapidly to heart disease as the leading mortality factor. In 2014, 22 states had populations 
that died from cancer more frequently than that of heart disease.9-10 Cancer is defined as 
the uncontrolled cell division of abnormal cells or malignant growth. Cancer is the 
generic term that only describes the malignant nature of abnormal cells, but different 
cancers have different starting points such as breast, pancreas, lung, and prostate. The 
cells in those regions lose their ability to regulate cell division, growth, and motility. 
Stages of cancer are used to describe the malignant nature of cancers, where stage 1 or 2 
indicates low motility and 3 or 4 indicate high levels of motility. In the later stages of 
cancer, cells classified as metastatic have the ability to invade and spread to a variety of 
tissues creating additional tumor sites making the cancerous disease more lethal.11 Over 
the past decade, there have been six well-studied sequences that cells become cancerous. 
Those sequences are: (1) resisting cell death, (2) evading growth suppressors, (3) 
enabling replicative immortality, (4) inducing angiogenesis, (5) activating invasion and 





Figure 1. The hallmarks of cancer.  
Source: Adapted from Hanahan, D.; Weinberg, R. A., Hallmarks of cancer: the next generation. Cell 2011, 
144 (5), 646-74. 
 
In resisting cell death cancers overcome the innate ability to undergo programmed 
cell death (apoptosis), whose function lose the tumor suppressor function such as TP53.  
Similarly, apoptosis is lost when there is an increase in the expression of anti-apoptotic 
regulators (Bcl-2, Bcl-xl) or when there is a downregulation of pro-apoptotic factors (Bax, 
Bim, Puma). Contributing to the robust nature of cancerous cells, the senescence and 
crisis are two limiting factors that viable cells undergo that usually led to cell death, but 
in cancerous cells, those two factors succeed, and cells continually proliferate. In a recent 
study, overcoming the senescence and crisis phases are attributed to telomerases that are 
inactive. The telomerase responsibility is to remove the telomere cap on chromosomes. 
Loss of telomerase activity has contributed to unlimited proliferation.12-14 
 As cancer progresses in adults, they induce an angiogenesis response to once 




Physiologically, the blood vessels within tumors begin advanced capillary sprouting, 
excessive vessel branching, enlarged vessel, erratic blood flow, and abnormal levels of 
endothelial cell proliferation and apoptosis.15-16 The progression of angiogenesis allows 
cancerous cells to become more invasive and metastatic as macrophages of the tumor can 
send matrix-degrading enzymes to attack neighboring cells. When the matrix-degrading 
enzymes attack neighboring cell, the cancerous cells send signals such as epidermal 
growth factor (EGF) to facilitate cell proliferation, survival, and morphogenesis.12, 17-20  
 The distinct characteristic of healthy cells and cancerous cells are their ability to 
regulate cell signals. The cell signals control and ensure homeostasis that makes the cells 
hypersensitive to growth factors and other extracellular ligands. Cancer cells can 
deregulate this hypersensitivity by manufacturing their on growth factor signaling or even 
produce signals to healthy cells to supply cancerous cells with essential growth  
factors.12, 21-22 Recent studies have shown that negative feedback loops are efficient in 
managing many cellular signals thus maintaining cellular homeostasis. The problem is 
that these negative feedback loops also lead to enhanced cellular proliferation. An 
example of negative feedback loop loss shown is with the loss of the protein, PTEN 
phosphatase that counteracts with a protein known as phosphotidylinositol-3 Kinase 
(PI3K) by degrading its product phosphotidylinositol (3,4,5) trisphosphate (PIP3). Mutant 
PTEN phosphatase or PTEN deletion that is lost by promoter methylation amplify PI3K 
signaling and promotes cellular proliferation, which is a major therapeutic target for 





2.2  Prostate Cancer 
Prostate cancer (PCa) is a complex multifaceted and biologically heterogeneous 
disease. PCa is the second most common cancer in the United States amongst men. It is 
similarly identified as the second leading cause of cancer death in men, only behind lung 
cancer.23 According to the American Cancer Society’s estimates, in 2016 from the United 
States, there are about 180,890 new cases of PCa and 26,120 deaths from PCa in which 
there is about 1 in 7 men that will be diagnosed with PCa in his lifetime. Statically, PCa 
is found more commonly in African-American men. Moreover, they are more likely to be 
diagnosed at an advanced stage and are nearly 2.5 times as likely to die from the disease 
compared with Caucasian men. Not only are African-American men more susceptible to 
prostate cancer, and they are also developing the disease at a younger age.11, 23 
The prostate is a gland that is found in only men, which in younger men is the size 
of a walnut that can be larger in older men (see Figure 2). PCa is a malignant tumor that 









Figure 2. Prostate and other organs. 
  





The majority of PCa (99%) is found to be adenocarcinomas, but can also be found 
as sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell 
carcinomas. PCa growth is usually slow and there has been a variety evidences that has 
shown that men sometimes die of other causes with undiscovered traces of PCa. The 
complex heterogeneity of PCa is related to its variety of rick factors such as age, 
ethnicity, lifestyle, genetic, heredity, location and nutrition.11 Previous studies show that 
in some forms of metastatic PCa the inappropriate activation of the androgen receptor 
(AR) is involved.25-26 
 2.2.1  Causes of Prostate Cancer 
 
 There are several possible causes of prostate cancer, but the direct cause of PCa 
has yet to be elucidated. The causes identified so far range from a series of factors such as 
obesity, chemical exposure, inflammation of prostate, sexually transmitted infections, and 
vasectomy. Those factors may lead to series genetic mutations that are either inherited or 
acquired. Genetic information is responsible for turning on and off oncogenes and tumor 
suppressors that control cellular homeostasis. Inherited genetic mutation is the result of 
10% of all PCa. Inherited mutations are passed down from parents to offspring. Scientist 
have discovered linked inherited genes responsible for PCa including RNASEL, a 
candidate hereditary prostate cancer gene (HPC1), that is associated with PCa from an 
inflammatory response that promote cancer cell survival.27  Inherited deoxyribonucleic 
acid (DNA) repair genes BRCA1, BRCA2, ATM, CHEK2, RAD51D, and PALB2 




BRCA2 is the frequency of mutation that leads lethal PCa.28 DNA mismatch repair genes 
are another class of inherited genes that contribute to the prevalence of PCa. MSH2, 
MLH1, MSH6 and PMS2 are genes that normally repair mismatches in DNA when the 
cell is undergoing mitosis. Mismatch mutation repair gene mutation enhances the 
likelihood that an individual will develop PCa. MSH2 mutation increases the chances of 
PCa almost two fold.29 Another significant inherited gene that causes PCa is HOXB13, 
which is important in developing the prostate gland. Though rare, HOXB13 gene is 
responsible for the early onset of PCa.30 
 Acquired DNA mutations account for more than 80% of PCa where they come 
from errors in genes as they are copied during mitosis. Some DNA is left uncorrected, 
and the genes encode the overexpression of essential proteins. The process of mitosis is 
increased as prostate cells grow leading to the increasing potential to acquire DNA 
mutation. Hormones, testosterones and insulin-growth factor-1 (IGF-1), are some the 
main hormones that contribute to enhancing prostate cancer growth. Males with increased 
production of those hormones are subjected to greater risk of obtaining PCa.  An 
extracellular factor that accounts for acquired DNA mutation in PCa is inflammation 
which may arise from bacterial species or sexually transmitted diseases exposure. 
Inflammation of the prostate causes oxidative DNA damage. Oxidative DNA damage 
influences DNA mutation by deleting DNA lesions.31 Treating these acquired DNA 
mutations via immunotherapy, chemotherapy or androgen deprivation therapy (ADT) is 






 2.2.2  Treating Prostate Cancer 
 
PCa in stages 1-3 has a meager metastasis rate of cancerous cells and the survival 
for 5-years indicated by the American Cancer Society is 100 %, but highly metastasized 
PCa in Stage 4 5-year survival rate is 28%.30 The category of men presenting with either 
a high risk localized cancer or with metastatic disease is usually treated aggressively with 
any of the followings: prostatectomy, radiation therapy and/or ADT, which have been 
expanded in recent years to include novel substantially more efficient drugs.32  As 
patients are treated of localized PCa, there has become a serious problem, because of 
severe health risks involved in prostatectomy, overtreatment of small molecules and other 
used approaches.33 ADT has been the mainstay of treatment towards patients with 
metastatic PCa.  The idea of hormone therapy is to reduce levels of male hormones, 
namely androgens, which stimulate prostate cancer cells to grow. Reducing androgen 
levels or stopping them from getting into prostate cancer cells often makes prostate 
cancers shrink or grow more slowly for a time.34-35 ADT involves various treatments both 
surgical and medicinal such as; Orchiectomy (Surgical Castration), Luteinizing hormone-
releasing hormone (LHRH) agonists and antagonists, CYP17 inhibitor, and anti-androgen 
drugs.30 Although most of the prostate cancer patients respond well to ADT initially, the 
outcome with long-term and continuous ADT sometimes involves nearly inevitable 
progression to castration resistant prostate cancer cells (CRPC). In this state, the tumor 
cells respond to >50 ng/dL of plasma located testosterones, which is biosynthesized 





2.3  Castration Resistant Prostate Cancer 
 
Castration-resistant (CR) PCa is a dynamic disease that starts with rising prostate-
specific antigen (PSA) levels with no metastases to a state of high bone metastases or 
even death.  Previous studies have reported that bone metastases are a shared outcome, 
affecting ~90% of men with CR PCa, causing unbearable pain.36-37 Moreover, 
biochemical relapse occurs in about 30% of patients who were treated aggressively.34 
CR-PCa is lethal with about 18-month median survival time. Currently, chemotherapy is 
the standard-of-care treatment for CR-PCa, but only provides a minimal improvement in 
survival rate.35 Shown in Figure 3, is the progression of cancerous cells as they become 
CR PCa. 
 
Figure 3. Castration Resistance Progression. 
 
 The progression of CR PCa is not entirely known as the complicity of disease 




idea that CR PCa is not entirely an androgen independent phenomenon, but still relies on 
androgen signaling.  The CRPCs are extremely sensitive to low levels androgen, and 
various hypotheses has proposed that CR PCa responds to those androgen levels via 
intratumoral androgen para-/autocrine production, AR mutation and ligand independent 
AR activation.38 Several studies are using chemical agents that suppress the biosynthesis 
of androgens or AR.39 
In 2011, Abiraterone (Figure 4) became a popular drug for CR PCa, which is 
responsible for the inhibition of cytochrome P450 17A1 (CYP17A1). CYP17A1 
inhibition eradicates the biosynthesis of androgens no matter the location. CYP17A1 
enzyme inhibition directly decreases the production 17-α-hydroxy-pregenoione and 










Figure 4. Structures of Abiraterone and Enzalutamide.  
Source: Adapted from Yin, L.; Hu, Q.; Hartmann, R. W., Recent progress in pharmaceutical therapies for 
castration-resistant prostate cancer. Int J Mol Sci 2013, 14 (7), 13958-78. 
 
Those compounds are precursors for the production dihydrotestosterone (DHT), 
which is an active compound in the signaling of AR. DHT is a natural ligand for AR and 




of AR by competitively binding to the ligand binding domain (LBD) of the AR and 
impairing transcriptional activity.  Supplying significance contribution to CR PCa, both 
Abiraterone and Enzalutamide have patients’ resistance at ~20-40%. Those patients 
exhibit no response with low PSA levels or no clinical evidence.39 
As mentioned, AR-dependent and AR-independent mechanisms play a vital role 
in the development of resistance to anti-androgen drugs. Those mechanisms include the 
upregulation of AR and CYP17, induction of AR splice variants, AR point mutation, 
upregulation of glucocorticoid receptor (GR), and the activation of other oncogenic 
pathways.39 
 2.3.1 AR Splice Variants 
 
Since 2008, there has been the discovery of 22 AR splice variants.  AR splice 
variants are developed from alternative mRNA splicing event through gene alterations. 
The multiple AR splice variants share common motifs of the N-terminal transactivation 
domain and the central DNA binding domain, but in PCa the increase in AR signaling 
comes from active AR variants lacking the LBD. AR variants AR-V7 (AR3) (Figure 5) 
and ARv567es (AR-V12) (Figure 5) are the most studied variants in PCa patients. AR-V7 
variant contains exon 1 (N-terminal domain), exon 2-3 (DNA binding domain, and a 
terminal cryptic domain (C-terminal domain) lacking LBD. The other well studied 






Figure 5. Reported splice variants of AR. AR gene contains eight exons. (U) indicates 
the cryptic regions, that’s not found in wildtype AR. (Zn) zinc finger region comes from 
the inclusion mutation of exon 2.  
Source: Adapted from Watson, P. A.; Arora, V. K.; Sawyers, C. L., Emerging mechanisms of resistance to 
androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015, 15 (12), 701-711. 
 
The activities of the AR in the early stages of PCa are mostly upregulated by 
natural ligands, but many of the splice variants of AR do not contain a LBD so the 
upregulation of AR are completely independent of ligands. Splice variants of AR interact 
with other transcriptional factors and co factors such as FOXO1, nuclear factor kappa-B 
(NF-κB2)/p52 and Vav3, and those interactions regulate the activity of AR splice variants 
through a variety of signaling pathways. Proposed mechanism for the emergence of 
splice variants is shaped by the genomic rearrangements within the AR gene locus that 
occurs in CR PCa and PCa cell lines.40  
 2.3.2 AR Point Mutation 
 
Initially, not found in primary PCa or hormone sensitive PCa, point mutation in 
the AR gene is found in ~30% of CR PCa.40, 42 The increase in AR expression from the 
growing copy of the mutated AR gene (gain-of-function point mutation) leads to the 




affects the LBD and allows for the non-specific binding of ligands such as weak 
androgens, progestins, glucocorticoids, estrogens, and anti-androgens.39, 43 AR point 
mutation of T878A is one the most observed point mutations that arise from the treatment 
of Abiraterone. The anti-androgen biosynthesis compound inhibits the production of 
DHEA and DHT, but increases the production of progesterone. The T878A point 
mutation causes for the non-specificity of steroid hormones such as progesterone and 
estrogen.39, 44-45 Another important AR point mutation is F877L that arises from the 
treatment of enzalutamide that actively binds to the LBD of the AR.  This mutation turns 
the antagonist enzalutamide into a sensitive agonist that promotes AR signaling and 
eliminates its inhibition nature.  Point mutation of the AR describes the progression 
metastasized PCa gaining resistance to novel anti-androgen therapeutics.39-40 
 2.3.3 Upregulation of Glucocorticoid Receptor (GR) 
 
Similarly, to AR, the GR belongs to a class I of nuclear steroid receptors. GR 
provides an alternative mode for PCa survival by bypassing the AR blockade that’s 
supplied by novel antiandrogens. GR and AR structural similarity allows for the AR 
promoters to constitutively bind to the GR. The induction GR is provided by AR 
promoters that have no ability interact with the AR.  GR signaling is comparable to that 
of AR based on the similar structure motifs, so they target some common sets of gene 
targets and transcriptomes.39,39, 46Studies have shown that the knockdown of GR, 






 2.3.4  Oncogenic Pathways 
 
Not limited to the other suggestions of developed resistance, oncogenic pathways 
play a role in resistance to antiandrogens therapies.  ADT and AR inhibition leads to 
activation of the numerous of amounts oncogenic signaling pathways that promote AR 
signaling shown in Figure 6. 
  
Figure 6. Summary of major AR signaling pathways in PCa.  
 
Source: Adapted from Lonergan, P.; Tindall, D., Androgen receptor signaling in prostate cancer 
development and progression. Journal of Carcinogenesis, 2011, 10 (1), 20-20. 
 
Interleukins are transmembrane proteins that implicate extracellular peptide 
signals from growth factors and cytokines to induce transcriptional activity of the AR in 
CR PCa. Cytokines (IL-6 and IL-8) are produced by prostate cells that once bind to 
interleukins receptors leading to a cascade of phosphorylation of proteins including 




upregulation of AR transcription increase in tumor growth.50 Similar to interleukins, 
growth factor receptors are located in the transmembrane region of the cell. Growth 
factor signaling is activated by extracellular signals that usually regulate the cell cycle, 
apoptosis, and differentiation in PCa. A common growth factor receptor in PCa, 
epidermal growth factor receptor (EGFR), and its ligand, EGF are directly related to 
incidence of metastatic PCa and the progression to CR PCa.51 The activation of EGFR 
via EGF leads to the activation of the MAPK pathway. EGFR involvement of MAPK 
pathway causes a cascade of events that modulate androgen response by increasing 
sensitivity. In an androgen independent environment, the EGFR induces the 
phosphorylation of AR by Src and Ack1 kinases. The phosphorylation of the AR allows 
for the formation of the dimer that leads to AR transcriptional activity.  Insulin growth 
factor receptor is much like EGFR, but responds to insulin growth factor 1(IGF-1) that 
allows the activation of AR by allowing a cascade of events that phosphorylate AR.48, 52 
Many of the extracellular events discussed lead to the intracellular activation of 
kinase signaling such as the MAPK pathway, but many intracellular events happen 
independently in the absents of extracellular induction.53 Targeting intracellular proteins 
is difficult, but targeting the intracellular proteins provide an insight into the role of AR 
in CR PCa.54 The MAPK pathway is made up of powerful oncogenes, sarcoma-related 
kinase (Src) and Ack1 that were mentioned previously induce AR transcriptional activity. 
Extracellular-signal-regulated kinase (ERK) 1 and 2 is also activated in the MAPK 






 2.3.5  PI3K/Akt Pathway 
 
Another intracellular event that encourages the resistance of ADT and 
antiandrogens is the activation of the PI3K/protein kinase B (Akt) signaling pathway 
that’s mutated or gain-of-function through receptor tyrosine kinases (RTK), G protein-
coupled receptors (GPCR), and other oncogene signaling networks such as RAS, shown 
in Figure 7.56 RTK and GPCR can induce PI3K/Akt signaling by becoming constitutively 
active. The oncogene Ras has been shown to increase PI3K/Akt signaling by 
allosterically binding to PI3K. Essential to the PI3K/Akt pathway, the loss of the 
phosphatase and tensin homolog (PTEN) tumor suppressor gene has many implications 
to the deregulation of PI3K/Akt signaling. The PI3K/Akt pathway is critical to PCa 
survival in a low androgen environment. Studies on Akt activation shows p300 to have a 
direct interaction with AR that promotes the transcriptional activity of AR. Loss of PTEN 
expression from heterozygosity or mutational silencing, results in the accumulation of 
PIP3 that leads to the phosphorylation of Akt. The role of PIP3 is a second messenger of 
Akt, that comes from the phosphorylation of phosphoinositol-(4,5)-bisphosphate (PIP2). 
PI3K is a protein kinase that leads to transformation PIP2 to PIP3, which in androgen 





Figure 7. Schematic representation of the PI3K/PTEN signaling network.  
Source: Adapted by Suzuki, A.; Nakano, T.; Mak, T. W.; Sasaki, T., Portrait of PTEN: Messages from 
mutant mice. Cancer Science, 2008, 99 (2), 209-213. 
 
 2.3.6 PTEN 
 
PTEN is a multifunctional phosphatase that when active negatively regulates the 
PI3K/Akt pathway thus suppressing tumorigenesis. The novel tumor suppressor gene is 
located in the 10q23 region of chromosome 10 encoding for 403- amino acids with 
molecular weight (MW) 47 kilo Daltons (kDa). In 1977, PTEN was discovered by three 
independent groups. The methods used to discover the PTEN homolog was positional 




homolog was characterized in 1999 by Lee et al., which  is composed of a PIP2 binding 
domain,  a catalytic phosphatase domain, a C2 lipid membrane-binding domain, and a 
class I postsynaptic density protein–Drosophila disc large tumor suppressor–zonula 
occludens 1 (PDZ) binding motif at the C-terminus, which identifies protein-protein 
interactions. The protein gene is actively expressed throughout mammals beginning in 
early embryogenesis.59-60 PTEN subcellular localization is cytoplasmic and membrane 
bound, with additional nuclear localization that plays a major role in some translocational 
processes.59  
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Figure 8. PTEN cellular functions. 
 
PTEN mutation occurs more frequently in human cancer cells than human normal 
cells through somatic mutations, gene silencing, or epigenetic mechanisms.  Majority of 




prostate cancers. More specifically in PCa, PTEN deletion and/or PTEN mutation is 30% 
in primary PCa and 63% in metastatic PCa. PTEN copy losses occur in 50% of PCa and 
appear in early changes of the prostate gland, found in the prostatic intraepithelial 
neoplasia (PIN). Monoallelic losses are more common in PIN and localized PCa, while 
bi-allelic PTEN losses are higher in CR PCa. Moreover, homozygous loss of PTEN is 
causative in progression to aggressive metastatic phenotype, castration resistance, and 
activation of Akt.61  In CR PCa, the activation of Akt shows increased activity from the 
hyperphosphorylation of PIP3 by Class I PI3K enzymes and loss of regulation provided 
by PTEN.  Activated PI3K/ AKT pathway is sufficient to compensate for androgen/ AR-
signaling blockade by inducing proliferation of basal/ progenitor cells and enhancing 
expression of a number of pro-proliferative factors including EGR1, c-JUN, and EZH2. 
Therapies of CR PCa and other diseases have been developed to provide a regulatory 
mechanism in stopping the hyperphosphorylation of PIP3 by targeting Class I PI3K 
enzymes.  
2.4  PI3K 
 
PI3K consists of three classes that are characterized based on structure and 
function, where, class I PI3K isoforms serve as the class of interest in human cancers. 
The class I PI3K kinases have five domains, an N-terminal adaptor-binding domain 
(ABD), a Ras-binding domain (RBD), a C2 domain, a helical domain and a C-terminal 




of PI3K. In class I, there are four isoforms, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ being the 
only isoform of class IB displayed in Figure 9.  
 
Figure 9. Schematic of Class I PI3Ks to PIP3 pathway.  
Source: Adapted from Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P., Targeting phosphoinositide 
3-kinase: moving towards therapy. Biochim Biophys Acta, 2008, 1784 (1), 159-85. 
 
The four isoforms exist as heterodimers with a regulatory subunit and catalytic 
subunit. Class IA PI3K contains subunits that are a combination of (p85, p55, or p50) 
regulatory subunit and a (p110-α, β, or δ) catalytic subunit.  This class of isoform 
responds primarily to signals from transmembrane RTKs.  Different from the class IA 
isoforms, the class IB isoform consists of p110 γ catalytic unit combined with regulatory 
subunits p84, p87, and p101. This class primarily responds to signals from GPCRs. The 
p110 α and β subunits are ubiquitous where they are insulin signaling sensitive, and the 




activation, mast cell degranulation, and leucocyte chemotaxis.  Other classes of the PI3K 
play a role in regulating membrane and vesicle translocation.64 Involved in promoting CR 
PCa, Class IA PI3Ks are the preferred choice for therapeutic treatments. Recent studies 
have shown that mutant PI3Kα (p110α) or overexpression of PI3K α, β (p110β), and δ 
(p110δ) contributes to incidence of metastasized cancers.  
 2.4.1  Structure of PI3K  
 
As shown in Figure 10, class IA catalytic subunits interact with regulatory 
subunits (p85, p55, or p50) with no binding specificity to a certain catalytic subunit. The 
regulatory subunit p85 serves as a stabilizing unit to the binding of polypeptides to the 
catalytic unit. It also serves two other roles in which p85 inhibits basal activity and 
recruits phosphorylated substrates for transmembrane RTKs and pY (phosphotyrosine 
containing motifs) containing peptides. The p85 regulatory subunit has N-terminal SH 
(Src Homology) 3 domain, break point cluster region domain (BCR), N-terminal SH2 
domain (nSH2), and C-terminal SH2 domain (cSH2).  The nSH2 and cSH2 domains are 
separated by intertwining coiled-coil domains (iSH2).  Acting downstream to RTKs, the 
class IA regulatory subunits activity is regulated by a phosphorylated Try-Xaa-Xaa-Met 





Figure 10. Domain organization of p110 catalytic subunit and their regulatory subunits.65 
Source: Adapted by Burke, J. E.; Williams, R. L., Dynamic steps in receptor tyrosine kinase mediated 
activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol 
Regul, 2013, 53 (1), 97-110. 
The first solved crystal structure of PI3Kα showed that the p85 iSH2 domain lies 
on crevasses of the p110, contacting the C2 and ABD domains of the catalytic subunit. 
The iSH2 domain acts a high affinity binding site for the p110 ubiquitin-like ABD. 66 The 
high affinity interaction between p110 and p85 caused by the iSH2 to the C2 domain is 
the role of p85 inhibitory effect to p110. The nSH2 and iSH2 domains of the p85 interact 
with three different domains of the p110: the helical domain around the Glu,545 the loops 
in C2 domain (β1-β2, β5-β6, and β7-β8) and residues in helix Kα10. The cSH2 domain 
interacts only with the kinase domain of the p110 subunit at helices kα11 and kα12. Other 
interactions with the kinase domain by cSH2 domain are with the kα7-kα8 loop in p110β, 
which shows the differential inhibitory effect against the different isoforms shown in 
Figure 11. Studies have shown that the p110 and p85 subunits are found in equimolar 





Figure 11. (A) model of PI3K heterodimer with ATP. (B) Regulatory arch class, labelled 
by color. Bottom represents inhibited and activated sites of PI3K enzymes.  
Source: Adapted from Vadas, O.; Burke, J. E.; Zhang, X.; Berndt, A.; Williams, R. L., Structural Basis for 
Activation and Inhibition of Class I Phosphoinositide 3-Kinases. Science Signaling, 2011, 4 (195). 
 
 2.4.2  C-terminal PI3k Regulatory Arch 
 
The regulatory arch is formed from three helical structures (kα10, kα11, and 
kα12) of the C-terminal domain in p110.  The arch covers the catalytic and activation 
loops of the C-lobe, which is essential in regulating the activity of p110 by limiting its 
catalysis region. The catalysis region is responsible for membrane binding and kinase 
activity on lipid membranes. The second function of the arch is to maintain a closed, 
inactive conformation of the PI3K and prevents substrate binding to the active site.  
Inactivation of the regulatory arch is from many mutated residues in PI3K, which has 




 2.4.3  Mutation of PI3K in Cancers 
 
Along with PTEN loss mutation and overexpression of PI3K isoforms in CR PCa, 
class I PI3K mutations have been indicated where PI3KCA, encoded gene for PI3Kα, is 
mutated in approximately 30% of endometrial, breast, ovarian, and colorectal cancers.   
The mutation of PI3KCA is the only catalytic subunit mutation to be somatic with gain of 
function. Other somatic mutation of the regulatory units’ (p85α and p85β) gene, PI3KR1 
and PI3KR2 respectively, has shown loss of inhibitory function, which contributes to 
gain-of-function of the p110 catalytic units. In cancer, the PI3KCA mutations occur in 
two locations, one in the helical domain at Glu542 and Glu545, and the other in the C-
lobe at His1047.68 The helical domain mutation prevents binding of nSH2, which 
removes the inhibitory activity of the p85 regulatory unit.  Though unresponsive to pY 
phosphopeptides signaling, the oncogenic nature of the mutation requires Ras 
signaling.69-70 According to Vadas et al., mutation of p110α can occur sporadically in 
every domain besides the RBD.68   
 2.4.4  Inhibitors of PI3K  
 
 The importance of the development of novel potent and selective PI3K inhibitors 
is related to their increased activity being able to influence many medical disorders such 
as cancer, inflammation, and thrombosis.68 The difficulty of designing selective inhibitors 





Figure 12. Schematic ATP binding pocket of PI3K.  
Source: Adapted by Williams, R.; Berndt, A.; Miller, S.; Hon, W.-C.; Zhang, X., Form and flexibility in 
phosphoinositide 3-kinases. Biochemical Society Transactions, 2009, 37 (4), 615-626. 
 
 2.4.5  Active Site of Class I PI3K 
 
Similar to all protein kinases, PI3K has the same organization where the ATP-
binding pocket is between a cleft of N- and C- hemispheres and share the same conserved 
catalytic residues. Protein kinase activity has been studied extensively elucidating which 
conformations indicate enzyme active or inactive. Inhibitors of the many protein kinases 
interact with N-lobe of the kinase domain. Different from other protein kinases, PI3K 
confirmation is highly conserved in the N-lobe with helices and the ABD tightly packed, 




the interaction of lipid substrates, membranes and regulatory subunits e.g. p85 
domains.63,72  
The N-lobe of all kinases is usually composed of five-stranded β sheet and the 
helix of kα3, an important regulatory function in protein kinases. The P-loop is a 
conserved region in most kinases. Interacting with ATP, unlike protein kinases A, PI3Ks 
P-loop contains alternative residues that do not allow ion pair interaction with ATP.  The 
C-lobe is mainly composed of α helices with a lipid substrate -binding site and ATP-
binding site. Conformational differences in the isoforms of PI3Ks lie in the catalytic loop, 
activation loop and the helix kα12. Features within those regions can determine the active 
and inactive conformation. In PI3Ks, the Asp-Arg-His (DRH) motif in the catalytic loop 
is highly conserved. The PI3Ks share an Asp-Phe-Gly motif (DFG) that’s located at the 
beginning of the activation loop which changes confirmation in different catalytic steps, 
known as DFG-out and in conformation.63, 72   
 2.4.6  PI3K Inhibitors  
 
As a separate set of protein kinases, PI3Ks active site binding has been compared 
to the inhibition and confirmation changes to all kinase enzymes. The initial designs of 
inhibitors were to simulate the ATP-bound conformational change. Inhibitors of this class 
are known as type I inhibitors. The type II inhibitors of kinases are made to bind to the 
inactive confirmation. Type I inhibitors effectiveness is by taking advantage of ATP 
binding pocket when the protein isn’t required to bind to the ATP substrate.73 




the hinge residue Val827 in p110 these residues are invariant in all of the class I PI3K 
isotypes.64  
Based on recent studies, an “adenine” pocket (hinge), a “specificity” pocket, an 
“affinity” pocket and the hydrophobic region II are located at the mouth of the active-
site.74 Of the core active-site residues, only two are in contact with inhibitors in all 
complexes: Val828 and Ile910. Residues 825-828 lines the “adenine” pocket and form a 
hinge between the N-lobe and C-lobe of the catalytic domain. The backbone amide of the 
hinge Val828 makes a characteristic hydrogen bond in all of the p110/inhibitor complexes. 
Additionally, the backbone carbonyl of hinge Glu826 establishes hydrogen bonds to most 
inhibitors.63, 73 
More specifically, PI3K inhibitors are classed in three different groups known as, 
pan-inhibitors, selective inhibitors and dual-PI3k /mTOR inhibitors.  Pan class I PI3K 
inhibitors, wortmannin and LY294002 (Figure 13) are the first PI3k inhibitors that were 
not subjected to clinical trial, because of their toxicity in animal studies.75 
 
 




 2.4.7  Selective PI3K Inhibitors   
 
Designing selective inhibitors of PI3Ks, the regions of the ATP-binding is 
explored to create increased potency and selectivity. The high frequency of PIK3CA 
mutation in solid tumors leads to the increase attention of PI3Kα-selective inhibitors. 64, 76 
Imidazo[1,5-a]pyridines were the initial class of selective PI3Kα inhibitors. Selectivity of 
the Imidazo[1,5-a]pyridine was increased by adding a sulfonylhydrazone linker and 
substituting an electron donating group bromine (Br) creating the analog PIK75 (PI-
387).64, 77 
  2.4.7.1 Selective PI3Kα Inhibitors 
 
 One of the most specific PI3Kα inhibitors is (2S)-N1-[2-(1,1-
Dimethylethyl)-4’-methyl[4,5-bithiazol]-2’-yl]-1,2-pyrrolidinedicarboxamide (A66) 
(Figure 14), the compound shows little to no activity against other classes of PI3K while 
maintaining activity to both wild type and mutant PI3Kα (E545K and H1047R). Other 
PI3Kα inhibitors includes NVP –BYL719 and INK1117 in Figure 14 which has been 
submitted to phase I clinical trials. They also displays activity to both wild type and 
mutant PI3Kα and no specificity to the other classes of PI3Ks. Shown in A66 and NVP-
BYL719, the H-bonding between carboxamide group and the Gln859 amino acid is 





Figure 14. Selective PI3Kα inhibitors. 
 
PI3Kα inhibition has been shown to induce G1 phase arrest without killing cells in 
vitro.79 Studies have demonstrated that HER2- and KRAS-driven solid heavily rely on 
PI3Kα signaling, so targeting that isoform in those cases halts tumor growth. PI3Kα in 
cancers affects cell metabolism, and immune modulation was increased glucose 
consumption, and alteration of immune cells help cancerous cell survival.  Clinical 
findings have shown where PI3Kα inhibitors are effective in patients containing PIK3CA 
mutation, but the drugs’ efficacy is lost with PTEN loss mutations. The losses of the 
effectiveness of the PI3Kα inhibitors were attributed to the increased PIP3 from the 
activity of PI3Kβ.71 
  2.4.7.2 Selective PI3Kβ Inhibitors 
 
 In cancer, p110β plays a vital role PTEN loss or mutation. PTEN loss is 
found in gliomas, breast, colon, lung, endometrial and prostate cancers. Molecules 




contain the 2-morpholinochromenone substituent that’s present in LY294002. Initially, 
structure activity relationship studies concluded that adding pyridopyrimidine-4-one 
gives rise to selective p110β inhibitors.80 
TGX221 (Figure 15) is the initial and most studied compound containing those 
two substituents increased p110β selectivity by 200-fold over p110α. Maintaining a high 
selectivity to PI3Kβ versus PI3Kα helps to prevent insulin resistance. Other p110β 
inhibitors are designed using the TGX221 scaffold, which has given rise to p110β 
inhibitors containing benzimidazole-4-carboxylic derivative GSK2636771 (Figure 15)  
that is a potent inhibitor at 5 nM and a 12-fold selectivity over p110δ and greater than 
1000 fold selectivity over the other PI3Ks and mTOR. Recent studies have shown tumor 
growth inhibition in advanced tumor cell with PTEN deficiency using p110β inhibitors, 
but there are concerns that a shift p110β inhibitor will lead to p110α dependencies.64, 71 
 
 






  2.4.7.3 Selective PI3Kδ Inhibitors 
 
 PI3Kδ inhibitors have been studied extensively for their role in regulating 
the functions of T cells, B cells, mast cells, and neutrophils. Found primarily in 
leukocytes, hyperactive PI3Kδ is common in leukemia and cultured leukocytes.  
Inhibitors of PI3Kδ forms H-bonding between purine and Val,882 Glu,880 and Met804 
causing minor conformational changes. The purinylmethylquinazoline (IC87114) (Figure 
16) was the first reported selective p110δ inhibitor. IC87114 selectively inhibits PI3Kδ 
58 folds greater than PI3Kγ and more than 100 folds greater than the other class I PI3Ks. 
Further modifications of IC87114 led to CAL101 (Figure 16) which improved selectivity 
and potency to p110δ over all other PI3Ks.64 Downstream to B cell receptors (BCR), 
PI3Kδ inhibition using CAL101 has shown increased survival for patients with non-
Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and 
multiple myeloma compared to earlier treatments. Although effective, other PI3Kδ 
inhibitors are designed differently from the initial class of p110δ inhibitors that are 
composed of a quinazoline group and induce a specificity pocket; these newly designed 
inhibitors bind directly into a shallow dimple, known as the “tryptophan shelf,” formed 
with amino acids Met,752 Thr,750 and Trp.760  The tryptophan shelf is accessed by 





Figure 16. Selective PI3Kδ inhibitors. 
 
  2.4.7.4 Selective PI3Kγ Inhibitor 
 
 The earliest crystallized isoform, p110γ is known to mediate the activation 
of chemotaxis. The loss of its gene PIK3CG has been shown to reduce thymocyte 
development and T cell viability, which related to the activation of chemotaxis and 
inflammation. Similar to other Class I PI3Ks, p110γ overexpression initiates cellular 
proliferation and survival.64 Development of p110γ inhibitors is valuable drugs for the 
treatment of inflammatory diseases and cancers. The first inhibitor of p110γ was 
discovered in 200582 by Serono, quinoxaline (AS-605240) (Figure 17), the compound 
displayed a high maximal inhibitory concentration (IC50) of 8 nM to p110γ and greater 








Figure 17. Selective PI3Kγ inhibitor. 
 
 Crystal structures elucidated the protein-ligand interaction where the 
thiazolidinedione forms a salt bridge with the Lys833 and the nitrogen located within that 
substituent, and the quinoxaline forms hydrogen bonding with one of the nitrogen and 
Val882. Other PI3Kδ inhibitors are designed to maintain the hydrogen bonding with Val882 
by constituting substituent thiazole. Over the last decades, there have been many patent 
applications for p110γ inhibitors for the use of leukocyte trafficking and immune 
response, but there are no known clinical studies for specific p110γ inhibitors.64, 71, 83 
2.5  Imidazopyridine and its Therapies  
In recent years, imidazopyridines, a class of compounds similar to imidazole and 
benzimidazole 1 (Figure 18) has shown promising pharmacological significance that 
functions as antibacterial, antiviral, antiulcer, and anticancer.  The heterocyclic moiety of 
the imidazopyridines plays an important role in the biological activity of the compounds. 








Figure 18. Imidazole and Fused-Benzene/Pyridine Derivatives. Benzimidazole(1). 
Imidazo[1,2-a]pyridine(2). Imidazo[4,5-c]pyridine(3). Imidazo[1,5-a]pyridine(4). 
 
The significance of this group is its structural similarities with biologically active 
compounds histidine, histamine, purines, and biotin, whereas benzimidazole derivatives 
contain a fused benzene and imidazole. Benzimidazoles are also known to show 
biological importance, because of their ability to coordinate to metal ions and imidazole 
group functionality. The constitutional isomer, imidazopyridine is a fused pyridine with 
an imidazole fused at various sides of the pyridine. The imidazopyridine moiety shares 
the same biological importance as benzimidazoles. Each of the mentioned parent 
compounds shares heterocyclic nitrogen atoms that have the ability to accept and donate 
electrons, also form weak interactions. Those interactions are shown because of the 
desirable electron rich characteristics within the structure; as a result, the compounds 
show extensive interactions with protein and other molecular structures. 
Benzimidazole 1, naturally occurring compound apart of vitamin B12, has been 




mentioned above, benzimidazoles have antihistaminic/ histamine receptor antagonist 
capabilities, where the histamine GPCR, H1, H2, H3, and H4, stimulate a variety of 
physiological and pathophysiological processes.7  Reported by Yu et al. the imidazole 
and benzimidazole rings are important for receptor affinity. In relation to the H1 receptor, 
the antagonistic activity is supported by benzimidazole and imidazole scaffolds with 
substitutions at 1-,2-position of the benzimidazole, and substitutions at the carbon 5 (C5) 
of imidazole increase selectivity.  Along with its antihistaminic effects, benzimidazole 
has also emerged as an antiulcer drug via inhibition of the proton pump by irreversibly 
blocking the H+-K+-ATPase, an antifungal drug via the inhibition of CYP450 dependent 
14α-lanosteroldemethylase enzyme that plays a role in fungal biosynthesis, an 
antiparasitic drug where aromatic nitro group containing compounds influences the 
formation of reactive oxygen species (ROS) that causes destruction to DNA and 
biological proteins. Used as both anticancer and antiviral drugs, benzimidazole and 
imidazole act as nucleoside analogs disrupting DNA synthesis halting cell growth and 
division. The biological importance of both benzimidazole and imidazole also includes 
their agonistic and antagonistic effects to angiotensin II type 1 (AT1) receptor by helping 
regulate blood pressure, and fluid and electrolyte homeostasis, androgenic receptor 
antagonist/agonist mainly interacting with α1-adrenergic receptor isoform, and 5-





 2.5.1  Imidazopyridine Derivatives  
 
Structural isomer to benzimidazole, imidazopyridines contains five isomers 
sharing similar names; imidazo[1,2-a]pyridine 2 (IMP12a),imidazo[1,2-b]pyridine 
(IMP12b), imidazo[4,5-c]pyridine 3 (IMP45c), imidazo[4,5-b]pyridine (IMP45b), and 
imidazo[1,5-a]pyridine 4 (IMP). These moieties have served as useful tools in material 
chemistry and medicinal chemistry.  
  2.5.1.1 Imidazo[1,2-a]pyridine 
  
 IMP12a has been the most investigated of all the imidazopyridine isomers, 
where a series of IMP12a has been used as commercial products listed in Figure 19. 
Novel IMP12a derivatives (Figure 19) Zolpidem 5 and Alpidem 8, are two of the first 
studied compounds, where they were used for insomnia and anxiety, respectively. Similar 
to Zolpidem and Alpidem, Necopidem 7 and Saripidem 10 shared anxiolytic capabilities. 
Other IMP12a derivatives such as Olprinon 6 are used for the treatment of heart failure, 
Zolimidine 9 is used for peptic ulcer, and HS-104 11 was the initial class of 






Figure 19. Imidazo[1,2-a]pyridine derivatives with different biological applications. 
 The development of IMP12a as inhibitors of PI3K, novel pan inhibitors 
PIK-75 and GSK 2126453 were used as modeled compounds in understanding the 
binding pocket using 3D structural software. The study suggested that using IMP12a 
allows the novel therapeutic to mimic adenosine of ATP binding in the hinge region. 
Similar in structure to adenosine, IMP12a increased selectivity and decreased activity of 
PI3K.84 
  2.5.1.2 Imidazo[4,5-c]pyridine  
 
 Along with IMP12a, imidazo [4,5-b] pyridine, 1-deazapurine (IMP45b) 
and imidazo [4, 5-c] pyridine, 3-deazapurine (IMP45c) (Figure 20) have a variety of 
biological applications, because of the nitrogen based heterocyclic structure. Early studies 
of these novel imidazopyridines were as nucleoside antibiotic.  In the last 5 years, 
deazapurine derivatives have been investigated as anti-cancer agents. The derivatives are 




nucleoside analogs. 1-(3-H-imidazo[4, 5-c]pyridin-2-yl)-3, 4-dihydro-2H-pyrido [2,1-a]-
isoindole-6-one 12 is a 3-deazapurine derivative used as an inhibitor of Hsp90 that binds 
to the N-terminal ATP domain maintaining the inactive form of Hsp90. Aurora A kinase 
inhibitor, 1-deazapurine derivative 13 is currently being studied showing the regions of 
protein the compound is interacting with using docking analysis, structure activity 
relationship (SAR) and 3D-quantitative structure activity relationship (QSAR). The 
Aurora A protein plays an essential role in mitotic spindle formation and centromere 
maturation.85 
 





2.6  Imidazo[1,5-a]pyridine 
 
 Imidazo [1,5-a] pyridine 4 (IMP) in the last decade has grown from novel OLED 
to a novel CRPC therapeutic. In 2007, Matteucci et al.86 developed lonidamine analogs 
for the treatment of benign prostatic hyperplasia, macular degeneration, and prostatic 
intraepithelial neoplasia. Lonidamine, 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic 
acid 14 (Figure 21), is an anticancer drug for breast, prostate and brain cancer, where it 




Figure 21. Lonidamine and its derivatives. 
 
 Matteucci synthesized a variety of lonidamine analogs that posed structure 
similarities to the indazole moiety 14. Antiproliferative properties of imidazo[1,5-
a]pyridines, 15-17 (Figure 21), were further investigated for IC50 at 12,10 and 11μM, 
respectively, against normal prostate cell with mild hyperplasia (PWR-1E). Secondly, 




cells (NCI-H460) at 48, 41 and 43 μM, respectively. Their results showed promising IMP 
anti-proliferative property against early onset prostate cancer and lung cancer.  
Later, Trotter et al.87 reported a new series of imidazopyridine CB2 agonist. Their 
investigation involved the structural optimization of imidazopyridine by improving 
selectivity to CB2 over CB1. CB1 and CB2 are cannabinoid receptors that induce 
analgesic effects.  They propose that having CB2 selectivity over CB1 reduces undesired 
psychotropic effects and increases pain-modulating activity.   
Previously, Gallant et al.88 used indole derivative (GW405833) 18 (Figure 22) 
that potently bind to CB2 receptor with moderate selectivity.  Trotter et al. investigated a 
series of imidazopyridines 19-21 for CB2 selectivity, because of its 6,5-fused 
heterocyclic structure which is similar to GW405833 and other potent CB2 agonist.   
 
Figure 22. GW405833 and its derivatives. 
 
Gallant et al. found that two particular compounds, 22 and 23 (Figure 23) are 




displayed IC50 5 and 33 nm to hCB2, respectively, and IC50 2565 and >17000 nm to 
hCB1, respectively.  They concluded analgesic effects were dependent on the inhibition 
of both CB2/CB1 receptors. 
 
Figure 23. CB2 inhibitors. 
Kamal et al. reported a series of oxindole derivatives of imidazo[1,5-a]pyrazines 
against nine different types of cancer cells: leukemia, lung, colon, CNS, melanoma, 
ovarian, renal, prostate and breast (Figure 24).89  Previously, Wu et al. investigated 3,6-
diarylimidazopyridine 24 as an inhibitor of vascular endothelial growth factor (VEGF)-
receptor. VEGF is a regulator of vascular permeability and an inducer of endothelial cell 
proliferation, migration, and survival. Activation of the VEGF pathway is a fundamental 
regulation of angiogenesis, the formation of new capillaries from established blood 
vessels.89-90 The results showed that compound 25 had significant anticancer properties 
against leukemia, lung, CNS, melanoma, ovarian, renal, prostate, and breast with growth 





Figure 24. Imidazo[1,5-a]pyrazines derivatives. 
 
Follman et al.91 developed novel substituted imidazopyridine and 
imidazopyridazine for the treatment of cardiovascular diseases (Figure 25). The novel 
compounds are known to be guanylate cyclase stimulators.  The guanylate catalyzes the 
biosynthesis of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate 
(GTP).  The production of cGMP plays a vital role in platelet aggregation and adhesion, 
also in neuronal signaling.  The suppression of cGMP causes hypertension, increased 
cellular proliferation, heart failure, and stroke. The same group as well investigated 
compounds 26-28 against recombinant guanylate cyclase reporter cell lines. The results 
have shown that compound 27 has a minimal effective concentration of 0.03 μM 




   
Figure 25. IMP as guanylate cyclase stimulators. 
 
In 2013, Kamal et al. reported a series of IMP-PBD conjugates displaying 
antitumor activity against breast cancer cell line (MCF-7). Pyrrolobenzodiazepines 
(PBDs) (DC-81 29) (Figure 26) are antitumor antibiotics produced by various 
Streptomyces species. The antitumor activity of this class of compounds is due to the 
formation of a covalent bond with C-2 amino group of guanine within the minor groove 
of DNA.92-93 The goal of developing these new IMP-PBD conjugates is to increase 
specificity to a tumor cell, where other PBDs are susceptible to displaying cytotoxicity to 
normal cells. Compounds 29 and 30 display anti-proliferative properties against MCF-7 
cellular lines at a value of 2 μM, also they have shown an increase in thermal 





Figure 26. DC-81 and its derivatives. 
 
Alcouffe et al.94 developed imidazopyridines derivatives for the use as fibroblast 
growth factor (FGF) receptor inhibitors (Figure 27). Targeting FGF receptors allows for 
an effective treatment of bladder cancer. FGFs are a family of polypeptides that are 
formed during the embryonic development. Previously, there has been a report 
demonstrating the prevalence of bladder cancer from the mutation of FGF.95 This 
mutated form of FGF-R3 is known to be a therapeutic target of choice for the treatment 
of superficial and noninvasive bladder cancers. TCC97-7 cell line is a model for FGF 
receptor 3, Ser249Cys mutation dependent bladder cancers and the overexpression of this 
mutated receptor FGF leads to bladder cancers. Alcouffe et al. has used TCC97-7 for 
evaluating the ability of the FGFR (fibroblast growth factor receptor) antagonists to 





Figure 27. IMP as Cysteine Proteases Inhibitors. 
 
Initially, Alcouffe et al. evaluated the derivative compound 31 and its anti-
proliferative properties against TCC97-7. Compounds 32-34 displayed high inhibition 
properties, 61, 80, and 27 %, respectively, at 10 μM.  After evaluating the anti-
proliferative properties, they investigated the inhibition of intracellular ATP and the 
inhibition of phosphorylated ERK. The result showed that compound 33 was the most 
active compound with 73% intracellular ATP inhibition and 93% pERK inhibition. 
Khan et al.96 reported 1-pyridylimidazo[1,5-a]pyridine as cysteine protease 






Figure 28. E-64c and IMP derivatives. 
 
Cysteine proteases (papain) are a family of enzymes that are important in the life 
cycle of many microorganisms. Papain inhibitors have gained importance in 
chemotherapeutics for their lack of mammalian prevalence, also antimicrobial action 
against papain. Initially, Khan et al. designed various derivatives of 1-substituted-
pyridylimidazo[1,5-a]pyridine and screened the compounds on the basis of their docking 
energies against papain. After conducting in silico studies compounds, 36-39 showed 
promising results of antimicrobial properties. Those compounds were then investigated 
based on their thermodynamic and kinetic properties. The results proved that in 
compounds 36-39 the pyridine moiety interacted with the S2 site of papain at residues 
Try61, Asn64, Gly65, and Try67.  The calculated binding energies were -6.12, -5.76,-6.84 
and -5.62 Kcal/mol, respectively, and were comparable to established inhibitor E-64c 35, 




binding energies of -6.86,-6.55, -5.71 and -5.64 Kcal/mol, respectively at 37⁰C. Finally, 
the antimicrobial activity was investigated amongst the four compounds with Ceftriaxone 
and Clotrimazole as negative controls. Compound 36 is shown to be most potent against 
all tested bacteria. Compound 39 is proved to have the tumorigenicity effect.96 
In 2014, Muniyan et al. reported the first class IMP for CR PCa using both a 
cellular model for androgen rich and androgen deprived (SR) media, in Figure 29.97 The 
biological studies included the use of PC3, DU145, and LNCaP-C81 cells. The first two 
cell lines are known as androgen null or independent, and the latter is androgen 
dependent or sensitive. PC3 and DU145 cells are immortalized metastasized PCa cells 
that are derived from bone and brain tissue respectively.  LNCaP-C81 is immortalized 
PCa derived from metastasized lymph node PCa with the ability to induce AR signaling 
via the production of cellular testosterone. Other studies conducted looked at IMP 
activity against the PI3K/Akt pathway. The results showed that the compounds were able 






Figure 29. IMP derivatives. 
 
Kamal et al.99 developed a series of IMP-benzimidazole hybrids for the inhibition 
of tubulin polymerization and PI3K/Akt pathway (Figure 30). Tubulin polymerization is 
a major function in microtubules as tubulin dimers assembly forming microtubules.  
Microtubules play a role in cellular motility, cell signaling, formation and maintenance of 
cell shape, also secretion and intracellular transport.  Compound 44 displayed a variety of 
anti-proliferative effects that provided the structure activity relationship (SAR) data. The 
results showed compounds 45 and 46 had significant growth inhibition in all cell lines 
tested with GI50 values in the range of 1.06-14.9 μM and 0.46 μM, respectively. Breast 







Figure 30. Nocodazole and IMP-benzimidazole derivatives. 
 
The inhibition of tubulin polymerization was investigated with compounds 45 and 
46 which are found to inhibit 47.92% and 71.27%, respectively, compared to the negative 
control nocodazole 47, 69.98%.  The molecules role in the PI3K/Akt pathway is also 
studied. The molecules significantly reduced pAkt and pPTEN levels showing the 
activity of the molecule in the PI3K/Akt signaling.99 
In 2016, Adams et al. reported100 the discovery of potent and selective MKK3/6 
inhibitors (Figure 31). The Map Kinase Kinase isoforms 3 and 6 (MKK3/6) are known to 
promote the phosphorylation and activation of p38.  The mitogen-activated protein kinase 
(MAPK) family is involved in the prevalence of diseases such as rheumatoid arthritis, 






Figure 31. MAKK3/6 inhibitors.  
 
Molecules that are designed to be selective to MKK3/6 have the ability to serve as 
a probe for further investigation of MKK/p38 pathway. Initially, compound 48 was the 
molecule of interest with IC50 values of 37 μM and 16 μM to MKK3 and MKK6, 
respectively.  Using compound 48 as active biological scaffold led to other compounds 
that may pose as MKK3/6 inhibitors. Compound 49 displayed high selectivity to MKK3 
and ligand efficiency, at 4 nM and 0.67 ligand efficiency (LE). In addition to the 
molecule MKK3 inhibition properties, the antiproliferative properties were also examined 
against human leukemic monocyte cells (U937). The results have shown a dose-
dependent inhibition curve against the phosphorylation p38 at 0.73 μM. The investigation 
of selectivity of compound 49 against a variety of MAPK signaling kinase has shown at 
least a 12-fold increase in inhibition to all kinases.   
Mazzaferro et al.101 reported morpholine and 1,4-oxazepane amines derivatives as 
somatostatin receptor subtype4 (SSRT4) agonist (Figure 32). Somatostatin, or 






Figure 32. Heterocycles for SRRT isoform inhibition. 
 
This peptide is produced widely in the human body and acts both systemically 
and locally to inhibit the secretion of various hormones, growth factors, and 
neurotransmitters. The effects of somatostatin are mediated by a family of G protein-
coupled receptors (GPCRs), of which five subtypes are known. These subtypes are 
divided into two subfamilies, the first comprising SSTR2, SSTR3 and SSTR5 and the 
second SSTR1 and SSTR4. Compounds 50 and 51 derivatives with fused 5,5; 6,5 ;6,6 
heterocyclic rings are selective to SSTR4. The use of 5,5; 6,5 ;6,6 heterocyclic rings is 
because of its implication to prevent and treat inflammation and pain. Based on an 
agonistic assay monitoring the amount of intracellular cAMP, it showed that compound 
52 is active in inhibiting the SSRT4 receptor at 4.5 nM. After quantifying the agonistic 
activity, the investigation of the binding energy and bio-stability revealed compound 52 
to have a binding affinity (Ki) at 218, 9480, 9630, 8690, and 9770 nM to SSRT4, SSRT1, 




selective to SSRT4 versus the other isoforms. Also, compound 52 displayed a bio-
stability for more than 130 minutes.  
Buil et al.102 reported a series of monocyclic and bicyclic core molecules with 
diphenylsulphone (tail) and acetic acid (head) 53 (Figure 33) for a chemoattractant 
receptor homologous molecule expressed on Th2 lymphocytes (CHTh2). CHTh2 is a 
GPCR involved in the chemotaxis of Th2 lymphocytes, eosinophils, and basophils.102-104 
CRTh2 also inhibits the apoptosis of Th2 lymphocytes  and stimulates the production of 
IL4, IL5, and IL13, cytokines involved in pro-inflammatory biological responses.102 
CRTh2 antagonists are therefore under active development as potential treatments in 
pathologies related to allergic inflammation.  
 
Figure 33. Schematic of CRTh2 inhibitor containing a heterocyclic core. 
 
Compound 54 (Figure 34) was designed with the imidazo[1,5-a]pyridine moiety 
as the core. The results showed that compound 54 was able to display an IC50 of 3 μM, 





Figure 34. CRTh2 inhibitor with IMP core. 
Rao et al.105 reported a series of imidazopyridinyl-1,3,4-oxaiazole for 
Topoisomerase Iiα inhibition (Figure 35). DNA topoisomerase (topo) is recognized as an 
important target in anticancer drug discovery.105-106 Topoisomerases I and II are nuclear 
enzymes that modulate in maintaining the topological changes of DNA and play a crucial 
role in the cellular processes such as transcription, replication, and chromosome 
segregation to resolve the topological problems of DNA double helix during the repeated 
cycles of DNA cleavage and ligation.105, 107 Human topo II exists in two isoforms namely 
topo-IIα and topo-IIβ and the level of topo-IIβ is constant throughout the cell cycle, 
whereas the degree of topo-IIβ is higher in rapidly proliferating cells.108 Topo-II inhibitor 
etoposide 55 is the most commonly used inhibitor. Several derivatives of IMP-134oxa 
have been evaluated against cancer cell lines. Compound 56 displayed the highest growth 
inhibition against prostate, breast, lung and ovarian collectively with a GI50 range of 1.30-





Figure 35. Etoposide and its derivative. 
 
Mukhopadhyay et al.109 designed bicyclic molecules for the inhibition of retinoic 
acid-related orphan receptor gamma (RORγ) (Figure 36). RORγ is one of three ROR 
family member of the nuclear receptor (NR) superfamily. RORγ is expressed as two 
isoforms due to alternative splicing from RORC gene. The shorter transcript called 
RORγt or RORγ2 lacks two exons at 5 -terminal. Unlike widely expressed RORγ in 
several tissues including the thymus, kidney, liver, and mussels, RORγt is expressed only 
in immature CD4+/CD8+ double positive thymocytes, also in a population of lymphoid 
tissue inducers (LTi) of the fetal liver.109-110 RORγt is the signature transcription factor 
for differentiation and function of IL-17 producing T Helper (Th17) cell lineage, a newly 
discovered subset of the T-helper cell population. Th17 cell causes a major inflammatory 
response by both direct and indirect methods, like neutrophil infiltration by IL-17, tissue 







Figure 36. Retinoic acid-related orphan receptor gamma inhibitors. 
 
Small molecule antagonists of RORγt are designed and are expected to inhibit 
production of these pro-inflammatory cytokines. Initially designed are nitrogen-based 
bicyclic molecules with (5,6) fused rings either containing salt or no salt. The results for 
compounds binding affinity to RORγ and RORγt showed that compound 57 and 58 had 
>5000 and <500 nM, respectively. 
Fuse et al.112 reported the synthesis of 1,3-disubstituted-imidazopyridines for the 
development of inhibitors of HIF-1 transcriptional activity in Figure 37. Hypoxia-
inducible factor (HIF) 1 is member of the core helix-loop-helix proteins of the PER-
ARNT-single-minded protein family of transcription factors. HIF-1 regulates the 
expression of genes involved in angiogenesis, cellular energy metabolism, and cell 








Figure 37. Hypoxia-inducible factor 1 inhibitors. 
 
HIF-1 binds to hypoxia response elements (HREs) and activates several hundred 
genes involved in angiogenesis (VEGF), glucose transport (GLUT1), glycolytic pathways 
(LDH-A), ROS signals (iNOS), and erythropoiesis (EPO).114 YC-1 59 was used as HIF-1 
inhibitor whose structural composition contains an indazole moiety. The alteration of the 
core from indazole to imidazo[1,5-a]pyridine offers structure-activity relationship to the 
different core units.  The results shows that compounds 60 and 61 were able to inhibit the 
transcriptional activity of HIF-1, 6.5 and 3.7 μM, respectively, which compound 59 
displayed a higher inhibitory activity at 1.2 μM.  
Tongmei et al.115 designed novel N-phenyl-2-aminopyrimidine derivatives for the 
inhibition of epidermal growth factor receptor (EGFR) (Figure 38). EGFR is a member of 
the erbB receptor family of transmembrane protein tyrosine kinases.  The binding of 
epidermal growth factors (EGF) leads to homologous dimerization, or with another 






Figure 38. Epidermal growth factor receptor inhibitors. 
 
ErbB receptor homology dimerization and /or hetero dimerization leads to the 
phosphorylation of the major tyrosine residues in the intracellular domain, which 
regulates many intracellular signaling involved in cell proliferation and survival 
conduction path. The body of the erbB family of signal transmission control 
abnormalities will promote cell proliferation, invasion, metastasis, blood vessels 
generation and generation of tumor cells.115-117 Compound 62 was investigated for the 
enzymatic activity Compounds 63, a modified version of 62, was highly effective in the 
inhibition of EGFR and mutated EGFR (mEGFR) Try90Met/Lys858Arg , displaying IC50 
values of 7.842 nM (EGFR) and 0.762 nM (mEGFR). Such compounds are also 
evaluated against several cancer lines: A431 (epidermal carcinoma), H1945 (lymphoma), 
PC-9 (prostate), and HCC827 (lung). The results show growth inhibition values of 620.8 





 2.6.1 Synthesis of Substituted IMPs 
 
  2.6.1.1 Condensation Reactions 
 
 Condensation reactions have been the most common and widely involved 
reactions for the synthesis of disubstituted IMPs using aldehydes, ketones, 
aminopyridines, amines, aryl-diones and carboxylic acids (Scheme 1).118  
 
Scheme 1. Condensation reaction mechanism involving aldehydes and ketones. 
 
Siddiqui et al.119 reported the synthesis of 1,3-disubstituted IMPs using Bronsted 
acidic ionic liquid 1-butylimidazolium tetrafluoroborate ([Hbim]BF4). As shown in 
Scheme 2, the condensation reaction involved aryl aldehydes, dipyridyl ketones and 
ammonium acetate, which afforded 1,3-disubstituted IMPs. Results have demonstrated 
that the reaction was completed between (1-12 h) with comparable yield to the method by 





Scheme 2. 1,3-disubstituted Imidazo[1,5-a]pyridine from aryl aldehyde, dipyridyl ketone 
and ammonium acetate using Bronsted acid. 
 
Kim et al.120 synthesized 1-substituted-3-2H-thoineimidazo[1,5-a]pyridine 
derivatives using 2-pyridinecarboxaldehyde, various organometallics and carbon 
disulfide or 1,1’-thio-carbonylimidazole in Scheme 3. They designed the reaction to 
produce amine intermediate that promotes cyclization after the addition of sulfur 
containing compounds. Initially they monitored the formation of amine intermediates 
with 2-pyridinecarboxaldehyde and lithium bis(trimethylsilyl)amide (LHMDS) at 0 ⁰C, 
and added lithiated compounds or Grignard reagents that produced the intermediate at 78-
98% isolated yield. Secondly, they reacted the amine intermediate with 1,1’-thio-
carbonyldiimidazole or carbon disulfide, which produced the product at 72-93% isolated 
yield.
 





In 2009, Crawford and Paoletti121 developed a one pot condensation reaction 
involving readily available aminopyridines and carboxylic acids compounds using 
propane phosphoric acid anhydride (T3P) in n-butyl acetate or ethyl acetate to produce 
1,3-disubstituted IMPs (Scheme 4). The reaction was able to increase isolated yields in 
mild conditions.  
 
Scheme 4. 1,3-disubstituted Imidazo[1,5-a]pyridine from aminopyridines and carboxylic 
acids using propane phosphoric acid anhydride. 
 
Mihorianu et al.122 developed a one pot synthesis of monosubstituted IMP using 
their synthesized product (3-chloro-5-trifluoromethyl)pyridin-2-yl)methenamine and 
thiophosgene and triphosgene in Scheme 5. The synthesis was able to be incorporated 
mild basic conditions, while maintaining high yields as they introduced the conditions at 





Scheme 5. Mono-substituted imidazo[1,5-a]pyridine from the condensation of ((3-chloro-
5-trifluoromethyl)pyridin-2-yl)methanamine with thiophosgene or triphosgene. 
 
Along with Mihorianu et al., Zhang et al.123 developed a method for the synthesis 
of mono-substituted IMPs using 1,1-dibromo-1-alkenes (Scheme 6). The reaction 
involved the condensation of 2-aminopyridine and 2-aryl-1,1-dibromoethane. Results 
showed adequate yield of mono-substituted IMPs, but showed an alternative route using a 
mild inorganic base, mild heating, and how 1,1-dibromo-1-alkenes acts as a synthon for 
activated carboxyl groups.  
 
Scheme 6. Mono-substituted Imidazo[1,5-a]pyridine from the condensation of  2-
aminopyridine and 2-aryl-1,1-dibromo-1-alkenes. 
 
Fulwa et al.124 first reported the synthesis of 1,3-disubstituted IMPs as a minor 




(Scheme 7). The group efforts were to create a series of imidazoles using a one-pot two 
component procedure.  
 
Scheme 7. Synthesis of 1,3-disubstituted Imidazo[1,5-a]pyridine using 2-cyanopyridine 
and 2-picolylamine. 
 
In 2012, the group reported the synthesis of 1,3-disubstituted IMP using 2-
cyanopyridine, hydrazine hydrate, and carboxaldehyde (Scheme 8). The procedure 
resulted in a three products of containing both IMP and triazole moiety, 1,3 disubstituted 
IMP moiety alone, and a 1,3 disubstituted triazole moiety.  Following this report, Fulwa 
et al. optimized the synthesis of 1,3 disubstituted IMPs using 2-cyanopyridine, aldehyde, 
and ammonium acetate, as a source of ammonia, in polyethylene glycol (PEG)-400. The 
group concluded that using 2:1 2-cyanopyridine to aldehyde ratio provided the 1,3-





Scheme 8: Synthesis of 1,3-disubstituted Imidazo[1,5-a]pyridine using 2-cyanopyridine 
and aryl aldehydes. 
 
Alvarez et al.127 reported the synthesis of mono-substituted IMP 
manganese(Mn)(II) complex using ammonium  diethyldithiophosphate (Scheme 9). The 
one pot synthesis demonstrated a condensation reaction involving two pyridine-2-
carboxaldehyde in the presence of MnCl2. Results showed an efficient method of 
obtaining a mono-substituted bidentate IMP with Mn(II).  
 
Scheme 9. Synthesis on monosubstituted imidazo[1,5-a]pyridine from the condensation 
of pyridine-2-carboxaldehyde with manganese chloride. 
 
Wang et al.128 developed the synthesis of mono-substituted imidazo[1,5-




proceeds with the introduction of iodine as a catalyst, KHCO3 as a base and 4 Ǻ 
molecular sieves as an additive (Scheme 10). The group monitored the condition of the 
reaction using various Lewis acids and iodine, which concluded that I2 produced the 
highest yield. They likewise monitored the use of TBHP, triethylamine, K2CO3, NaHCO3 
and KHCO3 as base. Finally, using I2 and KHCO3, they synthesized various products with 
amino acids and aromatic aldehydes. Results shown that they were able to produce to 1-
aliphatic substituted and 1- aromatic substituted imidazo[1,5-a]pyridine with isolated 
yields 52-90%.  
 
Scheme 10. Decarboxylative synthesis mono-substituted imidazo[1,5-a]pyridine with 
natural α-amino acids. 
 
 
  2.6.1.2 Cyclization Reactions  
 Vilsmeier-type cyclization of N-2-pyridyl methyl amides is the earliest 
and one the most common routes in synthesizing imidazopyridines.121 In 2006, Shibahara 
et al.129 (Scheme 11) reported the synthesis of mono-substituted IMP via iodine mediated 
oxidative desulfurization. Initially, they monitored the reaction conditions by altering the 
solvent and substrate. The substrates were N-2-pyridylmethyl amide substituted with 






Scheme 11. Synthesis of mono-substituted imidazo[1,5-a]pyridine with N-2-
pyridylmethyl using Iodine. 
 
The reaction afforded 2-azaindolizine at 89% yield and sulfur-bridged 2-
azaindolizine product at 7%. The other products afforded 59-95% yield. The reaction 
provided a breakthrough in an efficient and versatile method of making mono-substituted 
IMP using N-2-pyridyl methyl thioamides.   
Moulin et al.130 revisited the synthesis of IMP in an effort to increase the 
efficiency using Lawesson’s reagent and mercury (II) acetate (Scheme 12). The reaction 
involved the condensation of carboxylic acid and 2-methylamino pyridine with 
benzotriazol-1yloxy-tris(dimethylamino)phosphonium hexafluoride (BOP), then 
sulfurization of the carbonyl via lawesson’s reagent will cause the nucleophilic attack on 
the thiocarbonyl by the pyridine nitrogen leading an aromatized IMP product. The 
reaction mechanism following the sulfurization of the carbonyl has been concluded as a 






Scheme 12. Synthesis of mono-imidazo[1,5-a]pyridine  with carboxylic acid and 2-
methylaminopyridine with benzotriazol-1yloxy-tris(dimethylamino)phosphonium 
hexafluoride. 
 
In 2008, Bristol-Myers Squibb Company introduced the synthesis of 1,3-
disubstituted IMPs (Scheme 13) using Burgess reagent as less toxic and corrosive reagent 
to previously used POCl3, SOCl2, Ph3PCl2, and P2O5.
131 The group initially synthesized 2-
substituted pyridines from the condensation of Boc-L-isoleucine and 2-pyridine-2-yl 
methaneamine. The desired 2-substituted pyridine was added to a solution with Burgess 





Scheme 13. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine with 2-pyridine-2-yl 
methaneamine using Burgess reagent. 
 
In early 2009, Shibahara et al.132 reported the synthesis of 1,3-disubstituted  
imidazopyridines using two methods: the first method involved a three step reaction 
synthesizing  3-substituted IMP using  thioamides and I2/pyridine undergoing oxidative 
desulfurization-cyclization, then the 3-substituted IMP is halogenated via electrophilic 




Suzuki-Miyaura cross coupling with 1-halo-3 substituted IMP afforded the 1,3-
diarylsubstituted IMP with 48-93% isolated yield (Scheme 14). 
 
Scheme 14. Three step synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine. 
 
 The second method reported by Shibahara et al. involved the use of elemental 
sulfur, aldehydes, and aryl-2-pyridylmethylamines under catalyst free and mild 
conditions (Scheme 15). The reaction proceeded to undergo oxidative condensation-
cyclization and afforded 1,3-diarylsubstituted at low comparable yields.  
 
Scheme 15. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using aryl-2-





Following Shibahara et al., Murai et al.132 reported the formation of bis(1-
imidazo[1,5-a]pyridyl)arylmethanes using I2/pyridine (Scheme 16). The reaction 
undergoes intramolecular cyclization using N-thioacyl-1-(2-pyridyl)-1,2-amino alcohols. 
Results show that they were able to obtain good yield at an optimized reaction time 30 
minutes. Later in 2012, Murai et al. revisited the I2/pyridine mediated synthesis of 1,3-
disubstituted IMPs to optimize the conditions to obtain imidazo[1,5-a]pyridine-1-
ylalkylalcohols.  Murai et al. discovered that protecting the alcohol group on the N-
thioacyl-1-(2-pyridyl)-1,2-amino alcohol results in the imidazo[1,5-a]pyridine-1-
ylalkylalcohols  becoming the major product in the same conditions.  
 
Scheme 16. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine with N-thioacyl-1-(2-
pyridyl)-1,2-amino alcohols using iodine. 
 
In 2009, Arvapalli et al.133 reported a two-step synthesis of mono-substituted 
IMPs. The first synthesis involved the synthesis of picolinamides derivatives using 
methylpicolinate and amines.  Following the synthesis of picolinamides derivatives, the 
cyclization process is induced by phosphorus oxychloride under microwave irradiation 




to a moderate yield of the various mono-substituted IMPs with the highest resulting from 
3-(4-cyanophenyl)-imidazo[1,5-a]pyridine, 98% yield (Scheme 17). 
 
Scheme 17. Three step-synthesis of mono-imidazo[1,5-a]pyridine with methyl picolinate 
and  an amine under microwave irradiation.  
 
Qing Ge et al.134 developed substituted imidazo[1,5-a]pyridine functionalized 
with 1,3,4-oxadiazole for their applications in OLED (Scheme 18). Firstly, they 
synthesized the novel compounds using the synthesized 2-butyl-4chloro-1H-imidazole-
carbaldehyde and ethyl 4-bromobutyl-2-enoate and potassium carbonate. After 
synthesizing, 3-butyl-1-chloroimidazo[1,5-a]pyridine-7-carboxylate, they functionalized 
the compound further to afford their 1,3,4-oxadiazole derivatives. The precursor was 
synthesized at 86 %, which shows an alternative method of developing 1,3 and 7 
substituted imidazo[1,5-a]pyridine.  
 





More recently, Niyomura et al.135 reported the synthesis of substituted IMP using 
Selenium dioxide (Scheme 19). The group were able to synthesize 3-(2-
pyridyl)imidazo[1,5-a]pyridine, bis[3-(2-pyridyl)imidazo[1,5-a]pyridin-1-yl] selenide, 
and diselenide bridged bis[3-(2-pyridyl)imidazo[1,5-a]pyridin-1-yl]. The group was able 
to demonstrate an alternative approach to synthesize IMP and metal complexed IMPs. 
Results showed a percent yield of the products at 52%, 51% and 36% yield, respectively 
depending on the reaction conditions.  
 
Scheme 19. Synthesis of 3-substituted imidazo[1,5-a]pyridine using Selenium Dioxide. 
 
Li Y. et al.136 reported the synthesis of mono-substituted IMPs using lithiated 
benzylisonitrile (Scheme 20). The synthesis was carried out with substituted 2-
chloropyridine, potassium bis(trimethylsilyl)amide (KHMDS) as a base, and lithiated 
benzylisonitriles. The reaction undergoes cyclization after the generation of lithiated 







Scheme 20. Synthesis of mono-imidazo[1,5-a]pyridine using substituted 2-
chloropyridine, potassium bis(trimethylsilyl)amide (KHMDS) as a base, and lithiated 
benzylisonitriles. 
 
The group found that using KHDMS as base helps facilitate proton transfer which 
readily increases the yield of mono-substituted IMPs. Results indicated that substituted 2-
chloropyridine gives rise to higher yields compared to 2-chloropyridine, 29-72%, 
respectively.   
In 2016, Tverdiy D.O. et al.137 reported the synthesis of 1,3-disubstituted IMP via 
a cyclization reaction using trifluoroacetic anhydride (TFAA) (Scheme 21). The reaction 
occurs as a one pot synthesis containing acyl chlorides, 2-methylaminopyridine, and 
TFAA at very low temperature to prevent products destruction. Initially, Tverdiy D.O. et 
al. optimized the condition for the cyclization reaction using only intermediate N-
((pyridine-2-yl)methyl)acetamide and TFAA in the presence of pyridine, which they 
found at low temperature 1-(2,2,2-trifluoro)-3-substituted IMP. Results indicated the 






Scheme 21. Synthesis of 1,3-disubstituted IMP  using synthesis of 1,3-disubstituted IMP 
via a cyclization reaction using trifluoroacetic anhydride. 
 
El-Abadelah et al.138 reported the synthesis of 1,3-disubstituted IMP  using 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and 2-(N'-aryl)picolinohydrazonamides 
that undergoes cyclization after dehydration (Scheme 22). The reaction began with the 
development of  2-(N'-aryl)picolinohydrazonamide from ethyl glycinate and 2-pyridyl 
methyl amine using hydrazonoyl chlorides.  After the formation of 2-(N'-
aryl)picolinohydrazonamides, DDQ initiated dehydration and cyclization . Results shows 
moderate yield in a two-step reaction.   
 
Scheme 22. Synthesis of 1,3-disubstituted IMP  using 2,3-dichloro-5,6-dicyano-1,4-





  2.6.1.3 Multi Component Metal- and Metal Free- Catalyzed Reactions 
 In the previous section, I2 and S8 were shown to act as oxidant to promote 
intramolecular cyclization. Similarly, researchers have provided methods that use metal 
and metal free systems that promote oxidation/dehydration.  In 2007, Chuprakov et al.139 
reported the rhodium-catalyzed synthesis of 1,3-disubstituted IMPs using pyridotriazoles 
and nitriles (Scheme 23).  The group used a three-step synthetic route, which included the 
formation of 3-[4-(trifluoromethyl)phenyl][1,2,3]triazole[1,5-a]pyridine from pyridine-2-
yl[4-(trifluoromethyl)phenyl]methonone and hydrazine hydrate, then MnO2 is added to 
oxidize the amine to afford the triazole group. The final step used the synthesized 3-[4-
(trifluoromethyl)phenyl][1,2,3]triazole[1,5-a]pyridine, Rh2(OAc)4, and substituted nitrile 
to obtain the final product. The synthesis provided a direct synthetic approach to convert 
pyridotriazoles to 1,3-disubstituted IMPs in good yield. 
 
Scheme 23. (A) rhodium-catalyzed synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine 





Kottawar et al.140 reported the synthesis of 1,3-disubstituted IMPs using Lewis 
acid catalyst scandium(II)triflate(ScTf2) (Scheme 24). The reactions used various 
aromatic aldehydes, di-2-pyridyl ketone, and ammonium acetate in ethanol to afford a 
good yield.  
 
Scheme 24. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using Lewis Acid 
catalyst scandium(II)triflate. 
 
Rahmati and Khalesi141 developed a microwave mediated method, in the presence 
of Lewis acid as a catalyst (Scheme 25). The condensation reaction used 2,2-dipyridyl 
ketone, aryl aldehyde, ammonia acetate and various Lewis acids as the catalyst.  They 
initially subjected the reaction under microwave irradiation without the presence of a 
Lewis acid, which showed low yield with very low reaction time (rt) of 2-4 minutes in 
various solvents. Secondly, they subjected the reaction under microwave irradiation with 
various salts and solvents, which presented higher yields and comparable reaction time. 
Finally, the reaction was subjected to microwave irradiation without solvent, which 
presented low yield at comparable reaction time. The results showed that LiCl in acetic 





Scheme 25. Microwave mediated synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine 
using Lewis acid catalyst. 
 
In 2011, Ahmed et al.142-143 reported the synthesis of IMP using molecular I2 and 
potassium ferrocyanide in two separate papers (Scheme 26). Initially, Ahmed et al.143 
used molecular I2 to catalyze the three component reaction that included aromatic 
aldehyde, 1,2-dipyridyl ketone and ammonium acetate.  The reaction was used to 
investigate various Lewis acid catalysts to increase the rate.  In conclusion, Ahmed et al. 
were able to increase the reaction rate to 3 hours at 94% yield using 10 mol% of I2. Later, 
Ahmed et al.142 investigated the use potassium ferrocyanide as a catalyst for IMP. 
Potassium ferrocyanide is a highly stable catalyst, which allowed them to synthesize IMP 
using physical pressure at room temperature.  Results indicated that Ahmed et al. were 
able to produce 90-94% of IMPs in 18 minutes using a pestle and mortar.142-143 
 
Scheme 26. (a) Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using molecular 





In 2013, Pelletier and Charette144 developed a metal free catalyzed mono-
substituted imidazo[1,5-a]azines and mono-substituted imidazo[1,5-a]pyridines using 
triflate anhydride (Scheme 27). The reaction proceeded with N-(2-pyridiylmethyl) 
benzamide with presence of Tf2O and a base additive (2-substituted pyridine). Results 
concluded that high yield is obtainable with the base additive 2-methoxypyridine at a 
reaction time of 16 hours.  
 
Scheme 27. Synthesis of  mono-substituted imidazo[1,5-a]azines and mono-substituted 
imidazo[1,5-a]pyridines using triflate anhydride. 
 
Also in 2013, Yan et al.145 developed a method to synthesis IMP without the use 
of expensive transitional metals as catalyst (Scheme 28). The route proposed by Yan et 
al. was using iodine-catalyzed Csp3 – H amination involving ethyl 2-(pyridine-2-yl) 
acetate and benzylamine. The group initially used I2 as the catalyst in tert-butyl 
hydroperoxide (TBHP) as the oxidant, which shown good yield at a rt of 12 h. Secondly, 
Yan et al. removed the presence of I2 that shown I2 is essential in the oxidant-cyclization 
reaction.  Finally, Yan et al. proceeded to change the iodine source to N-iodosuccinimide 
(NIS), which gave higher yields. Results shown that Yan et al. were able to produce 1,3 





Scheme 28. Synthesis of mono-substituted imidazo[1,5-a]pyridine using iodine-catalyzed 
Csp3 – H amination involving ethyl 2-(pyridine-2-yl) acetate and benzylamine. 
 
 
In 2014, Shi et al.146 reported the synthesis of 1,3-disubstituted imidazo[1,5-
a]pyridine using rhodium as a catalyst and pyridotriazoles and nitriles (Scheme 29). That 
required activating groups, Cl, Br, and OMe at carbon 7, also required an electron 
withdrawing group at carbon 3. In this synthesis, they were able to use amides with 
pyridotriazoles to produce the IMP product in two steps.  Initially, they subjected the 
pyridotriazoles with any of the amines derivatives and rhodium catalyst in dichloroethane 
(DCE), which produce picolylamine derivatives. After synthesizing the picolyamine 
derivative, cyclization is then promoted through the introduction of 4-toluensulfonic acid. 






Scheme 29. Rhodium catalyze synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine. 
 
Li et al.147 reported the synthesis of mono- and disubstituted IMPs using copper 
(Cu) catalyzed to provide a direct intramolecular Csp3-H amination between N-
heteroarenes (Scheme 30). The reaction involved the introduction 2-acylpyridines and 
aliphatic amines with Cu(I) salts in presence of O2. Results shown by Li et al. displayed 
the development of a one pot synthesis of mono-substituted IMP by employing a copper 
catalyst under oxidizing conditions.  
 






Wang et al.148 developed a method employing Cu as the catalyst for the synthesis 
of 1,3-disubstituted IMP (Scheme 31). The reaction included pyridine ketone and 
benzylamine under aerobic conditions. Initially, they decided to investigate which 
transitional metal would serve as an efficient catalyst. The group found out that many 
Lewis acids gave desired product, but at low yields, however they found copper(II) 
acetate Monohydrate to be an efficient catalyst producing high yields in air.    
 
Scheme 31. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine with pyridine ketone 
and benzylamine.  
 
Xie et al.149 reported the synthesis of 1,3-disubstituted IMP via Csp3-H amination 
using benzyl substituted N-heterocycles, aldehydes, and azidotrimethylsilane (TMSN3) 
(Scheme 32). Xie et al. first investigated the reaction conditions by changing acid 
additive between pivalic acid, trifluoroacetic acid, p-toluensulfonic acid, and 
trifluoromethanesulfonic acid, which concluded that pivalic acid only provided sufficient 
yield. Next, Xie et al. optimized the salt and solvent condition showing that o-
dichlorobenzene (DCB) and Cu(TFA)2 H2O to be the most efficient conditions for this 






Scheme 32. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using N-heterocycles, 
aldehydes, and azidotrimethylsilane. 
 
Wang et al.150 reported the synthesis of 1,3-disubstituted IMP containing alkyl 
groups (Scheme 33). From the group previous report, they reported an efficient copper 
catalyzed synthesis of 1,3-diaryl substituted IMP, but lack good yield of alkyl substituted 
IMP. Currently, Wang et al. developed a method that efficiently produced 1,3-diaryl-or1-
alkyl-3-aryl substituted IMPs. The group initially used leucine and 2-benzoylpyridine 
under different oxidative and catalyst conditions. Wang et al. concluded that di-tert-butyl 
peroxide (DTBP) and Cu(OTf2) with iodine as a co-catalyst to be the best condition. 
Results shown that this method produces good yields of 1,3-disubstituted IMP at 66-93%.   
 
Scheme 33. Copper Catalyzed-Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine 




Following the Wang et al. method, Joshi et al.151 developed a copper catalyzed 
denitrogenative transannulation reaction of pyridotriazoles using both amino acids and 
benzylamine to produce 1,3-disubstituted IMPs (Scheme 34). Joshi et al. study involved 
the optimization of copper source, solvent and reaction time. Joshi et al. concluded that 
CuI and dichlorobenzene at 6 h were the optimal condition. Results shows that they were 
able to afford various derivatives of 1,3-disubstituted IMP at 26-95% isolated yield.  
 
Scheme 34. Copper iodine Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using 
pyridotriazoles and amino acids. 
 
Wu et al.152 investigated the iodine-promoted synthesis of 1,3-disubstituted IMP 
without the addition of copper and peroxide oxidants (Scheme 35).  The newly developed 
method includes aryl methyl ketones and (pyridin-2-yl)methylamines to produce the IMP 
skeleton. The investigation presented by Wu et al. confirmed dual Csp3-iodination process 
which helps facilitate the condensation between aryl methyl ketone and (pyridine-2-
yl)methylamines. The optimization of the method involved changes in the type of acid 
and amount of Iodine and pyridine-2ylmethylamine. Results have shown desired 





Scheme 35. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using aryl ketones and 
(pyridin-2-yl)methylamines with iodine. 
 
Most recently, Joshi et al.153 developed a method synthesizing 1,3-disubstituted 
IMPs using a metal free catalyzed system (Scheme 36). The metal free catalyzed system 
incorporates a Lewis acid system, BF3/Et2O. The transannulation process involves 
pyridotriazoles and nitriles to produce the desired products. The optimization of the 
condition afforded to a mixture of 1,2-dichlorobenzene (DCB) and dichloroethane (DCE) 
(0.2 to 0.25, respectively). The method produced high yield multiple 1,3-disubstituted 
IMP with yields 60-99%.  
 
Scheme 36. Tranannulation Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using 





Nguyen et al.154 reported the synthesis 1,3 –disubstituted IMP using 
heterogeneous catalyst Cu-MOF-74 (Scheme 37). The methods proceeds through the 
condensation–cyclization reaction between 2-benzoyl pyridine and different 
benzylamines via oxidative amination of the C(sp3)–H bond to form 1,3-diarylated 
imidazo[1,5-a]pyridines using air as the oxidant. Nguyen et al. concluded that Cu-MOF-
74 exhibits better catalytic activity for the transformation than other MOFs including 
Cu(BDC), Cu2(BDC)2(DABCO), Cu3(BTC)2, Cu2(BPDC)2(BPY), Cu(OBA), 
Cu2(OBA)2(BPY), and Cu(INA)2. The alternative benefit to using Cu-MOF-74 is 
recyclability. Results have shown that a heterogeneous catalyst produces 1,3-
diarylsubstituted IMP at 53-73% yield. 
 
 
Scheme 37. Synthesis of 1,3-disubstituted imidazo[1,5-a]pyridine using Heterogeneous 
Catalyst Cu-MOF-74, 2-benzoyl pyridine and benzylamine. 
 
 
Ramesha et al.155 reported iodine mediated synthesis of 3-sulfenylimidazo[1,5-
a]pyridines using dithioesters, 2-methylaminopyridines, and sulfonyl. The reaction 
involved p- toluenesulfonyl hydrazide, phenyl dithioester and 2-methylaminopyridine at 
70 ⁰C to afford 3-sulfenyliimidazo[1,5-a]imidazopyridine. Later, they incorporated 




inducing hydrolysis of sulfur. Results confirmed that they were able to produce mono-
substituted IMP at 73-89% yields hydrazine (Scheme 38).  
 
Scheme 38. Tandem approach, synthesis of synthesis of 3-sulfenylimidazo[1,5-
a]pyridines using dithioesters, 2-methylaminopyridines, and sulfonyl hydrazine.  
 
Inspired by their previous work, Ramesha et al.156 developed a T3P-DMSO 
mediated desulfurative cyclization method for the synthesis on mono-substituted IMPs 
(Scheme 39). The reaction was carried out using dithioesters, 2-methylaminopyridine, 
dimethyl sulfoxide, and T3P as a sulfur scavenger. The conditions of the reaction were 
adjusted by the addition and removal of DMSO and amount T3P, which affected the yield 
tremendously. The subtraction of DMSO led to the reaction not occurring. T3P amount 
wasn’t effective under or increase activity above 1.0 equivalence (eq.). Results indicated 
they were able to produce mono-substituted IMP at 67% to 89%. 
 
Scheme 39. Synthesis of mono-substituted imidazo[1,5-a]pyridine using dithioesters and 




2.7  Objective and Rationale of the Study  
  
Phosphoinositide 3 Kinase inhibitors (PI3Ki) have been important in an alternative 
therapy for mCR PCa. Current PI3Ki have serious limitations resulting from poor 
biodistribution, including ineffectively low concentrations in solid tumors and off-target 
toxicity, which is hampering clinical progress. To address this problem, we designed PI3Ki 
with selectivity to PI3Kβ/δ and increased solubility in aqueous media. We have equipped 
these PI3Ki with an ethyl glycol (-OCH2CH2OH) unit assist with further functionalization 
and solubility. We have also produced 4,5,6,7-tetrahydroimidazopyridines that have 
displayed increased potency to prostate cellular lines. The resulting compounds have shown 
excellent anticancer activity, minimal toxicity (in vitro), PI3K/Akt pathway activity and 
binding affinity to PI3Kβ. 
 2.7.1  IMPs for CRPCa  
  
 Muniyan et al.97 investigated the initial series of IMPs for CR PCa. We have 
synthesized IMP compounds that target prostate tumors by targeting the PI3K/Akt 
pathway. The newly synthesized shows anticancer activity against hormone independent 
(AR-) DU145 prostate cancer, and even more so against hormone dependent (AR+) 
LNCaP with little to none toxicity to normal PCa cells RWPE1. These newly synthesized 
IMPs show halt to AR transcriptional activity at low molar concentrations. They inhibit 
key isoforms of PI3K with low nanomolar potency. Once PCa progresses to the 
castration-resistant stage, existing androgen deprivation therapies including the pan-PI3K 
inhibitor LY29004 displays toxicity to normal cells for the none specificity to PI3K 




from AR signaling. Numerous factors are causative for transcriptional activity of AR, 
including mutations in the PI3K/Akt pathway where PTEN loss involves the 
overexpression of AR activity. Therefore, there is an urgent need to develop isoform 
specific PI3K therapeutics that target CR PCa.   
 The novel strategy was to explore different substituted groups on the phenyl rings 
attached to the imidazopyridine moiety against PCa cell lines, also investigate reduced 
imidazopyridine moiety in comparison to unreduced imidazopyridine moiety against PCa 
cell lines. The ATP binding pocket of the different PI3K isoforms is the drugs target, 
which will help create ATP competitive inhibitor that prevents hyperphosphorylation of 
PIP3. The ATP binding is located in the catalytic domain of the PI3Ks which is essential 
for the kinase activity. Thus, targeting ATP binding pocket provides the potential for 
inhibiting not only wild-type PI3K but also clinically relevant mutant forms of PI3K. 
Although the developed lead compound needs further preclinical assessment, it has 
already demonstrated prospective therapeutic for advanced and castration resistant PCa.  
2.8  Thesis Layout  
 
Chapter II provided the background information on PCa, structure, and function 
of PI3K/Akt pathway, and review of the synthesis of IMPs. Chapter 3 presents materials 
and methods applied in the current work. Chapter IV and V summarize results of the 
research project aimed to the development and investigation novel IMPs as potential 








3.1  Materials 
 
 Reactions were carried out in a closed or open system with nitrogen or air 
atmosphere. All the chemicals were used as received. Palladium on activated carbon 
(10%) from Aldrich was used as the catalyst. KI from Sigma Aldrich was used as a 
catalyst. Melting points were obtained in open capillary tubes with Barnstead 
Electrothermal Mel-Temp 1201D melting point apparatus and are uncorrected. 1H NMR 
(500 and 400 MHz), and 13C NMR (126 and 101 MHz) spectra were recorded with TMS 
as an internal reference on Bruker Ultrashield 500 and 400 plus, respectively. Deuterated 
solvents DMSO-d6 and CDCl3 were used for NMR. Infrared (IR) Spectra were run on 
Bruker Alpha FT-IR spectrometer in the solid state. TLC was carried out using Sorbent 
Technologies pre-coated silica or alumina neutral gel plates with UV 254 indicator. The 
TLC plates were visualized using Spectroline Longlife Filter with short (254 nm) and 
long (365 nm) UV wavelength. X-ray Crystallography was performed by the X-ray 
Crystallography Center at Clemson University, Clemson, SC. For the MTS assay 
Promega CellTiter 96® AQueous One Solution Reagent was used. The cells were counted 




3.2  Synthesis of IMPs 
 
 3.2.1  General Method 1A: Williamson Etherification of Substituted 
 Hydroxybenzaldehydes  
 
A mixture of hydroxybenzaldehyde (1m mol), potassium carbonate powder (2.25 
mmol), potassium iodide (0.05 mmol), and tetra-butyl ammonium bromide (TBAB) (0.5 
mmol) in DMSO, was heated to 110-119 °C while vigorously stirring. Afterwards, 2-
chloroethanol (1.5 mmol) was added after solution stirred for 1 hour. Then the reaction 
mixture was heated to reflux for 3 - 5 hours while stirring continuously. The completion 
of the reaction was monitored by thin layer chromatography. (ethyl acetate, hexane, and 
ethanol). The unreacted potassium carbonate salt was filtered off via gravity filtration 
afterwards, and the reaction mixture was poured in ice cold DI water. Then the aqueous 
layer was extracted with dichloromethane (DCM), 3 times. The DCM layer, containing 
the product, was washed five times with cold DI water and then twice with saturated 
sodium chloride solution. The DCM was removed under vacuum pressure, which 
afforded pure product. 
 4-(2-hydroxyethoxy)benzaldehyde (64): Compound 64 157(92%) was obtained 
as a viscous yellow oil.; 1H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 7.89-7.82 (m, 2H), 
7.13 (dd, J =  9.1, 2.3 Hz, 2H), 4.93 (t, J =  5.5 Hz, 1H), 4.13-4.07 (m, 2H), 3.75 (dd, J =  
10.2, 5.1 Hz,  2H). 13C NMR (101 MHz, DMSO) δ 191.95, 164.20, 132.32, 129.94, 
115.41, 70.39, 59.71.  
 2-(2-hydroxyethoxy)benzaldehyde (65): Compound 65158 (89 %)was obtained 




1.8 Hz, 1H), 7.65-7.60 (m, 1H), 7.22 (d, J =  8.4 Hz, 1H), 7.07 (dd, J = 10.9, 4.1 Hz,  
1H), 4.96 (t, J =  5.8,  1H), 4.17-4.12 (m, 2H) 3.78 (td, J =  5.6, 3.4 Hz,  2H). 13C NMR 
(101 MHz, DMSO) δ 190.50, 161.66, 136.93, 127.85, 124.80, 121.15, 114.13, 70.87, 
59.80.  
 3-(2-hydroxyethoxy)benzaldehyde (66): Compound 66157 (87 %)was obtained 
as a viscous brown oil.; 1H NMR (400 MHz, DMSO) δ 9.97 (s, 1H), 7.53-7.48 (m, 2H), 
7.42 (s, 1H), 7.28 (ddd, J =  10.0, 3.2, 1.7 Hz, 1H), 4.91 (t, J =  5.5 Hz, 1H), 4.06 (t, 2H), 
3.75 (q, 2H). 13C NMR (101 MHz, DMSO) δ 193.85, 159.51, 137.87, 130.88, 122.92, 
121.95, 114.13, 70.04, 59.80.  
 5-chloro-2-(2-hydroxyethoxy)benzaldehyde (67): Compound 67 (92 %)was 
obtained as a light yellow oil.; 1H NMR (400 MHz, DMSO) δ 10.37 (s, 1H), 7.65 (dd, J = 
8.9, 2.8 Hz, 1H), 7.58 (d, J = 2.8 Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 4.15 (t, 2H), 3.77 (t, 
2H).13C NMR (101 MHz, DMSO) δ 189.13, 160.34, 135.99, 126.87, 125.94, 125.37, 
116.62, 71.56, 59.85. 
 5-bromo-2-(2-hydroxyethoxy)benzaldehyde (68): Compound 68158 (89 %)was 
obtained as a light brown oil.; 1H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 7.84 (d, J = 
2.7 Hz, 1H), 7.58 (dd, J = 8.9 Hz, 1H), 6.87 (d, J =  8.8 Hz, 1H), 4.16 (t, J =  4.5 Hz, 2H), 
4.00 (t, J = 4.3 Hz, 2H), 3.56 (s, 1H). 13C NMR (101 MHz, DMSO) δ 190.50, 161.66, 
136.93, 127.85, 124.80, 121.15, 114.13, 70.87, 59.80.  
 2-(2-hydroxyethoxy)-4-methoxybenzaldehyde (69): Compound 69158 (87 %) 
was obtained as a brown viscous oil.; 1H NMR (400 MHz, DMSO) δ 10.27 (s, J = 2.1, 




1.4 Hz, 1H), 4.96 (s, 1H), 4.48 (s, 1H), 4.14 (td, J = 4.8, 1.7 Hz, 2H), 3.85 (s, 3H), 3.77 
(dd, J = 6.8, 2.7 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 188.27, 166.41, 163.64, 129.72, 
118.83, 107.44, 99.45, 71.08, 65.44, 59.89, 56.25, 40.01. 
 3.2.2  General Method 1B: Williamson Etherification of Substituted IMPs  
A mixture of substituted hydroxyl imidazo[1,5-a]pyridine (1mmol), potassium 
carbonate powder (2.25 mmol), potassium iodide (0.05 mmol), and tetra-butyl 
ammonium bromide (TBAB) (0.5 mmol) in DMSO, was heated to 110-119 °C while 
vigorously stirring. Afterwards, 2-chloroethanol (1.5 mmol) was added to the solution 
after 1 hour. Then the reaction mixture was heated to reflux for 5 - 8 hours while stirring 
continuously. The completion of the reaction was monitored by thin layer 
chromatography (ethyl acetate, hexane, and ethanol). The unreacted potassium carbonate 
salt was filtered off via gravity filtration afterwards, and the reaction mixture was poured 
in ice cold DI water. Then the aqueous layer was extracted with dichloromethane (DCM), 
3 times. The DCM layer, containing the product, was washed five times with cold DI 
water and then twice with saturated sodium chloride solution. The DCM was removed 
under reduced pressure, which afforded pure product. 
 2-(2-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol (70): 
Recrystallization (ethanol) afforded compound 70 (95 %) as a yellow crystal. mp 144-
148 °C; 1H NMR (400 MHz, DMSO) δ 8.63 – 8.56 (m, 2H), 8.10 (dt, J = 8.1, 1.1 Hz, 
1H), 7.84 – 7.77 (m, 2H), 7.63 – 7.53 (m, 2H), 7.29 (d, J = 8.5 Hz, 1H), 7.21 – 7.15 (m, 
2H), 7.07 (dddd, J = 9.2, 6.4, 2.8, 1.0 Hz, 1H), 6.78 (dddd, J = 6.4, 5.2, 3.2, 1.7 Hz, 1H), 




DMSO) δ 170.48, 162.07, 156.45, 155.22, 149.52, 136.95, 132.88, 131.58, 131.56, 
129.81, 129.46, 124.60, 122.17, 121.72, 120.84, 120.65, 119.41, 113.39, 113.29, 66.67, 
62.71, 20.94. FTIR.  
 2-(3-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol (71): 
Recrystallization (ethanol) afforded compound 71 (92 %) as a yellow crystal. mp 154-
156 °C; 1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 9.2 Hz, 2H), 8.64 (d, J = 4.9 Hz, 2H), 
8.25 (d, J = 6.8 Hz, 4H), 7.73 (td, J = 7.7, 2.0 Hz, 2H), 7.46 – 7.37 (m, 6H), 7.11 (ddd, J 
= 7.8, 4.9, 1.5 Hz, 2H), 6.99 (dt, J = 7.5, 2.3 Hz, 2H), 6.92 (dd, J = 9.3, 6.3 Hz, 2H), 6.64 
(t, J = 6.8 Hz, 2H), 4.77 (s, J = 1.6 Hz, 1H), 4.17 – 4.12 (m, 4H), 3.96 (t, J = 4.6 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 159.23, 154.87, 149.00, 137.76, 136.31, 131.26, 130.49, 
130.27, 130.10, 121.79, 121.72, 121.15, 120.76, 120.54, 120.00, 115.47, 114.64, 114.03, 
69.46, 61.14.  FTIR.  
 2-(4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol (72): 
Recrystallization (ethanol) afforded compound 72 (96 %) as a yellow crystal. mp 172-
174 °C; 1H NMR (400 MHz, DMSO) δ 8.60 (d, J = 11.1 Hz, 2H), 8.40 (d, J = 7.2 Hz, 
1H), 8.13 (d, J = 8.0 Hz, 1H), 7.91 – 7.71 (m, 3H), 7.23 – 7.12 (m, 3H), 7.04 (t, J = 7.8 
Hz, 1H), 6.81 (t, J = 5.9 Hz, 1H), 4.94 (td, J = 5.6, 2.2 Hz, 1H), 4.09 (td, J = 5.0, 2.3 Hz, 
2H), 3.77 (qd, J = 5.2, 2.3 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 159.61, 155.09, 
149.51, 138.01, 136.97, 130.05, 129.84, 129.48, 122.91, 122.35, 122.07, 121.23, 120.93, 




 3.2.3  General Method 2A: Synthesis using 2-benzoylpyridine under 
 Microwave Conditions   
A mixture consisting of 2-benzoylpyridine (1 mmol), substituted benzaldehyde 
(1.2 mmol), ammonium formate (4 mmol) in 25 ml glacial acetic acid at 210 W. After 40 
minutes, the reaction mixture was cooled to room temperature and poured into 250 mL of 
ice water. The formed solid was then filtered, dried, and recrystallized with appropriate 
solvents. If there no solid formed, the mixture was extracted with CH2Cl2 and washed 
with brine and then water. The organic layer was separated and dried over Na2SO4. Upon 
the removal of solvent, the residue was recrystallized in appropriate solvents, then dried 
to afford pure compound. 
 1,3-diphenylimidazo[1,5-a]pyridine (73): Recrystallization (ethanol) afforded 
compound 73 (90 %) as a yellow crystal. mp 132-133 °C; 1H NMR (400 MHz, DMSO) δ 
8.48 (d, J = 7.2 Hz, 1H), 8.02 (d, J = 9.3 Hz, 1H), 7.96 (dd, J = 8.3, 1.3 Hz, 2H), 7.90 
(dd, J = 8.3, 1.3 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.54 – 7.45 (m, 3H), 7.30 (t, J = 7.3 
Hz, 1H), 6.98 (dd, J = 9.3, 6.4 Hz, 1H), 6.79 (t, J = 6.8 Hz, 1H). 13C NMR (101 MHz, 
DMSO) δ 154.88, 149.54, 137.01, 131.35, 130.80, 129.87, 124.73, 123.27, 122.31, 
120.99, 119.50, 118.86, 118.32, 116.98, 113.71. 
 3-(2-methoxyphenyl)-1-phenylimidazo[1,5-a]pyridine (74): Recrystallization 
(ethanol) afforded compound 74 (88 %) as a yellow crystal. mp 112-114 °C; 1H NMR 
(400 MHz, CDCl3) δ 7.99 (dd, J = 8.4, 1.3 Hz, 2H), 7.88 (dt, J = 9.3, 1.3 Hz, 1H), 7.71 
(dd, J = 7.5, 1.8 Hz, 1H), 7.62 (dt, J = 7.2, 1.1 Hz, 1H), 7.52 – 7.44 (m, 3H), 7.33 – 7.28 
(m, 1H), 7.16 (td, J = 7.6, 1.1 Hz, 1H), 7.08 (dd, J = 8.3, 1.1 Hz, 1H), 6.83 (ddd, J = 9.2, 




157.45, 136.19, 135.26, 132.86, 131.51, 130.82, 128.81, 128.61, 127.43, 126.94, 126.74, 
126.23, 123.54, 121.26, 119.46, 118.62, 111.97, 111.20, 55.58. 
 3-(3-methoxyphenyl)-1-phenylimidazo[1,5-a]pyridine (75): Recrystallization 
(ethanol) afforded compound 75 (88 %) as a yellow crystal. mp 128-129 °C; 1H NMR 
(400 MHz, DMSO) δ 8.60 (d, J = 9.2 Hz, 2H), 8.10 (d, J = 8.1 Hz, 1H), 7.80 (t, J = 7.7 
Hz, 1H), 7.76 (d, J = 7.2 Hz, 1H), 7.62 – 7.54 (m, 2H), 7.27 (d, J = 9.0 Hz, 1H), 7.17 (dd, 
J = 14.5, 7.3 Hz, 2H), 7.07 (dd, J = 9.5, 6.2 Hz, 1H), 6.79 (t, J = 7.5 Hz, 1H), 3.82 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 138.89, 138.32, 135.02, 131.94, 130.07, 129.62, 
129.24, 128.78, 128.69, 127.61, 126.83, 126.48, 125.10, 121.89, 119.58, 119.13, 113.09, 
21.49. 
 3-(4-methoxyphenyl)-1-phenylimidazo[1,5-a]pyridine (76): Recrystallization 
(ethanol) afforded compound 76 (85 %) as a yellow crystal. mp 118-119 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.71 (d, J = 9.3 Hz, 1H), 8.65 (d, J = 4.7 Hz, 1H), 8.26 (d, J = 8.0 
Hz, 1H), 8.20 (d, J = 7.3 Hz, 1H), 7.78 (d, J = 8.7 Hz, 2H), 7.74 (td, J = 7.7, 2.0 Hz, 1H), 
7.13 – 7.07 (m, 3H), 6.92 (dd, J = 9.3, 6.1 Hz, 1H), 6.65 (t, J = 6.8 Hz, 1H), 3.91 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.44, 136.20, 135.26, 132.87, 131.50, 130.85, 128.63, 
127.44, 126.75, 123.56, 121.26, 119.50, 118.63, 112.00, 111.18, 55.59. 
 1-pheny-3-(o-tolyl)-limidazo[1,5-a]pyridine (77): Recrystallization (ethanol) 
afforded compound 77 (91 %) as a yellow crystal. mp 113-115 °C; 1H NMR (400 MHz, 
DMSO) δ 8.42 (d, J = 7.2 Hz, 1H), 7.95 (dd, J = 9.2, 7.9 Hz, 3H), 7.77 (dd, J = 8.1, 1.8 
Hz, 2H), 7.47 (t, J = 6.9 Hz, 2H), 7.39 (d, J = 7.1 Hz, 2H), 7.28 (t, J = 7.4 Hz, 1H), 6.95 




155.03, 149.52, 138.90, 138.03, 137.00, 130.03, 129.66, 128.43, 127.24, 122.99, 122.24, 
121.25, 121.01, 119.57, 117.43, 116.90, 114.69, 21.42. 
 1-pheny-3-(m-tolyl)-limidazo[1,5-a]pyridine (78): Recrystallization (ethanol) 
afforded compound 78 (88 %) as a yellow crystal. mp 128-129 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.26 (dd, J = 7.3, 1.0 Hz, 1H), 7.98 – 7.95 (m, 2H), 7.86 (dd, J = 9.3, 1.1 Hz, 
1H), 7.70 (s, 1H), 7.64 (d, J = 6.6 Hz, 1H), 7.49 (t, J = 7.8 Hz, 2H), 7.44 (t, J = 7.6 Hz, 
1H), 7.34 – 7.28 (m, 2H), 6.80 (ddd, J = 9.3, 6.3, 0.9 Hz, 1H), 6.59 (t, J = 6.8 Hz, 1H), 
2.48 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 138.89, 138.32, 135.02, 131.94, 130.07, 
129.62, 129.24, 128.78, 128.69, 127.61, 126.82, 126.48, 125.10, 121.89, 119.58, 119.13, 
113.09, 21.49. 
 1-pheny-3-(p-tolyl)-limidazo[1,5-a]pyridine (79): Recrystallization (ethanol) 
afforded compound 79 (90 %) as a yellow crystal. mp 132-133 °C; 1H NMR (400 MHz, 
DMSO) δ 8.65 – 8.57 (m, 2H), 8.46 (dt, J = 7.2, 1.0 Hz, 1H), 8.14 (dt, J = 8.0, 1.0 Hz, 
1H), 7.85 – 7.76 (m, 3H), 7.41 (dd, J = 7.8, 0.7 Hz, 2H), 7.20 (ddd, J = 7.5, 4.9, 1.2 Hz, 
1H), 7.06 (ddd, J = 9.2, 6.4, 0.9 Hz, 1H), 6.84 (ddd, J = 7.2, 6.4, 1.3 Hz, 1H), 2.42 (s, J = 
1.9 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 155.03, 149.52, 138.90, 138.03, 137.00, 
130.03, 129.66, 128.43, 127.24, 122.99, 122.24, 121.25, 121.01, 119.57, 114.69, 21.42. 
 2-(1-phenylimidazo[1,5-a]pyridine-3-yl)phenol (80): Recrystallization (ethanol) 
afforded compound 80 (94 %) as a yellow crystal. mp 183-185 °C; 1H NMR (500 MHz, 
DMSO) δ 9.88 (s, J = 2.9 Hz, 2H), 8.35 (dt, J = 7.2, 1.1 Hz, 2H), 7.95 (dd, J = 14.6, 8.2 
Hz, 7H), 7.68 (d, J = 8.7 Hz, 4H), 7.46 (dd, J = 8.3, 7.4 Hz, 4H), 7.28 (t, J = 7.3 Hz, 2H), 




= 2.7 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.47, 141.68, 138.32, 135.36, 130.28, 
130.04, 129.16, 127.26, 126.51, 126.37, 122.85, 121.45, 120.95, 120.85, 119.01, 116.24, 
113.79. 
 3-(1-phenylimidazo[1,5-a]pyridine-3-yl)phenol (81): Recrystallization (ethanol) 
afforded compound 81 (92 %) as a yellow crystal. mp 190-191 °C; 1H NMR (500 MHz, 
DMSO) δ 9.74 (s, 1H), 8.44 (d, 1H), 7.99 (d, 1H), 7.94 (d, J = 7.5 Hz, 2H), 7.49 (t, 2H), 
7.39 (t, J = 7.8 Hz, 1H), 7.32 – 7.25 (m, 3H), 6.98 – 6.89 (m, 2H), 6.82 – 6.75 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 148.60, 137.18, 133.03, 131.00, 130.02, 128.85, 128.23, 
127.43, 127.10, 126.89, 126.27, 124.72, 122.06, 119.03, 117.16, 116.61, 113.71. 
 4-(1-phenylimidazo[1,5-a]pyridine-3-yl)phenol (82): Recrystallization (ethanol) 
afforded compound 82 (95 %) as a yellow crystal. mp 187-188 °C; 1H NMR (500 MHz, 
DMSO) δ 9.89 (s, J = 9.5 Hz, 1H), 8.35 (d, J = 7.3 Hz, 1H), 7.96 (d, J = 9.3 Hz, 1H), 
7.93 (dd, J = 8.2, 1.4 Hz, 2H), 7.68 (d, J = 8.5 Hz, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.28 (t, J 
= 7.4 Hz, 1H), 6.99 – 6.96 (m, 2H), 6.91 (ddd, J = 9.3, 6.4, 1.2 Hz, 1H), 6.73 (ddd, J = 
7.3, 6.3, 1.2 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 158.61, 155.15, 149.54, 138.46, 
137.01, 130.17, 129.72, 129.32, 122.95, 121.22, 120.91, 120.79, 119.53, 116.29, 114.46. 
 3-(4-bromophenyl)-1-phenylimidazo[1,5-a]pyridine (83): Recrystallization 
(ethanol) afforded compound 83 (98 %) as a yellow crystal. mp 188-189 °C; 1H NMR 
(400 MHz, DMSO) δ 8.47 (d, J = 7.2 Hz, 1H), 8.00 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 6.9 
Hz, 2H), 7.85 (d, J = 8.6 Hz, 2H), 7.75 (d, J = 8.5 Hz, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.28 




MHz, DMSO) δ 161.37, 136.95, 135.11, 130.80, 130.72, 129.19, 127.76, 126.75, 126.46, 
122.85, 121.34, 119.02, 116.57, 116.36, 114.23. 
 3-(4-chlorophenyl)-1-phenylimidazo[1,5-a]pyridine (84): Recrystallization 
(ethanol) afforded compound 84 (95 %) as a yellow crystal. mp 181-182 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.75 (dt, J = 9.3, 1.4 Hz, 1H), 8.66 (dd, J = 6.1, 1.7 Hz, 1H), 8.24 
(ddt, J = 11.8, 7.3, 1.3 Hz, 2H), 7.82 (d, J = 8.5 Hz, 2H), 7.75 (td, J = 7.7, 1.9 Hz, 1H), 
7.55 (d, J = 8.5 Hz, 2H), 7.13 (ddd, J = 7.6, 4.9, 1.4 Hz, 1H), 6.96 (ddd, J = 9.3, 6.5, 1.2 
Hz, 1H), 6.70 (ddd, J = 7.6, 6.3, 1.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 158.61, 
155.15, 149.54, 138.46, 137.01, 130.17, 129.72, 129.32, 122.95, 121.99, 121.22, 120.91, 
119.53, 116.29, 114.46. 
 3-(4-fluorophenyl)-1-phenylimidazo[1,5-a]pyridine (85): Recrystallization 
(ethanol) afforded compound 85 (92 %) as a yellow crystal. mp 167-169 °C; 1H NMR 
(400 MHz, DMSO) δ 8.42 (d, 1H), 8.00 (d, 1H), 7.97 – 7.89 (m, 4H), 7.51 – 7.38 (m, J = 
21.5 Hz, 4H), 7.29 (t, 1H), 7.00 – 6.93 (m, 1H), 6.78 (t, 1H). 13C NMR (101 MHz, 
DMSO) δ 163.82, 161.37, 136.95, 135.11, 130.81, 129.19, 127.76, 126.78, 126.71, 
126.46, 122.85, 121.34, 119.02, 116.57, 114.23. 
 3-(2-nitrophenyl)-1-phenylimidazo[1,5-a]pyridine (86): Recrystallization 
(ethanol) afforded compound 86 (92 %) as a red crystal. mp 189-192 °C; 1H NMR (400 
MHz, CDCl3) δ 8.22 (dd, J = 7.8, 1.2 Hz, 1H), 8.08 (dd, J = 9.3, 8.0 Hz, 2H), 7.93 – 7.90 
(m, 2H), 7.80 (dd, J = 4.8, 2.1 Hz, 2H), 7.71 – 7.67 (m, 1H), 7.58 – 7.54 (m, 1H), 7.46 (d, 
J = 6.3 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 6.89 (dd, J = 9.3, 6.4 Hz, 1H), 6.62 (ddd, J = 




131.74, 131.19, 129.28, 128.47, 127.03, 126.60, 123.32, 123.02, 122.72, 122.14, 119.02, 
114.05. 
 3-(3-nitrophenyl)-1-phenylimidazo[1,5-a]pyridine (87): Recrystallization 
(ethanol) afforded compound 87 (94 %) as an orange crystal. mp 168-169 °C; 1H NMR 
(400 MHz, DMSO) δ 8.66 (d, J = 2.0 Hz, 2H), 8.60 (d, J = 7.1 Hz, 2H), 8.36 (d, J = 7.8 
Hz, 2H), 8.30 (dd, J = 10.7, 2.4 Hz, 2H), 8.04 (d, J = 9.3 Hz, 2H), 7.96 (d, J = 8.3 Hz, 
4H), 7.85 (t, J = 8.1 Hz, 2H), 7.48 (t, J = 7.8 Hz, 4H), 7.31 (dd, J = 11.2, 4.9 Hz, 2H), 
7.07 – 7.01 (m, 2H), 6.89 – 6.85 (m, 2H). 13C NMR (101 MHz, DMSO) δ 148.75, 
135.56, 134.80, 134.07, 131.69, 131.63, 131.09, 129.23, 128.53, 126.97, 126.60, 123.34, 
123.06, 122.83, 122.01, 119.12, 114.85. 
 3-(4-nitrophenyl)-1-phenylimidazo[1,5-a]pyridine (88): Recrystallization 
(ethanol) afforded compound 88 (95 %) as a dark red crystal. mp 201-202 °C; 1H NMR 
(400 MHz, DMSO) δ 8.69 (dt, J = 7.3, 1.1 Hz, 3H), 8.40 – 8.34 (m, 6H), 8.26 – 8.19 (m, 
6H), 8.08 (dt, J = 9.3, 1.2 Hz, 3H), 7.97 (dd, J = 8.5, 1.3 Hz, 6H), 7.50 (t, J = 7.8 Hz, 
6H), 7.36 – 7.28 (m, 3H), 7.09 (ddd, J = 9.3, 6.4, 1.0 Hz, 3H), 6.92 (ddd, J = 7.4, 6.5, 1.3 
Hz, 3H). 13C NMR (101 MHz, DMSO) δ 146.86, 136.28, 135.61, 134.63, 132.43, 129.26, 
129.20, 128.66, 127.17, 126.71, 124.67, 123.50, 122.55, 119.23, 115.25. 
 3-(4-isopropylphenyl)-1-phenylimidazo[1,5-a]pyridine (89): Recrystallization 
(ethanol) afforded compound 89 (95 %) as a yellow crystal. mp 158-160 °C; 1H NMR 
(500 MHz, DMSO) δ 8.44 (dt, J = 7.3, 1.2 Hz, 1H), 8.00 (dd, J = 5.2, 4.1 Hz, 1H), 7.95 
(dd, J = 8.3, 1.2 Hz, 2H), 7.80 (d, J = 8.2 Hz, 2H), 7.47 (t, J = 7.8 Hz, 2H), 7.43 (d, J = 




1H), 2.78 – 2.65 (m, 3H), 1.25 (d, J = 7.6 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 
144.97, 137.94, 135.23, 130.70, 129.19, 128.86, 128.85, 128.42, 127.67, 126.65, 126.44, 
122.94, 121.20, 119.05, 114.09, 28.51, 15.95 
 3-(4-ethylphenyl)-1-phenylimidazo[1,5-a]pyridine (90): Recrystallization 
(ethanol) afforded compound 90 (96 %) as a yellow crystal. mp 92-94 °C; 1H NMR (400 
MHz, DMSO) δ 8.03 – 7.81 (m, 4H), 7.47 (t, J = 7.8 Hz, 2H), 7.28 (t, J = 7.4 Hz, 1H), 
7.13 (dd, J = 15.3, 7.9 Hz, 2H), 6.94 (ddd, J = 18.7, 12.0, 7.1 Hz, 2H), 6.74 (t, J = 6.8 Hz, 
1H), 4.14 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 
147.85, 136.72, 135.33, 129.93, 129.19, 127.20, 126.48, 126.31, 124.76, 123.18, 121.03, 
118.57, 117.42, 114.26, 112.89, 64.74, 15.14.  
 2-nitro-4-(1-phenylimidazo[1,5-a]pyridin-3-yl)phenol (91): Recrystallization 
(ethanol) afforded compound 91 (89 %) as a dark red crystal. mp 230-231 °C; 1H NMR 
(400 MHz, CDCl3) δ 10.75 (s, 1H), 9.94 (s, 1H), 8.62 (d, J = 16.4 Hz, 2H), 8.23 – 8.10 
(m, 3H), 7.97 – 7.84 (m, 4H), 7.49 (s, 2H), 7.38 – 7.29 (m, 3H), 6.86 (t, 1H), 6.69 (t, 1H). 
13C NMR (101 MHz, CDCl3) δ 188.44, 155.07, 137.53, 136.27, 135.17, 134.52, 133.61, 
132.56, 128.79, 128.03, 126.99, 123.70, 121.22, 120.98, 120.02, 119.40, 114.11. 
 5-ethoxy-2-(1-phenylimidazo[1,5-a]pyridin-3-yl)phenol (92): Recrystallization 
(ethanol) afforded compound 92 (88 %) as a brown crystal. mp 133-135 °C; 1H NMR 
(400 MHz, DMSO) δ 8.03 – 7.85 (m, 5H), 7.47 (t, 2H), 7.28 (t, 1H), 7.18 – 7.08 (m, J = 
7.4 Hz, 2H), 7.00 – 6.88 (m, J = 20.1 Hz, 2H), 6.74 (t, 1H), 4.13 (q, 2H), 1.40 (s, 3H). 13C 




126.31, 125.56 124.76, 123.18, 121.97, 121.03, 118.57, 117.42, 114.26, 112.89, 64.74, 
15.14. 
 5-chloro-2-(1-phenylimidazo[1,5-a]pyridin-3-yl)phenol (93): Recrystallization 
(ethanol) afforded compound 93 (88 %) as a yellow crystal. mp 108-110°C; 1H NMR 
(500 MHz, DMSO) δ 10.69 (s, 1H), 8.01 (dd, J = 9.2, 4.2 Hz, 1H), 7.95 (d, J = 7.5 Hz, 
2H), 7.87 (d, J = 7.2 Hz, 1H), 7.56 (t, J = 2.5 Hz, 1H), 7.47 (t, J = 7.2 Hz, 2H), 7.43 (dd, 
J = 8.8, 2.8 Hz, 1H), 7.29 (ddd, J = 9.0, 3.1, 1.5 Hz, 1H), 7.09 (dd, J = 8.8, 2.7 Hz, 1H), 
7.02 – 6.96 (m, 1H), 6.78 (td, J = 6.2, 3.4 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 
158.47, 138.32, 135.36,132.89, 131.52, 130.28, 130.04, 129.16, 127.26, 126.51, 126.37, 
122.85, 120.95, 120.85, 119.01, 116.24, 113.79. 
 3.2.4  General Method 2B: Synthesis using 2,2′-dipyridyl ketone under  
 Microwave Conditions   
A mixture consisting of 2,2′-dipyridyl ketone (1 mmol), substituted- 
benzaldehyde (1.2 mmol), and ammonium formate (4 mmol) in 25 ml glacial acetic acid 
at 210 W. After 40 minutes, the reaction mixture was cooled to room temperature and 
poured into 250 mL of ice water. The formed solid was then filtered, dried, and 
recrystallized with appropriate mixed solvent. If there was no solid formed, the mixture 
was extracted with CH2Cl2 and washed with brine and then water. The organic layer was 
separated and dried over Na2SO4. Upon the removal of solvent, the residue was 
recrystallized to afford analytically pure compound. 
 2-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenol (94): Recrystallization 
(ethyl acetate/hexane) afforded compound 94 (95%) as a yellow crystal. mp 188-190 °C; 




1H), 7.82 (td, J = 7.7, 1.7 Hz,1H), 7.57 (dd, J = 7.7, 1.6 Hz, 1H), 7.41 (td, J = 8.3, 1.7 Hz, 
1H), 7.12-7.07 (m, 2H), 7.02 (dd, J = 7.3, 6.5 Hz, 1H), 6.84-6.81 (m, 1H). 13C NMR (126 
MHz, DMSO) δ 156.32, 155.54, 149.94, 137.27, 132.47, 131.62, 130.02, 129.58, 124.98, 
123.85, 122.49, 121.25, 121.19, 120.27, 119.80, 117.38, 116.99, 114.41 
 3-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenol (95): Recrystallization 
(ethyl acetate/hexane) afforded compound 95 (97%) as a yellow crystal. mp 251-252 °C; 
1H NMR (500 MHz, CDCl3) δ 8.54 (d, J = 7.4 Hz, 1H), 7.94-7.89 (m, 3H), 7.80 (dd, J = 
7.8, 1.5 Hz, 1H), 7.55-7.50  (m, 2H), 7.40-7.33 (m, 2H), 7.22 (dd, J = 8.2, 1.1 Hz, 1H), 
7.04 (td, J = 7.7, 1.2 Hz, 1H), 6.89 (ddd, J = 9.3, 6.4, 0.8 Hz, 1H), 6.72 (ddd, J = 7.4, 6.4, 
1.2 Hz,  1H). 13C NMR (126 MHz, CDCl3) δ 154.82, 153.78, 149.04, 136.33, 132.15, 
131.83, 131.28, 130.52, 126.60, 124.67, 123.21, 122.06, 121.39, 120.68, 119.99, 
117.81,116.65 114.41 
 4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenol (96): Recrystallization 
(ethyl acetate/hexane) afforded compound 75 (94%) as a yellow crystal. mp 251-252 °C; 
1H NMR (500 MHz, DMSO) δ 9.93 (s, 1H), 8.63-8.57 (m, 2H), 8.39 (d, J = 7.2 Hz, 1H), 
8.13 (dt, J = 8.1, 1.0 Hz, 1H), 7.82 (ddd, J = 8.0, 7.5, 1.8 Hz, 1H), 7.72-7.68 (m, 2H), 
7.19  (ddd, J = 7.4, 4.8, 1.2 Hz, 1H), 7.06-7.01 (m, 1H), 6.82-6.78 (m, 1H). 13C NMR 
(126 MHz, DMSO) δ 158.61, 155.15, 149.54, 138.46, 137.01, 130.17, 129.72, 124.34, 
122.95, 121.99, 121.22, 120.91, 120.79, 119.53, 116.29, 114.46. 
 2-(2-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol (70): 
Recrystallization (ethanol) afforded compound 97 (95 %) as a yellow crystal. mp 144-




1H), 7.84 – 7.77 (m, 2H), 7.63 – 7.53 (m, 2H), 7.29 (d, J = 8.5 Hz, 1H), 7.21 – 7.15 (m, 
2H), 7.07 (dddd, J = 9.2, 6.4, 2.8, 1.0 Hz, 1H), 6.78 (dddd, J = 6.4, 5.2, 3.2, 1.7 Hz, 1H), 
4.36 – 4.23 (m, 3H), 4.16 – 4.13 (m, 1H), 1.85 (s, J = 2.7 Hz, 1H). 13C NMR (101 MHz, 
DMSO) δ 170.48, 162.07, 156.45, 155.22, 149.52, 136.95, 132.88, 131.58, 131.56, 
129.81, 124.60, 122.17, 121.72, 120.84, 120.65, 119.41, 113.39, 113.29, 66.67, 62.71. 
FTIR.  
 2-(3-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol (71): 
Recrystallization (ethanol) afforded compound 71 (92 %) as a yellow crystal. mp 154-
156 °C; 1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 9.2 Hz, 2H), 8.64 (d, J = 4.9 Hz, 2H), 
8.25 (d, J = 6.8 Hz, 4H), 7.73 (td, J = 7.7, 2.0 Hz, 2H), 7.46 – 7.37 (m, 6H), 7.11 (ddd, J 
= 7.8, 4.9, 1.5 Hz, 2H), 6.99 (dt, J = 7.5, 2.3 Hz, 2H), 6.92 (dd, J = 9.3, 6.3 Hz, 2H), 6.64 
(t, J = 6.8 Hz, 2H), 4.77 (s, J = 1.6 Hz, 1H), 4.17 – 4.12 (m, 4H), 3.96 (t, J = 4.6 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 159.23, 154.87, 149.00, 137.76, 136.31, 131.26, 130.49, 
130.27, 130.10, 121.79, 121.72, 121.15, 120.76, 120.54, 120.00, 115.47, 114.64, 114.03, 
69.46, 61.14.  FTIR.  
 2-(4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol (72): 
Recrystallization (ethanol) afforded compound 72 (96 %) as a yellow crystal. mp 172-
174 °C; 1H NMR (400 MHz, DMSO) δ 8.60 (d, J = 11.1 Hz, 2H), 8.40 (d, J = 7.2 Hz, 
1H), 8.13 (d, J = 8.0 Hz, 1H), 7.91 – 7.71 (m, 3H), 7.23 – 7.12 (m, 3H), 7.04 (t, J = 7.8 
Hz, 1H), 6.81 (t, J = 5.9 Hz, 1H), 4.94 (td, J = 5.6, 2.2 Hz, 1H), 4.09 (td, J = 5.0, 2.3 Hz, 




149.51, 138.01, 136.97, 130.05, 129.84, 129.48, 122.91, 122.35, 122.07, 121.23, 120.93, 
119.53, 115.44, 114.55, 70.21, 60.02. FTIR.  
 2-(4-chloro-2-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol 
(97): Recrystallization (ethanol) afforded compound 97 (92 %) as a yellow crystal. mp 
164-165 °C; 1H NMR (400 MHz, DMSO) δ 8.61 – 8.50 (m, 2H), 8.05 (d, J = 8.0 Hz, 
1H), 7.77 (ddd, J = 8.9, 5.6, 1.5 Hz, 2H), 7.59 – 7.51 (m, 2H), 7.28 – 7.21 (m, 1H), 7.18 – 
7.14 (m, 1H), 7.07 (dd, J = 9.2, 6.4 Hz, 1H), 6.77 (dd, J = 9.8, 3.8 Hz, 1H), 4.26 – 4.20 
(m, 2H), 4.07 (dd, J = 11.5, 7.5 Hz, 2H), 1.77 (s, 1H). 13C NMR (101 MHz, DMSO) δ 
170.82, 155.24, 154.63, 149.54, 137.13, 134.78, 131.84, 131.09, 129.99, 129.60, 125.37, 
124.49, 122.57, 121.15, 120.58, 119.58, 115.03, 113.77, 67.07, 62.60. FTIR 
 2-(5-methoxy-2-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenoxy)ethanol 
(98):  Compound 98 (87 %) as a brown viscous oil 1H NMR (500 MHz, CDCl3) δ 8.88 
(d, J = 9.3 Hz, 1H), 8.80 (d, J = 4.4 Hz, 1H), 8.56 (d, J = 8.0 Hz, 1H), 8.03 – 7.96 (m, 
3H), 7.54(d, J = 8.5 Hz, 1H), 7.33 (d, J = 3.9 Hz, 1H), 7.24 (d, J = 7.0 Hz, 1H), 6.88 (t, J 
= 6.8 Hz, 1H), 6.73 - 6.70 (m, 1H), 6.69 – 6.66 (m, 1H), 4.26 – 4.24 (m, 2H), 3.91 (s, 
3H), 3.87 – 3.84 (m, 2H), 3.56 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 171.12, 158.61, 
138.78 136.21, 135.42, 132.29, 126.71, 126.01, 125.32, 123.98, 122.40, 122.99, 121.41, 
121.06, 119.78, 116.88, 115.55, 106.66, 60.67, 55.66, 20.54 
 3.2.5  General Method 3: Reduction of Phenyl-IMPs 
 
To a flame dried two necked round-bottom flask, a mixture of IMP (1 mmol), 
10% Pd/C (0.03 mmol), and 25 ml of hot ethanol was added. The reaction was stirred at 




The reaction was monitored by TLC. Once reaction goes to completion, Pd/C was 
removed by gravity filtration and the solvent was evaporated off to half of original 
volume. Drops of H2O was added to the solution with minimum heat. The compound is 
vacuum filtered, recrystallized in ethanol and dried under a lamp to afford pure products 
as crystals. 
 1,3-diphenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (99): Recrystallization 
of Compound 99 in ethanol resulted in (91 %) as a white crystal. mp 190-192 °C; 1H 
NMR (400 MHz, DMSO) δ 7.81 – 7.66 (m, 5H), 7.53 – 7.31 (m, J = 48.8 Hz, 6H), 7.19 
(t, 1H), 4.11 (t, 2H), 3.04 (t, 2H), 1.90 – 1.83 (m, 4H). 13C NMR (101 MHz, DMSO) δ 
145.10, 135.97, 134.88, 131.41, 128.88, 128.77, 128.68, 128.55, 126.24, 126.05, 125.96, 
45.27, 40.02, 23.37, 20.21. 
 2-(1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)phenol (100): 
Recrystallization of Compound 100 in ethanol resulted in (95 %) as a white crystal. mp 
160-164 °C; 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 6.9 Hz, 2H), 7.71 (d, J = 7.0 Hz, 
1H), 7.50 – 7.38 (m, 5H), 7.25 (t, J = 7.4 Hz, 1H), 4.10 (t, J = 5.9 Hz, 2H), 3.13 (t, J = 
6.3 Hz, 2H), 2.03 – 1.91 (m, 4H), 1.75 (s, J = 6.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
157.52, 134.96, 133.87, 133.02, 132.65,129.12, 128.43, 127.21, 126.49, 125.00, 119.49, 
117.67, 116.86, 44.90, 23.06, 21.87, 20.47. 
 3-(1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)phenol (101): 
Recrystallization of Compound 101 in ethanol resulted in (96 %) as a white crystal. mp 
187-190 °C; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, 2H), 7.40 (t, 2H), 7.35 – 7.32 (m, 




2H), 1.94 – 1.90 (m, 4H).13C NMR (101 MHz, CDCl3) δ 158.52, 135.90, 132.91, 132.05, 
131.43, 129.44, 128.67, 126.99, 126.15, 125.00, 119.49, 118.18, 116.86, 44.84, 23.06, 
21.32, 20.47 
 4-(1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)phenol (102): 
Recrystallization of Compound 102 in ethanol resulted in (97 %) as a white crystal. mp 
200-202 °C; 1H NMR (400 MHz, DMSO) δ 7.73 (d, J = 7.6 Hz, 4H), 7.49 (t, J = 7.5 Hz, 
2H), 7.41 – 7.36 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 4.11 (t, J = 5.3 Hz, 2H), 3.03 (t, J = 
6.2 Hz, 2H), 1.87 (td, J = 8.0, 4.9 Hz, 4H). 13C NMR (101 MHz, DMSO) δ 145.10, 
135.97, 134.88, 131.41, 128.88, 128.77, 128.68, 128.55, 126.24, 126.05, 125.96, 45.27, 
23.37, 23.09, 20.21. 
 1-phenyl-3-(o-tolyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (103): 
Recrystallization of Compound 103 in ethanol resulted in (93 %) as a white crystal. mp 
132-134 °C; 1H NMR (400 MHz, DMSO) δ 7.71 (dd, J = 8.7, 1.1 Hz, 2H), 7.63 (d, J = 
8.5 Hz, 2H), 7.38 (t, J = 7.7 Hz, 2H), 7.19 (tt, J = 8.7, 1.6 Hz, 1H), 7.02 (d, J = 8.6 Hz, 
2H), 4.08 (dt, J = 12.5, 6.3 Hz, 4H), 3.02 (t, J = 6.1 Hz, 2H), 1.91 – 1.80 (m, 4H), 1.36 (t, 
J = 6.9 Hz, 3H).13C NMR (101 MHz, DMSO) δ 145.10, 135.97, 134.88, 131.41, 130.07, 
128.88, 128.77, 128.68, 128.55, 126.24, 126.05, 125.96, 116.66, 45.27, 40.02, 23.37, 
23.09, 20.21. 
 1-phenyl-3-(m-tolyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (104): 
Recrystallization of Compound 125 in ethanol resulted in (92 %) as a white crystal. mp 
134-136 °C;  1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.3, 1.6 Hz, 2H), 7.57 (s, J = 




(m, 1H), 7.24 (ddd, J = 10.4, 6.8, 1.3 Hz, 2H), 4.09 (t, J = 5.7 Hz, 2H), 3.12 (t, J = 6.2 
Hz, 2H), 2.43 (s, J = 3.8 Hz, 3H), 2.01 – 1.90 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
145.88, 138.32, 135.80, 135.47, 131.09, 129.64, 129.50, 129.10, 128.39, 128.11, 126.52, 
125.97, 125.27, 45.25, 23.33, 22.24, 21.65, 20.76. 
 1-phenyl-3-(p-tolyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (105): 
Recrystallization of Compound 126 in ethanol resulted in (91 %) as a white crystal mp 
140-143 °C;  1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 8.3, 1.5 Hz, 2H), 7.60 (d, J = 
8.1 Hz, 2H), 7.41 (t, J = 7.8 Hz, 2H), 7.28 – 7.20 (m, 3H), 4.08 (t, J = 5.9 Hz, 2H), 3.12 
(t, J = 6.3 Hz, 2H), 2.41 (d, J = 8.5 Hz, 3H), 1.98 – 1.90 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 145.86, 138.19, 135.48, 129.12, 128.83, 128.63, 128.29, 126.48, 126.28, 
125.76, 125.04, 45.14, 23.31, 23.27, 21.31, 20.53. 
 3-(4-isopropylphenyl)-1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine 
(106): Recrystallization of Compound 127 in ethanol resulted in (80 %) as a white 
crystal. mp 158-160 °C;  1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.3, 1.4 Hz, 2H), 
7.63 (d, J = 8.3 Hz, 2H), 7.41 (t, J = 7.8 Hz, 2H), 7.33 (d, J = 8.2 Hz, 2H), 7.24 (t, J = 7.4 
Hz, 1H), 4.10 (t, J = 5.6 Hz, 2H), 3.12 (t, J = 6.2 Hz, 2H), 3.03 – 2.92 (m, 1H), 2.02 – 
1.90 (m, 4H), 1.30 (d, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 149.14, 145.90, 
135.50, 135.46, 128.70, 128.61, 128.28, 126.52, 126.25, 125.74, 124.99, 45.14, 33.97, 
23.91, 23.34, 23.26, 20.55. 
 3-(4-ethylphenyl)-1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (107): 
Recrystallization of Compound 107 in ethanol resulted in (92 %) as a white crystal. mp 




Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.20 (t, J = 7.3 Hz, 1H), 4.09 
(t, J = 5.6 Hz, 2H), 3.02 (t, J = 6.1 Hz, 2H), 2.67 (q, J = 7.6 Hz, 2H), 1.91 – 1.82 (m, 4H), 
1.24 – 1.22 (m, 3H). 13C NMR (101 MHz, DMSO) δ145.17, 144.21, 136.02, 134.70, 
128.87, 128.73, 128.66, 128.24, 126.00, 125.98, 125.87, 118.19, 45.22, 34.82, 30.23, 
23.39, 20.24, 15.93. 
 3-(2-methoxyphenyl)-1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine 
(108): Recrystallization of Compound 108 in ethanol resulted in (82 %) as a white 
crystal. mp 145-147 °C;  1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.3, 1.4 Hz, 2H), 
7.52 (dd, J = 7.5, 1.8 Hz, 1H), 7.46 – 7.35 (m, 3H), 7.21 (t, J = 7.4 Hz, 1H), 7.07 (dd, J = 
8.1, 6.9 Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 3.85 (s, J = 2.5 Hz, 5H), 3.15 – 3.08 (m, 2H), 
1.98 – 1.89 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 157.63, 143.69, 135.61, 135.28, 
132.63, 130.58, 128.19, 126.18, 125.53, 124.76, 120.90, 120.62, 110.89, 55.54, 43.58, 
23.25, 22.94, 20.74. 
 3-(4-methoxyphenyl)-1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine 
(109): Recrystallization of Compound 109 in ethanol resulted in (85%) as a white crystal. 
mp 152-153 °C;  1H NMR (400 MHz, DMSO) δ 7.71 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.8 
Hz, 2H), 7.38 (t, J = 7.8 Hz, 2H), 7.19 (t, J = 6.8 Hz, 1H), 7.04 (d, J = 9.0 Hz, 2H), 4.06 
(t, J = 5.7 Hz, 2H), 3.82 (s, 3H), 3.02 (t, J = 6.3 Hz, 2H), 1.92 – 1.79 (m, 4H). 13C NMR 
(101 MHz, DMSO) δ 145.10, 135.97, 134.88, 131.41, 128.88, 128.77, 128.68, 128.55, 
126.24, 126.05, 125.96, 45.27, 40.02, 23.37, 23.09, 20.21. 
 2-(1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline (110): 




155-157 °C; 1H NMR (500 MHz, DMSO) δ 7.71 (dd, J = 8.4, 1.2 Hz, 2H), 7.38 (t, J = 
7.9 Hz, 2H), 7.20 (dt, J = 8.7, 1.3 Hz, 1H), 7.11 (t, J = 7.9 Hz, 1H), 6.96 (t, J = 2.0 Hz, 
1H), 6.83 (dt, J = 7.6, 1.4 Hz, 1H), 6.61 (ddd, J = 7.9, 2.3, 1.0 Hz, 1H), 5.21 (s, 2H), 4.06 
(t, J = 5.8 Hz, 2H), 3.02 (t, J = 6.3 Hz, 2H), 1.89 – 1.83 (m, 4H). 13C NMR (126 MHz, 
DMSO) δ 155.58, 149.20, 147.74, 143.95, 136.73, 133.59, 129.77, 129.06, 120.51, 
119.54, 115.89, 115.74, 113.63, 45.33, 24.20, 23.25, 20.02. 
 3-(1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline (111): 
Recrystallization of Compound 111 in ethanol resulted in (92 %) as a white crystal. mp 
164-166 °C;  1H NMR (500 MHz, DMSO) δ 8.53 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.94 
(dt, J = 7.9, 1.1 Hz, 1H), 7.76 (ddd, J = 8.1, 7.3, 1.8 Hz, 1H), 7.29 (dd, J = 7.7, 1.6 Hz, 
1H), 7.15 – 7.09 (m, 2H), 6.82 (dd, J = 8.2, 1.3 Hz, 1H), 6.64 (td, J = 7.4, 1.2 Hz, 1H), 
5.85 (s, J = 19.7 Hz, 2H), 3.99 (t, J = 5.8 Hz, 2H), 3.25 (t, J = 6.1 Hz, 2H), 1.88 – 1.82 
(m, 4H). 13C NMR (126 MHz, DMSO) δ 156.33, 147.46, 145.89, 143.78, 139.70, 130.60, 
129.85, 128.98, 122.61, 120.34, 117.77, 115.65, 114.61, 49.94, 27.21, 23.69, 21.08. 
 4-(1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline (112): 
Recrystallization of Compound 112 in ethanol resulted in (93 %) as a white crystal. mp 
172-174 °C;  1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 9.2 Hz, 4H), 7.48 (dd, J = 9.0, 
2.8 Hz, 4H), 7.43 – 7.37 (m, 4H), 7.22 (td, J = 7.2, 2.1 Hz, 2H), 6.73 (dd, J = 9.1, 2.8 Hz, 
4H), 4.02 (t, J = 5.7 Hz, 4H), 3.82 (s, J = 16.0 Hz, 3H), 3.08 (t, J = 6.2 Hz, 4H), 1.97 – 
1.87 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 146.70, 135.62, 135.05, 129.93, 128.26, 





(113): Recrystallization of Compound 113 in ethanol resulted in (90 %) as a white 
crystal. 1H NMR (400 MHz, CDCl3) δ 7.89 – 7.82 (m, 2H), 7.79 (dd, J = 8.5, 1.3 Hz, 
2H), 7.69 – 7.67 (m, 1H), 7.41 (dd, J = 8.2, 7.5 Hz, 2H), 7.26 – 7.23 (m, 1H), 4.16 (s, 
1H), 4.06 (s, 2H), 3.62 (t, J = 6.3 Hz, 2H), 3.12 (t, J = 6.3 Hz, 2H), 2.01 – 1.93 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 157.90, 145.01, 139.35, 137.01, 136.52 130.64, 130.56, 
128.34, 126.77, 126.27, 125.24, 115.61, 115.40, 45.13, 27.86, 23.22, 20.45. 
 3-(4-fluorophenyl)-1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (114): 
Recrystallization of Compound 114 in ethanol resulted in (96 %) as a white crystal. 1H 
NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.4, 1.2 Hz, 2H), 7.62 (dd, J = 8.0, 1.6 Hz, 1H), 
7.44 (t, J = 7.8 Hz, 2H), 7.34 – 7.29 (m, 1H), 7.27 – 7.23 (m, 1H), 7.12 (dd, J = 8.3, 1.3 
Hz, 1H), 6.92 (ddd, J = 8.6, 7.3, 1.3 Hz, 1H), 4.35 (t, J = 6.1 Hz, 2H), 3.15 (t, J = 6.5 Hz, 
2H), 2.06 – 1.94 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 157.84, 134.11, 131.31, 129.51, 
128.46, 126.34, 126.10, 125.34, 124.91, 117.65, 114.09,40.54, 23.49, 23.37, 19.88. 
3.3  Biological Methods 
  
 3.3.1  Cell Culture  
LNCaP, LNCaP-C81, PC3, RWPE1, and DU145 human PCa cells were provided 
by Dr. Shafiq Khan, Center for Cancer Research and Therapeutic Development, Clark 
Atlanta University. RWPE1 was maintained in keratinocyte serum free medium (KSFM) 
containing 50 μg/ml gentamycin, 0.05 mg/ml bovine pituitary extract (BPE), and 5 ng/ml 




routinely maintained in RPMI 1640 containing 4 mM glutamine, and 50 μg/ ml 
gentamycin. DU145 and PC3 cells were cultured in Eagle's minimum essential medium 
with Earle's salts with 0.1 mM of the following amino acid supplements: L-alanine, L-
asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine, and L-glycine. The 
medium additionally contained 4 mM L-glutamine, 2.5 g/l NaHCO3, 1.5 mM HEPES, 
100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B and 50 μg/ml 
gentamycin. Both MEM and RPMI media (Mediatech, Herndon, VA) were supplemented 
with 5% fetal bovine serum (HyClone, South Logan, Utah). PC3 and DU145 cells were 
grown in Eagle’s Minimum Essential Media (MEM) medium supplemented with Earle’s 
salts with 0.1 mM of the necessary amino acid supplements. (FBS) (Invitrogen). For 
castration-resistant model, LNCaP and C-81 cells were grown in phenol-red-free RPMI 
1640 medium supplemented with 5% charcoal-stripped serum. All cells were maintained 
at 37o C in 5% CO2.  
 3.3.2  MTS Assay  
Cell proliferation was determined using the MTS cell proliferation assay (Synergy 
H1 Hybrid Multi-Mode Reader, Biotek) following incubation with the compound (0-100 
μM) over 72h (CellTiter 961 Aqueous One Solution Reagent, Promega). In brief, 30 μL 
of the reagent was added to cells in each well of the 96-well plate containing 200 μL of 
media and incubated for 90 minutes at 37°C in 5% CO2. The production of formazan was 




 3.3.3  PI3 Kinase Activity  
PI3K kinase inhibition by IMP derivatives and Wortmannin was determined in a 
competitive assay using four purified recombinant enzymes class I PI3 kinases (p110α, β, 
δ, and γ). In principle, the kinase monitors the activity of PI3 kinases converting PIP2 into 
PIP3. Recombinant GRP-1 is also included in the assay to bind PIP3 with high specificity 
and affinity. Once PIP3 is captured by GRP-1, the glutathione S-transferase bound to 
GRP-1 attaches to the glutathione plate. The positive control biotinylated PIP3 
competitive binds to the GRP-1 protein, which allows quantitation of PIP3 bound to the 
glutathione plate. The captured biotinylated PIP3 is detected using streptavidin-HRP 
conjugate and a colorimetric readout at 450 nm. (EMDmilliporeTM) 
 3.3.4  Statistical Analysis 
 All experiments were performed at least three times using different cell 
preparations. Data from representative experiments are shown in the figures in Chapter 
IV.  The significance of the differences among treatments was determined using one-way 
ANOVA using the statistical package from GraphPad Prism 7.0 program for Windows, 
version 11.0 
3.4  In Silico Modeling  
 
 3.4.1 Preparation of the Protein Structure for Docking  
PI3K crystal structures α 4ZOP (2.62Å resolution, 0.258 R-value)159, β 4BFR (2.8 
Å resolution, 0.275 R-value)160, γ 4URK (2.9 Å resolution, 0.309 R-value)161, and δ 4V0I 




docking. These structures were prepared using the Protein Preparation Wizard within 
Molecular Operating Environment (MOE) (Chemical Computing Group, LLC). All 
solvent molecules have been deleted, and the bond order for the ligand and protein has 
been adjusted. The missing hydrogen atoms have been added, and side chains have then 
been energy-minimized using the Amber10:EHT force field, as implemented by MOE. 
The active site was defined by a 12 Å box centered on the crystallographic ligands, NVP-
BYL719, 2-[2-(2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-
one, AZD6482, and 2-[2-(2-methyl-2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-
yl-3H-pyrimidin-4-one for 4ZOP, 4BFR, 4URK and 4V0I, respectively. No van der 
Waals scaling factors were applied; the default settings were used for all other adjustable 
parameters.  
 3.4.2  Ligand Preparation  
All the compounds presented in this thesis were imported into a molecular 
database using Molecular Operating Environment (MOE version 2014.0901). Hydrogen 
atoms were added after these structures were ‘washed’ (a procedure including salt 
disconnection, removal of minor components, de-protonation of strong acids and 
protonation of strong bases). The following energy minimization was performed with 
MMFF94x force field as it is implemented by the MOE and the optimized structures were 
exported into Maestro suite in the SD file format.  
 3.4.3  Virtual Screening  
All the prepared compounds were docked into ATP site of PI3K crystal structures 




into MOE. This program approximates a complete systematic search of the 
conformational, orientational, and positional space of the docked compound. In this 
search, an initial rough positioning and scoring phase that dramatically narrows the 
search space is followed by torsionally flexible energy optimization on an Amber 
10:EHT non-bonded potential grid for a few hundred surviving candidate poses. The very 
best candidates are further refined via a Monte Carlo sampling of pose conformation, 
which is a crucial step for obtaining an accurate docked pose.  
The final poses are scored according to GlideScore 2.5. The starting point for 
Glide scoring is the empirically based ChemScore function of Eldridge et al.164 
GlideScore 2.5 modifies and extends the ChemScore function as follows.  
ΔGbind = ΔG0 + ΔGHbond + ΔGmetal+ ΔGlipo + ΔGrot    (3.1) 
ChemScore= ΔGbind +Pclash +cinternalPinternal + (ccovalentPcovalent +Pconstraint) (3.2) 
The GlideScore 2.5 modifications of ChemScore calculations for binding affinity (ΔGbind) 
is:   
ΔGbind = ΔG0 + ΔGHbond + ΔGmetal+ ΔGlipo + ΔGrot+ ΔGpolar+ ΔGcoul+ΔGvdW+solvation 
terms,          (3.3) 
where, Hbond is hydrogen bond, metal is metal bond, lipo is lipophilicity, rot is rotation, 
coul is coulomb force, vdW is van der Waals force. 
ΔGlipo =Clipo-lipo Σf(rlr)        (3.4) 
where, r is distance and C is physical contribution  
ΔGHbond =CHbond-neut-neut Σg(Δr) h(Δα) + CHbond-neut-charged Σg(Δr) h(Δα) + Chbond-charged-
charged Σg(Δr) h(Δα)        (3.5) 
where, neut is neutral charge and α is angle  




ΔGrot =CrotbHrotb          (3.7) 
ΔGpolar= Cpolar-phobVpolar-phob       (3.8) 
ΔGcoul= CcoulEcoul          (3.9) 
ΔGvdW= CvdWEvdW         (3.10) 
The lipophilic-lipophilic term (3.4) is defined as in ChemScore. The hydrogen-bonding 
term (3.5) also uses the ChemScore form but is separated into differently weighted 
components that depend on whether the donor and acceptor are both neutral, one is 
neutral and the other is charged, or both are charged.  
 3.4.4  Dataset Preparation for QSAR Models  
A dataset of 8 synthesized imidazopyridine derivatives with anti-PI3 Kinase 
activity in the range of low and high micro-molar range and Pan-PI3K inhibitor 
Wortmannin BF3 inhibitors are collected. These compounds were built and prepared 
using the MOE 2014 program as described above. All the prepared compounds were 
docked into ATP binding site of PI3K crystal structures α (4ZOP), β (4BFR), γ (4URK), 
and δ (4V0I) using PyRX and GOLD program. No constraints were applied, and all other 
adjustable settings were kept as default. Top ranked conformation for each compound 






SYNTHESIS OF IMIDAZOPYRIDINE 
 
The pharmaceutical applications of imidazopyridines include their uses as 
aromatase inhibitors in estrogen-dependent diseases, thromboxane A2 synthase inhibitor, 
and angiotensin II receptor antagonists. A variety of methods has been reported in the 
literature for the synthesis of these IMPs. Most of the methods used were variations of the 
traditional Vilsmeier-type cyclization of N-2-pyridyl methyl amides or its carboxylic acid 
derivatives with various catalysts such as dicyclohexylcarbodiimide, mercuric salts, and 
iodine/pyridine. These methods generally give low to moderate yields, require harsh 
conditions whilst giving tarry products and require the use of environmentally toxic 
reagents. In this chapter, first, the discussion of Williamson etherification synthesis will 
be shown with substituted benzaldehydes and IMPs with various bases and solvents. 
Then, the synthesis of novel imidazo[1,5a]pyridines by reacting 2-benzoyl pyridine with 
aldehydes to give the corresponding IMP using microwave irradiation will be shown. The 
description, the scope, and limitations of this method is explained. Finally, the discussion 
of reducing the imidazopyridine moiety using Pd/C and hydrazine mono hydrate is 






Reagents and conditions: (a) Williamson etherification, Base, PTC, KI, DMSO 86-96%; (b) Microwave 
Synthesis, Ammonium Source, AcOH, Dipyridyl Ketone or 2-Benzoylpyridine,  µW92%-98%; (c) 
Hydrogenation, 10% Pd/C. NH2NH2*H2O, Ethanol 96%-99%, Ar=phenyl or pyridyl 
 
Scheme 40. Synthetic route for Novel Imidazopyridine derivatives. 
 
 
4.1  Williamson Etherification Synthesis 
 
Although most of the imidazopyridines are soluble in most of the organic solvents 
at elevated temperature, the solubility in pure aqueous media or in aqueous media 
containing 5% DMSO (v/v) is generally poor. Some of the imidazopyridines have been 




of available derivatives. However, the solubility property limits the effectiveness of the 
investigation. In this thesis, one of the goals is to address an issue by embedding new 
structural features to make imidazopyridines possess desirable solubility property. 
The approach includes the use of ethylene glycol (OCH2CH2OH) unit. The 
imidazopyridines embedded with a single unit (referred as PEG) will be designed and 
developed. The use of PEG is expected to enhance the solubility, especially in aqueous 
media because of its hydrophilicity. Also, PEG is a biocompatible component. The 
introduction of PEG into imidazopyridines may help improve the biological property as 
well. From the synthetic point of view, etherification can occur between the substituted 
hydroxybenzaldehyde (Scheme 41a) or IMP (Scheme 41b). This provides an important 
opportunity to examine and correlate not only solubility but the biological property with 





Scheme 41. Williamson Etherification of Benzaldehyde and IMP. 
 4.1.1  Mechanism 
The reaction occurs through an SN2 mechanism, and the phenoxide serves as a 
nucleophile and alkyl halide the electrophilic substrate (Scheme 42). The addition of 
potassium iodide as a catalyst converts the alkyl halide into alkyl iodide, which has 
increased solubility in organic solvents as described in Finkelstein reaction. The 
formation of the alkyl iodide creates a substrate that has increased solubility in aprotic 





Scheme 42. Mechanism for the Williamson Etherification of Benzaldehyde. 
 
  
 4.1.2  Mono-substituted PEG IMP 
Initially, the development of mono-substituted PEG IMPs was optimized by 
changing the conditions: first, the substrate 2-chloroethanol or 2-bromoethanol was 
alternated with the optimization of temperature (Table 1), and then the optimal molar 
ratio was investigated (Table 2). Next, we optimized the conditions by changing the 
























Table 3. Optimization of the Synthesis of 4-(2-Hydroxyethoxy)Benzaldehyde: Base, 
Solvent, and Catalyst 
 
After optimizing the conditions by changing the molar ratio, solvent, temperature, 
and base, it was important to investigate the use of hydroxyl substituted benzaldehyde or 
hydroxyl substituted IMP (Table 4 and Table 5). The completion of the reaction was 














Table 5. Synthesis of Ether Alcohol Substituted IMP 
 
The initial optimization of Williamson etherification of hydroxybenzaldehyde 
involves base, potassium carbonate (K2CO3), DMSO, and reagents: 2-substituted halogen 
ethanol, and 4-hydroxybenzaldehyde. The temperature was regulated based on the 2-
substituted halogen ethanol boiling points, which 2-bromoethanol boiling point 
(163⁰C166) and 2-chloroethanol boiling point (129 ⁰C167), so optimization of the 
temperature was maintained within the boiling point range. Increasing the temperature 
from 50⁰C to 120⁰C shortened the reaction time from 75 hours. to 6 hours. The 2-
chloroethanol was successful at producing 64, probably, because of its higher 




isolated yield and reaction time. Finally, Table 1, run 6, indicated that 2-chloroethanol at 
120⁰C can produce an isolated yield of 64 at 90%. Thus, it was decided to use 2-
chloroethanol at 120⁰C for the synthesis of Williamson etherification products.  
Following the optimization based on temperature and 2-substituted halogen 
ethanol, the molar ratio of 4-hydroxybenzaldehyde, 2-chloroethanol, and K2CO3 was 
investigated. Understanding that changing one hydroxyl group into an ether substituent, it 
is understood that there is a formation of a phenoxide in basic conditions, which will 
influence SN2 reaction (Scheme 42), and the 2-chloroethanol undergoes nucleophilic 
substitution displacing the Cl ion. Using that understanding, 1:1 molar ratio of 4-
hydroxybenzaldehyde to 2-chloroethanol (Table 2, run 1) was used first, which resulted 
in an incomplete reaction after 72 hours. The initial molar ratio indicated that the reaction 
failed to completely react after 72 hours, with no presence 2-chloroethanol reagent, which 
results from the formation side products. Next, the molar amount of 2-chloroethanol 
(Table 2, runs 2-5) was increased, which started producing adequate product at 1 to 1.2 to 
2.5 molar amount ratio of hydroxybenzaldehyde, 2-chloroethanol, and K2CO3, 
respectively (Table 2, run 3). Increasing the molar ratio (Table 2, runs 2-5) didn’t 
significantly increase the amount 64 produces. Finally, the molar amount of base at 2 mol 
equivalence (Table 2, runs 6 and 7) was used at the optimal conditions. In comparison, 
runs 4 and 6, showed a significant difference in reaction time and the amount of product 
being formed.  Run 6 did not complete the reaction. Run 7 completed the reaction at 




than  run 5. Upon, optimizing the conditions, the molar ratio 1:1.5:2.5 (benzaldehyde:2-
chloroethanol:base) was used as the optimal molar ratio. 
In optimizing the base and solvent condition, K2CO3, cesium carbonate (Cs2CO3), 
and 10% sodium hydroxide in the respective solvent, DMSO, dimethylformamide 
(DMF), acetone, acetonitrile or 1,4-dioxane is used. In addition, the reaction is monitored 
with the use of catalyst and without the use of catalyst. The yield of 64 increased with the 
addition of catalyst potassium iodide (KI) and PTC (Table 3, run 5). However, there was 
no significant change in time and yield when modifying the base from K2CO3 to NaOH 
or Cs2CO3 (Table 3, runs 1, 5, and 7). The investigation of using different solvents was 
influenced by the difficulty of work up when using DMSO. The polar aprotic solvent; 
acetone, acetonitrile, DMF, and DMSO are essential for making a semi homogeneous 
solution. The change to acetone leads to the no reaction after 24 hours (Table 3, run 2) 
and acetonitrile resulted in the formation of 64 at 56% isolated yield in 84 hours (Table 3, 
run 3). Based on the results from Table 3, the optimal condition from Table 3, run 5) are 
used for further reactions.  
The optimized conditions determined for Williamson etherification (Table 3, run 
5) was used for the synthesis of 4-(2-hydroxyethoxy)benzaldehyde, 2-(2-
hydroxyethoxy)benzaldehyde, and 3-(2-hydroxyethoxy)benzaldehyde (64-66) (Table 4). 
For the Williamson etherification 2.5 mol of K2CO3, 0.005 mol of PTC, 0.03 mol of KI, 1 
mol of substituted hydroxybenzaldehyde and 1.5 mol of 2-chloroethanol were used and 
the reaction was monitored via TLC. The reaction produced products as yellow oils at 




of the lower acidity of the hydroxyl group on the starting benzaldehyde. The highest yield 
was obtained from the ortho- and para- substituted products 65 and 66. The reactions 
took less than six hours to get completed (Table 4, runs 1 and 3). 
The overall goal of making ether alcohol substituents on benzaldehyde was to 
make IMPs that contain the ether substituents. Using the optimized conditions, the ether 
substituent is directly linked to the phenyl ring on carbon 1 of the IMP moiety versus 
making the oily benzaldehyde starting products (71-73). The optimized conditions 
determined for Williamson etherification was used for the formation of ether alcohol 
substituted-IMP (70-72) (Table 5), and the reaction was monitored via TLC. The reaction 
produced products at an increased isolated yield as solid yellow products that were 
recrystallized in hot ethanol. High yields were obtained for all of the ether alcohol 
substituents with the meta-product, 71 resulting in the lowest yield of 92 % (Table 5, run 
2). It’s probable that the acidity of the hydroxyl group on the reagent IMP effects the 
reaction yield. The reactions took less than six hours to complete (Table 5, runs 1 and 3). 
The isolated yield increased from this route (benzaldehyde to the IMP), because of the 
ease of work up that afforded solid products after continuous washing with water.  
 4.1.3  Poly-substituted PEG IMP 
For the development of multi-substituted PEG IMP, halogen-, methoxy-, ethoxy-, 
methyl-, and nitro substituents were investigated at either position R2, R3, R4, or R5 or at 
two of those positions simultaneously along with the hydroxyl substituent, which is used 




chlorobenzaldehyde was investigated using the optimized conditions from mono-
substituted benzaldehydes and IMPs. 
The reaction was initially carried out using 1 mol of 5-chlorosalicylaldehyde, 1.5 
mol of 2-chloroethanol, 2.5 mol of K2CO3, and a catalytic amount of PTC (.005 mol) and 
KI (.03 mol.) (Table 6, entry 1).  
 






The highest isolated yield was obtained by chloro- substituted in the R5 position 
(67, 92%), followed by bromo- substituted in the R5 position (68, 89%) and methoxy- 
substituted in the R4 (69, 87%). The ethoxy- substituted in the R4 position (Table 6, entry 
3) did not complete after 24 hours and nitro-substituted in the R4 position (Table 6, entry 
5) went unreacted with only starting material being detected by TLC. Generally speaking, 
The di-substituted benzaldehydes afforded a good yield at 87-92% yield, while tri-
substituted benzaldehydes were unreacted after 72 hours (Table 6, entries 6-8). Those 
limitations could be a result of steric hindrance caused by the neighboring groups.  
Following, the synthesis PEG substitution of aldehydes, we used the optimized 
conditions to synthesize di-substituted IMP (Table 7, entries 1-4). The reaction resulted in 
the successful synthesis of compounds (97 and 98). The Williamson etherification of R3 
hydroxy- and R4 methoxy-disubstituted IMP was unreacted after 72 hours, possibly the 





















Table 7. Synthesis of Poly Substituted IMP 
 
 
 4.1.4  X-ray Crystallography of 4-(2-hydroxyethoxy)-imidazo[1,5-a]pyridine 
 
For the X-ray crystallography of 72 (Figure 39), the parameters used for deducing 
the crystal structure, bond length, and bond angle for the compound can be seen in Tables 









Table 8: Sample and Crystal Data for 72 
 
Chemical formula C20H17N3O2 
Formula weight 331.36 g/mol 
Temperature 123(2) K 
Wavelength 0.71073 Å 
Crystal size 0.104 x 0.156 x 0.178 mm 
Crystal system Monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 20.5549(13) Å α = 90° 
 




c = 8.0261(4) Å γ = 90° 
Volume 1622.73(16) Å3 
 
Z 4 
Density (calculated) 1.356 g/cm3 






Table 9. Data Collection and Structure Refinement for 72 
 
Theta range for data 
collection 
2.29 to 25.25° 
Index ranges -24<=h<=24, -11<=k<=11, -9<=l<=9 
Reflections collected 30476 
Independent reflections 2936 [R(int) = 0.0554] 
Max. and min. transmission 1.0000 and 0.9417 
Structure solution technique direct methods 
Structure solution program SHELXT-2014 (Sheldrick 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014 (Sheldrick 2014) 
Function minimized Σ w(Fo
2 - Fc
2)2 
Data / restraints / parameters 2936 / 1 / 230 
Goodness-of-fit on F2 1.094 
Final R indices [I>2σ(I)] 
R1 = 0.0467, wR2 = 
0.1150 
 
R indices(all data) 









Largest diff. peak and hole 0.267 and -0.294 eÅ-3 




















O1-C1 1.419(2) O1-H1 0.932(17) C7-C8 1.387(2) C7-H7 0.95 
O2-C3 1.359(2) O2-C2 1.435(2) C8-H8 0.95 C10-C11 1.345(3) 
N1-C9 1.377(2) N1-C10 1.390(3) C10-H10 0.95 C11-C12 1.429(3) 
N1-C14 1.401(2) N2-C9 1.325(2) C11-H11 0.95 C12-C13 1.354(3) 
N2-C15 1.375(2) N3-C20 1.341(3) C12-H12 0.95 C13-C14 1.423(3) 
N3-C16 1.349(3) C1-C2 1.505(2) C13-H13 0.95 C14-C15 1.386(3) 
C1-H1A 0.99 C1-H1B 0.99 C15-C16 1.466(3) C16-C17 1.390(3) 
C2-H2A 0.99 C2-H2B 0.99 C17-C18 1.381(3) C17-H17 0.95 
C3-C8 1.393(2) C3-C4 1.401(2) C18-C19 1.384(3) C18-H18 0.95 
C4-C5 1.373(2) C4-H4 0.95 C19-C20 1.371(4) C19-H19 0.95 
C5-C6 1.402(2) C5-H5 0.95 C20-H20 0.95 
  
















C1-O1-H1 106.3(18) C3-O2-C2 117.65(13) C12-C13-H13 120 
C9-N1-C10 130.58(16) C9-N1-C14 107.13(15) C15-C14-N1 105.36(16) 
C10-N1-C14 122.03(16) C9-N2-C15 107.26(15) N1-C14-C13 117.40(19) 
C20-N3-C16 116.6(2) O1-C1-C2 113.83(15) N2-C15-C16 121.74(17) 
O1-C1-H1A 108.8 C2-C1-H1A 108.8 N3-C16-C17 122.39(19) 
O1-C1-H1B 108.8 C2-C1-H1B 108.8 C17-C16-C15 121.83(17) 
H1A-C1-H1B 107.7 O2-C2-C1 108.66(14) C18-C17-H17 120.3 
O2-C2-H2A 110 C1-C2-H2A 110 C17-C18-C19 118.5(2) 
O2-C2-H2B 110 C1-C2-H2B 110 C19-C18-H18 120.7 
H2A-C2-H2B 108.3 O2-C3-C8 125.20(16) C20-C19-H19 120.8 
O2-C3-C4 115.47(15) C8-C3-C4 119.33(16) N3-C20-C19 124.6(2) 
C5-C4-C3 120.64(16) C5-C4-H4 119.7 C19-C20-H20 117.7 
C3-C4-H4 119.7 C4-C5-C6 120.80(16) C14-C13-H13 120 
C4-C5-H5 119.6 C6-C5-H5 119.6 C15-C14-C13 137.23(19) 
C7-C6-C5 118.15(16) C7-C6-C9 124.21(16) N2-C15-C14 109.70(16) 
C5-C6-C9 117.55(15) C8-C7-C6 121.47(16) C14-C15-C16 128.50(17) 
C8-C7-H7 119.3 C6-C7-H7 119.3 N3-C16-C15 115.77(19) 
C7-C8-C3 119.60(16) C7-C8-H8 120.2 C18-C17-C16 119.5(2) 
C3-C8-H8 120.2 N2-C9-N1 110.54(15) C16-C17-H17 120.3 

















C11-C10-N1 119.37(19) C11-C10-H10 120.3 C20-C19-C18 118.4(2) 
N1-C10-H10 120.3 C10-C11-C12 120.3(2) C18-C19-H19 120.8 
C10-C11-H11 119.9 C12-C11-H11 119.9 N3-C20-H20 117.7 
C13-C12-C11 120.61(19) C13-C12-H12 119.7 
  C11-C12-H12 119.7 C12-C13-C14 120.1(2)   
 
In the X-ray crystallography of 72 (Figure 39), the six-member heterocyclic ring 
(N1C10C11C12C13C14) is fused to the imidazo ring (N1N2C9C14C15) at N1 and C14 
atoms. The pyridine ring attached to C15 of the imidazole is twisted to each other at a 
dihedral angle of 3.539° between the planes C14C15 and C16N3, respectively. Similarly, 
the 4-(2-hydroxyethoxy) benzyl ring attached to the imidazo at C9 is twisted at a greater 
angle to each other as is evident from the dihedral angle of 43.51° between planes of 
C7C6 and C9N1, respectively. 
The X-Ray crystallography reveals the presence of π-π stacking interaction as 
seen through short distances between the aromatic rings. A partial overlapping of two 
intermolecular rings occurs between two pyridines (at the 3-position of 72). Furthermore, 
there is evidence of π-π stacking interaction with the imidazopyridine moiety of the 







Figure 40. The 3D depiction of 72 in a molecular crystal structure. Red is oxygen. Blue 
is nitrogen. 
 
In addition, X-ray crystallography also revealed that H-bonding occurred between 
imidazole and PEG moiety. Since the PEG group (O1) provides H, which is an acceptor, 
the nitrogen (N2) in imidazole becomes a donor (Figure 41). Along with H-bonding 
between the (O1) of PEG moiety and (N2) of imidazole moiety, there is H-bonding 
amongst (O1) and (O1) in various regions of the molecular crystal. Interestingly, there is 
no H-bonding between the PEG group and pyridine (at the 1-position of 72) even though 





Figure 41. The 3D depiction of 72. (A) Horizontal view. (B) Vertical view. Red is 
oxygen. Blue is nitrogen 
 
 
 4.1.5  Conclusion 
 Using Williamson etherification to make PEG –IMP provides an efficient 
synthetic approach to developing this class of compounds. Williamson etherification of 
hydroxyl-substituted aldehydes was less effective than the hydroxyl-substituted IMP 
based on the acidic nature of the hydroxyl group. The aromaticity of the IMP allows for 
the stabilization of the phenoxide formation. It is also found that inductive effect and 
mildly electron withdrawing is what induced the formation of phenoxide increasing the 
yield and lowering reaction time. The bulkiness and number of substituents restrict 
phenoxide ability to attack the 2-chloroethanol because of steric hindrance. 
4.2  Microwave Synthesis of Imidazopyridine Derivatives 
 
This section is devoted to the microwave-assisted synthesis of imidazo[1,5-a 






the formation of 1-substituted-3-pyridin-2-yl-imidazo [1, 5-a] pyridines (IMP) is 
investigated using microwave irradiation with an open vessel at 200 W (Scheme 43). 
 
Scheme 43. Plausible mechanism for the synthesis of IMP. 118. 
 4.2.1  History of Microwave Assisted Organic Synthesis 
Microwave radiation is electromagnetic radiation which ranges from 300 MHz to 
300 GHz in frequency. Initially, it was ventured that microwaves lowered reaction rates 
by lowering the activation energy of reactions, but there have been no findings to support 
these claims. Microwaves provide enough energy to overcome activation energies 
quicker than conventional heating, by supplying an excess of energy relative to that 
needed to achieve the product formation.  In comparison, x-rays, gamma-rays, ultraviolet 
(UV), visible or infrared radiation have enough energy to break bonds or influence bond 
vibrations, which can induce changes in the molecular structure of organic compounds 





Figure 42. (a) depiction of microwave radiation (b) H2O wiggle in relation to the electric 
field induced by microwave radiation. 169 
Source: Kappe, C. O.; Stadler, A.; Dallinger, D., Introduction: Microwave Synthesis in Perspective. In 
Microwaves in Organic and Medicinal Chemistry, Wiley-VCH Verlag GmbH & Co. KGaA: 2012; pp 1-7. 
 
The energy needed to cleave molecular bonds is 80-120 kcal/mole, microwave 
radiation does not contain that much energy, therefore, microwave radiation will not 
break chemical bonds.  Microwave radiation (μW) creates losses of energy from 
molecules as the dipole moments try to align to the electric field. The phenomenon that 
causes heat is known as dielectric heating, where μW is absorbed and released in the 
form of heat. μW influences the dipole moment changes in molecules in relation to the 
electric field based on evidence that μW consists of a magnetic and electric field. More 
explicitly, dipole rotation occurs when organic molecules (either reactants or solvents) 




place. This attempt to align with the electric field generates friction between the 
absorbing molecules and neighboring molecules producing heat. 169 
Conventional heating uses Bunsen burner, heating mantle, or hotplate that 
depends on the transfer of heat from an external source through various mediums that 
have different thermal conductivity. The heat source traveling through a variety of 
medium causes indirect heating, which heat distribution is uneven. Most glassware and 
some reaction solvents (non-polar solvents) are permeable to μW that allows the direct 
passing of 2450 MHz directly to reactant causing an even distribution of radiation.170 
Microwave-assisted organic reactions have been investigated to proceed in shorter 
run times with similar or improved reaction yields in comparison to those from 
conventionally heated reactions. More importantly, microwave-assisted organic synthesis 
(MAOS) has proven useful in the area of combinatorial chemistry in regards to the rapid 
synthesis and screening of libraries of biologically active compounds for drug discovery. 
The history of MAOS began in 1986 by Geyde et al.169 They used household microwaves 
to produce traditional reactions such as esterification, hydrolysis, and oxidation.171 
Experiments conducted during the primitive times of MAOS often involved the use of 
Teflon or glass vessels without temperature or pressure monitors, so reactions often 
resulted in explosions under closed conditions. Since the early reports of MAOS, 
reproducibility has also been a factor in experiments by the lack of controlled 
environments without uniformed heating.  Currently, there has been a surge in the 




increase in microwave publications.169-170 Accordingly, in the area of heterocyclic 
chemistry, MAOS has been utilized as a viable means of improving reaction conditions. 
 4.2.2  Microwave Synthesis of 1, 3-diphenyl-IMP 
Initially, Dyers et al.168 explored MAOS of novel 1-substituted-3-pyridin-2-yl 
IMPs risen to an in-depth understanding of the conditions needed for an efficient 
synthesis. The rationale for this project is to build on the foundation of the MAOS for 
new IMP (Scheme 44). We have explored a different set of objectives: (1) to reduce 
reaction time, while maintaining high yields comparable both Bu et al. (conventional 
synthesis)118 and Dyers et al., (2) to investigate the use of open vessel in both air and 
nitrogen atmosphere, (3) to investigate this reaction with various ammonium sources, and 
(4) to investigate the reagents molar ratio.  
 
Scheme 44. Microwave synthesis of 3-substituted-1-phenylimidazo[1,5-a]pyridine. 
 
 4.2.3  Microwave Synthesis of IMP 
MAOS on CEM® instruments have the capability of using pressurized closed 
vessels and the use of traditional round-bottom flask for an open vessel that allows the 
exposure air or N2 gases. Open systems provide a gas flow controlled system at 




delivering the same uniformity of heat surrounding the flask. High yields are obtained of 
novel 1-substituted-3-phenyl IMP.  
Initially, the synthesis 76 via microwave (Table 12) using the standard conditions 
reported by Bu et al.118 was investigated. The reaction was monitored every 5 minutes via 
TLC. After 2 h, under reflux with air, we found 73 at 89% isolated yield (Table 12, run 
2), which was a significant improvement to the standard reaction time of ~8 hours. The 
reaction was monitored every 5 minutes via TLC. 
Table 12. Synthesis of 1,3-Diphenyl[1,5-a]Pyridine 
 
 
 4.2.4  Optimization of Molar Ratio (Benzaldehyde and Ammonium Acetate) 
Understanding the conditions set by Wang et al.118 for the synthesis of IMPs using 
conventional thermal conditions, in this thesis those conditions are reinvestigated under 
MW conditions . Wang et al. initially used a 1:2:5 (2,2-Dipyridyl Ketone: Aldehyde: 
Ammonium Acetate) molar ratio which gave good yields under those conditions. Shown 




with MW conditions. Initially, the optimization of aldehyde to ketone ratio was 
investigated, which shown no significant change in the product yield as the amount very 
slightly increases from 88% to 89%, when changing the ratio to 2.0|1.0 from 1.5|1.0 
(Table 13, runs 3-4). Correspondingly, the reaction time is partially related to the molar 
ratio as the time decreases with the molar amount of benzaldehyde. However, there was 
an incomplete reaction after 4 hours. when changing the ratio 1.0|1.0 (Table 13, run 1).  
The optimization of ammonium source amount, 88% yield of 73 was obtained 
when 5.0 mol ratio amount was used (Table 13, run 2 and 5). The yield of 73 slightly 
decreased to 86% as the NH4OAc was decreased to 4.0 mol (Table 13, run 6), but the 
reaction time was 1 h. Next, the molar amount was decreased to 3.0 mol and the yield of 
73 was 56% (Table 13, run 7), which was significantly lower than the previous two 
reactions. Finally, the molar amount is lowered to 2.0 mol (Table 13, run 8), which 




Table 13. Optimization of the Molar Ratio for the Synthesis of 73 
 
 
Run Molar ratioa Source of ammonia rt (Hr:Min) Power Yield (%) of 73c 
1 1.0|1.0|5.0 NH4OAc 4:00 210 b 
2 1.2|1.0|5.0 NH4OAc 1:20 210 88% 
3 1.5|1.0|5.0 NH4OAc 1:30 210 88% 
4 2.0|1.0|5.0 NH4OAc 2:00 210 89% 
5 1.2|1.0|5.0 NH4OAc 1:20 210 88% 
6 1.2|1.0|4.0 NH4OAc 1:00 210 86% 
7 1.2|1.0|3.0 NH4OAc 1:40 210 56% 
8 1.2|1.0|2.0 NH4OAc 4:00 210 b 
a Molar Ratio (benzaldehyde(I):2-benzoylpyridine(II): Ammonium Acetate) 
b Incomplete Reaction 
c Isolated Yield 
 
  4.2.5  Investigation of Ammonium Source and Optimization of   
  Reaction Time  
 In developing novel IMP using MW conditions in acetic acid, it was 
essential for us to make the RxN more efficient. In efforts to make the synthesis more 




footprint, also reduce the total RxN time. The ammonium sources used ranged from the 
previous ammonium acetate (NH4OAc) to ammonium hydroxide (NH4OH) that contains 
virtually no carbon atoms. Then we decided to monitor the RxN time to see if the source 
of ammonium causes a fluctuation. In Table 14 and Table 15, the optimized molar ratios 
are used in monitoring the effects of the ammonium sources in acetic acid.  








rt (hr:min)a Power 
yield (%) of 
73b 
1 1.2|1.0|4.0 NH4OAc 1:00 210 88% 
2 1.2|1.0|4.0 NH4Cl 2:00 210 32% 
3 1.2|1.0|4.0 HCO2NH4 0:40 210  90%  
4 1.2|1.0|4.0  (NH4)3PO4 0:20 210 58% 
5 1.2|1.0|4.0 (NH4)2C2O4 1:10 210  40%  
6 1.2|1.0|4.0  NH4OH  0:40 210 c 
7 1.2|1.0|4.0 (NH4)2SO4 1:20 210 c 
a Hours: Minutes 




c Tar-Like Product 
 
Table 15. Optimization of Reaction (RxN) Time 
 
Runa Source of ammonia RxN time (min) Power (µW) 
Yield (%) of 
73b 
1 HCO2NH4 10 210 12% 
2 HCO2NH4 20 210 45% 
3 HCO2NH4 30 210 56% 
4 HCO2NH4 40 210 90% 
a Used optimized molar ratio 
b Isolated Yield 
 
The investigation of the ammonium source shows that various sources can 
facilitate the intermediate imine formation shown in Scheme 44. Traditionally, NH4OAc 
was used as ammonium source with very few limitations. Compound 73 under 
microwave conditions yields 88% with NH4OAc as ammonium source (Table 14, run 1). 
The reaction using ammonium formate (HCO2NH4) produced 90% yield of 73 in 40 
minutes (Table 14, run 3).  Using more basic NH4 sources, 73 wasn’t formed, only tar 
like by-products was obtained (Table 14, run 3and 4).  Ammonium chloride (NH4Cl), 
ammonium phosphate ((NH4)3PO4), and ammonium oxalate ((NH4)2C2O4) formed 73 
with 32, 58, and 40%, respectively (Table 14, run 2, 4, and 5). It was then decided to 




In the optimization of the reaction time, the previously optimized conditions with 
1.2 mol of benzaldehyde and 4 mol of ammonium formate was used. The initial run was 
for 10 minutes that yield 12% of 73 (Table 15, run 1). As the time increased from to 10 
minutes to 40 minutes by 10 minutes increments the yield increased (Table 15, runs 1-4), 
with 20 and 30 minutes showing close yields of 45 and 50%, respectively (Table 15, runs 
2 and 3).  
 4.2.6  Development of Novel 1-substituted phenyl-3-phenyl IMPs 
Using optimized conditions mentioned above in section 3 and 4, novel 1-
substituted phenyl-3-phenyl IMPs is prepared. The fixed molar ratio was 1.0|1.2|4.0 (2,2-
dipyridyl ketone: substituted benzaldehyde: HCO2NH4). In the synthesis of IMP via 
microwave irradiation, high yields were obtained for most compounds. The yield for IMP 
ranged from 87-98%. Based on the yields obtained of various functionalized IMPs, it can 
be postulated that various substituents in different positions influence the yield of IMP 




Table 16. Yields of Imidazo[1,5-a]Pyridine (IMP) 
 
Entry Ra in I Yield b Entry Ra in I Yield b 
1 (73) H 88% 11 (83) 4-Br 98% 
2 (74) 2-OCH3 88% 12 (84) 4-Cl 95% 
3 (75) 3-OCH3 92% 13 (85) 4-F 92% 
4 (76) 4-OCH3 85% 14 (86) 2-NO2 92% 
5 (77) 2-CH3 91% 15 (87) 3-NO2 94% 
6 (78) 3-CH3 88% 16 (88) 4-NO2 95% 
7 (79) 4-CH3 90% 17 (89) 4-iC3H7 95% 
8 (80) 2-OH 94% 18 (90) 4-C2H5 96% 
9 (81) 3-OH 92% 19 (91) 3-NO2,4-OH 89% 
10 (82) 4-OH 95% 20 (92) 2-OH,4-OC2H5 88% 
a R=Position-Substituent 21 (93) 2-OH,5-Cl 88% 
b Isolated Yield 
Molar Ratio (2-benzoylpyridine,R-Benzaldehyde|Ammonium Formate) (1.0|1.2|4.0) 
Reaction time: 40 minutes 
 
Of the IMP synthesized, electronic and steric effect shows little involvement in 
the isolated yield. In compounds (83-85), negative inductive effect (-I) negatively 
influences the yield of each compound, 98, 95, and 92% (Table 16, entries 11-13). 




yield lower than molecules containing electron-withdrawing groups. Moreover, di-
substituted benzaldehydes didn’t show any decrease in product yield in relation to mono-
substituted benzaldehydes (Table 16, entries 19-21).  
Along with creating 3-phenyl IMP, we decided to monitor the reaction with using 
di-2-pyridyl ketone instead of 2-benzoylpyridine to create 3-pyridyl IMP (Table 17). The 
results showed that the optimized conditions would successfully produce 1-substituted-3-
pyridyl IMP. 
Table 17. Yields of Imidazo[1,5-a]Pyridine (IMP) 
 
Entry R in I Yield 
1 (94) 2-OH 95% 
2 (95) 3-OH 97% 
3 (96) 4-OH 94% 
4 (70) 2-OC2H2OH 95% 
5 (71) 3-OC2H2OH 92% 
6 (72) 4-OC2H2OH 96% 
7 (97) 2-OC2H2OH, 5-Cl 92% 





 4.2.7  Conclusion 
 Using MAOS, it has been demonstrated that upon subjecting the reagents for the 
one-pot synthesis of imidazopyridine under microwave irradiation condition, a shorter 
reaction time, better and comparable yields is achieved. In conclusion, ammonium 
formate is the more efficient and economical alternative ammonium source. The 
ammonium formate is one of the most acidic ammonium salts (HCO2NH4 > NH4OAc > 
NH4Cl > (NH4)2C2O4 > (NH4)3PO4 >(NH4)2SO4 > NH4OH). The acidity of the 
ammonium formate allows for the acidic nature of the ammonium to attack the carbonyl 
group more readily.  
4.3  Reduction of Imidazopyridine 
 Along with IMP, tetrahydroimidazopyridine (THIP) is an importance moiety 
sharing structural similarities with imidazoles, benzimidazole, imidazo[1,2-a]pyridine 
and imidazo[4,5-c]pyridine. As previously mentioned, compounds that contain the 
imidazole moiety display important medicinal and biological properties; for instance, 
they have been used as anti-cancer, 172-174 anti-inflammatory,175 anti-hypertensive, 176 
anti-microbial, 177-178 and anti-bacterial agents. 179  
In comparison to traditional IMPs, THIP consists of a five-membered aromatic 
imidazole ring fused to a six membered piperidine ring (Figure 43). THIP consists of a 
variety of structural isomers such as, 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine 1 (rIMP), 




a]pyridine 3, which are  found to be the most commonly used (Figure 43). Barring a 
similar geometry, the structures are often pursued closely in biomedical research. 
 
Figure 43. Structure of IMP and THIP, and its isomers  
 
Bu et al. group initially investigated the role of 1,3-disubstituted- 5,6,7,8-
tetrahydro[1,5-a]pyridines (rIMPs), a specific class of THIP, against PCa cell180.  The 
motive for such inquiry was the success of IMPs role against CR PCa cells. Sharing 
direct similarity to IMPs with the addition of a saturated fused ring to the imidazole will 
allow us to verify and investigate the structural role IMPs and rIMPs have in being 
cytotoxic to PCa cells and more importantly CR PCa.    
 4.3.1  Reduction of IMP 
In 1972, THIP was first reported by Kametani et al. 175and they synthesized THIP 
derivatives from a mixture of pyridoxal and histamine. The most commonly used 
synthetic pathway for the synthesis of THIP is the catalytic hydrogenation of IMP. The 
methodology employs molecular hydrogen gas at high pressure in the presence of the 




rIMP, we employed the transfer hydrogenation process to Pd/C from hydrazine mono 
hydrate using procedures developed by Bu et al., which developed the technique to carry 
out the reduction of IMPs as seen in Scheme 45. The conditions utilized in the reduction 
will be investigated in the reduction of 1-substituted-3-phenyl IMPs. 
 
Scheme 45. Synthesis of rIMP using Pd/C and hydrazine. 
 
 4.3.2  Mechanism  
 
 
As mentioned, the catalytic hydrogenation of imidazopyridines is the most 
frequently used pathway to the synthesis of reduced imidazopyridines. Previously the 
synthesis novel rIMPs using hydrazine hydrate as a hydrogen source and Pd/C as catalyst 
Scheme 45 is used. In Figure 44, a plausible mechanism is proposed using the 





Figure 44. Proposed mechanism of reduction reaction using Pd/C and hydrazine. 
 4.3.3  Optimization of Reduced IMP 
 
Understanding, D’Cunha et al. optimization of the synthesis of rIMP using Pd/C 
and hydrazine hydrate, this thesis evaluates those conditions when synthesizing new 
rIMP. Initially, 1:1:1 (IMP: 10% Pd/C: hydrazine monohydrate (NH2NH2•H2O)) molar 
ratio at an optimized temperature of 90⁰ C is used, which concluded to no yield under 
those conditions. As shown in Table 18, 90⁰ C is the threshold in optimizing the 




Table 18. Optimization of Phenyl-rIMP by Changing Molar Amount of Hydrazine 
Hydrate and 10% Pd/C at 90⁰ C 
 
In optimizing the molar ratio for the reduction of 73, the change in hydrazine 
hydrate (NH2NH2) and 10% palladium on carbon (Pd/C) molar equivalence at a max 
reaction time of 96 hours was used in Table 18. The initial run using 1 molar eq. of Pd/C 
(Table 18, runs 1-5) went unreacted after being monitored for 96 hours via TLC.  Next, 
there’s an increase both Pd/C and NH2NH2 amount over the next runs, which lead to the 
increase in yield and decrease in reaction time. The best optimization condition for 




 4.3.4  Development of Novel Tetrahydroimidazopyridine  
Novel rIMPs were synthesized using the optimized conditions in the previous 
section. Using the optimized conditions afforded yields of various rIMP (99-114) at 78-
96% yield. The use of Pd/C as a catalyst for the reduction of IMP leads to unspecific 
transformation of other functional groups.  
For nitro substituted IMP, the reduction was specific to the nitro group and the 
double bond of fused pyridine, as none of the other substituents, hydroxy (100-102), alkyl 
(103-107) and ester groups (108 and 109) were affected (Table 19 and Table 20). There 

















The results were confirmed using NMR. The reduction of 73 resulted in the 
reduction of double bonds in the fused pyridine ring to give 99. Reduction of 
halogenated-IMPs, Br (83) and Cl (84) resulted in products (99) that were all like the 




the replacement of halogens by hydrogen. The results were confirmed by NMR. 
However, the reduction of fluorine-IMP (85) resulted in product 114 in which the 
fluorine was not hydrogenolyzed. The strong σ-bonding between the sp2 carbon and 
fluorine could possibly prevent the C-F bond from being hydrogenolyzed. Likewise, the 
reducing conditions did not affect the esters and amide functional groups (see Figure 45). 
 
Figure 45. NMR of 87 and 111, reduction reaction. 
 
 
The 1H NMR of the rIMP (111) was compared to the 1H NMR in deuterated 
DMSO of known nitro IMP 87. The protons on the fused pyridine ring in imidazo[1,5-
a]pyridine and its adjacent phenyl rings are in the distinct range δ = 6.60–8.80 ppm. 
Similarly, the protons that on the imidazole moiety and phenyl rings are the similar range, 




rIMP NMR. The protons appear in the aliphatic range of δ = 1.60–4.00 ppm as two 
distinct triplets and a multiplet for 111. The two protons of the primary amine (-NH2) 
appear as a singlet in the range δ = 5.50-6.00 ppm for compound 111.  
 4.3.5  Conclusion 
The hydrogenation of the imidazopyridine moiety was successful, allowing an 
efficient one pot synthesis using recyclable Pd/C/. We were able to test the reaction 
condition using various amount hydrazine hydrate and Pd/C. Recently, Bu et al., reported 
the synthesis of the reduced moiety using imidazo[1,5-a]pyridine. Using similar 
conditions, we decided to use phenylimidazo[1,5-a]pyridine to further investigate the 
reaction. We have shown that upon subjecting the comparable reagents for the one-pot 
synthesis of reduced phenylimidazo[1,5-a]pyridine, similar reaction time and yields was 
achieved. Furthermore, we were able to conclude that the optimized condition is 30 eq. 
hydrazine hydrate and 30 mol% Pd. The Furthermore, the halide groups (–Cl and –Br) 
underwent hydrogenolysis in the presence of reducing condition of the reaction. Fluorine 
based phenylimidazo[1,5-a]pyridine was immune to such conditions. As well, we have 
discovered that hydroxyl based compounds result in the highest yield that’s a result of the 
simple workup. Nitro- based compounds underwent double reduction, which includes the 









5.1  Biological Evaluation of Imidazopyridine Derivatives against PCa  
 PCa as mentioned in Chapter I is the second leading cancer cause of death in men 
in the United States.  Prostate cancer (PCa) is a complex multifaceted and biologically 
heterogeneous disease. PCa is identified as the second leading cause of cancer death in 
men. Statically, PCa is found more commonly in African-American men. Moreover, 
they are more likely to be diagnosed at an advanced stage and are nearly 2.5 times as 
likely to die from the disease compared with Caucasian men. Not only are African- 
American men more susceptible to prostate cancer based on statistics, but they are also 
developing the disease at a younger age.23 32 
The category of men presenting with either a high risk localized cancer or with 
metastatic disease is usually treated aggressively with any of the followings: 
prostatectomy, radiation therapy and/or androgen deprivation therapies (ADT), which 
has been expanded in recent years to include novel substantially more efficient drugs.32  
As patients are treated of localized PCa, there has become a serious problem, because 
of severe health risks involved in prostatectomy, overtreatment of small molecules and 




 ADT has been the mainstay of treatment towards patients with metastatic PCa. 
The idea of hormone therapy (also commonly referred to androgen deprivation 
therapy (ADT) or androgen suppression therapy) is to reduce levels of male hormones, 
namely androgens (AR), which stimulate prostate cancer cells to grow. Reducing 
androgen levels or stopping them from getting into prostate cancer cells often makes 
prostate cancers shrink or grow more slowly for a time.34-35 Although most of the 
prostate cancer patients respond well to ADT initially, outcome sometimes involves 
nearly inevitable progression to castration resistant disease (CRPC), metastases, and 
death.  Moreover, biochemical relapse occurs in about 30% of patients who have been  
treated aggressively.35 Castration-resistant (CR) PCa is lethal with about 18-month 
median survival time.182 Currently, chemotherapy is the standard-of-care treatment for 
CR PCa, but only provides a minimal improvement in survival rate.  Therefore, it is 
imperative to develop and identify novel therapeutic agents to improve the efficacy of 
CR PCa treatment.  
Recently, this study investigates IMP antiproliferative effect against a panel of 
PCa cancer cell lines including both AR-positive and AR-negative androgen 
independent (AI) PCa cells which exhibit diverse phenotypes of CR PCa. The results 
show that imidazopyridine derivatives inhibit CR PCa cell proliferation, decrease 
migration, and in-vitro tumorigenicity. The data, to the best of our knowledge, is the 
first report that clearly shows the potential of this family of compounds to serve as 





The most common known genomic alterations in PCa involve four 
pathways/genes: the androgen receptor pathway, phosphoinositide-3-kinase (PI3K) 
pathway, rearrangements that place members of the ETS transcription factor family 
under control of androgen responsive promoter TMPRSS2, and loss of function of the 
prostate tumor suppressor NKX3. Activation of phosphoinositide-3-kinase (PI3K) 
pathway, most often through Phosphatase and tensin homolog (PTEN) copy losses occur 
in 50% of PCa, and appears to be an early change, found already in prostate 
intraepithelial neoplasia (PIN).  
PTEN is a phosphatase that is well-known as a tumor suppressor down regulating 
the PI3K pathway activity. PTEN deletions and/or mutations are found in 30% of primary 
prostate cancers183 and 63% of metastatic prostate tissue samples,57 placing PTEN 
mutation among the most common genetic alterations reported in human prostate cancers.  
Monoallelic losses are more common in PIN and localized PCa, but bi-allelic PTEN 
losses are higher in CRPC. Moreover, homozygous loss of PTEN is causative in 
progression to aggressive metastatic phenotype and castration resistance.61  Aberrations 
of PI3K pathway contribute to the development of the castration-resistance in PCa. 
Castration-resistant growth is an intrinsic property of PTEN null prostate cancer cells, 
independent of cancer development stage. Deletion of AR in PTEN null epithelium 
promotes proliferation of PTEN null cells and then leads to the activation of Akt. 
Activated PI3K/ AKT pathway is sufficient to compensate for androgen/ AR-signaling 
blockade by inducing proliferation of basal/ progenitor cells and enhancing expression of 




evidence suggests that ADT benefits are reduced in PCa with PI3K activation and that 
combining ADT with PI3K pathway inhibition is significantly more efficient.184-185 
 In light of the promising antiproliferative property of imidazopyridines towards 
CR PCa treatment by targeting the PI3K/Akt pathway, in this chapter, we will explore the 
relationship between structure & antiproliferative property.  
 5.1.1  Cytotoxicity Study against Prostate Cell Lines  
 
 Prostate cells such as PC-3, DU-145, RWPE1, and LNCaP are used for the study, 
which is located in the Clark Atlanta University Center for Cancer Research and 
Therapeutic Development (CCRTD). The number of viable cells remaining after 
appropriate treatment will be determined by MTS assay. LNCaP C-81 will be cultured in 
regular medium and also in steroid-reduced condition, mimicking androgen-ablation 
therapy in clinics.  Typically, cells are seeded (4,000 cells/well in 100 μL of appropriate 
growth medium) in 96-well microtiter plates and incubated for 24 hours before treatment.  
 5.1.2  Anti-proliferation of Prostate Cell Lines 
The discussion in Chapter II of detailed materials and methods are mentioned, 
which is used in this section to help determine the viability or survival of PCa cell lines 
DU145, PC3, and LNCaP, along with normal prostate epithelial cells (RWPE-1).  DU145 
cellular lines were isolated in 1978 by Stone et al. from grade IV brain metastasis of 
prostate cancer in a 69-year-old Caucasian male.  PC3 cellular lines were isolated in 1979 
by Kaighn et al. from a grade IV Bone metastasis of prostate cancer from a 62-year-old 
Caucasian male.186  The cell lines have weak phosphatase and DHT activity, which it is 




DU145 have measurable levels of AR but show no response to stimulation. 187 The cell 
lines are representative of late stage androgen receptor mutant (DU145) and late stage 
androgen receptor null (PC3) PCa. Alternatively, LNCaP cells are originated from 
supraclavicular lymph node metastasis and are poorly aggressive Table 21 shows the 
physiological properties of the 3 metastasized PCa.  
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Using this array of prostate epithelial cells, we decided to investigate the 
antiproliferative capability of novel IMPs and rIMPs against PCa as their different 
functional groups may pose significant insight to the imidazopyridine antiproliferative 









  5.1.2.1 Imidazopyridine MTS Assay against PC3 
 PCa cell line, PC-3, was analyzed by an accurate in vitro method MTS 
assay in a time dependent manner of parent structures HIMP,HIMB, HrIMP, and HrIMB. 
Figure 47 demonstrates the MTS cell proliferation for PC3 at 4, 8, 12, 18, 24, 36, and 72 





























Figure 47. Time dependent response of imidazopyridine derivatives against PC-3. Cells 
were treated with (HrIMP), (HrIMB), (HIMP), and (HIMB) with 0.1 % DMSO as the 
delivery vehicle at 10 μM. Error bars indicate the standard deviation.    
 
We observed a decrease in cell survival for PC-3 cells after 24 hours of incubation 
with IMP derivatives. HrIMP and HIMP showed the most activity at a lower incubation 
time of 18 hours with cell survival values at 81.04 % and 87.89%, respectively.  After 36 
hours of incubation, all the tested compounds had cell survival values less than 79% with 
HrIMP having the lowest cell survival of 33.56 %. Seventy-two hours of incubation is the 
standard incubation for MTS and H-rIMP displayed the lowest amount of cell survival at 
11.32 %.  After monitoring the time dependent nature of PC-3 cells with the treatment of 
IMP derivatives, we tested the dose dependency of the molecules against PC-3 using 





Figure 48. Dose dependent response of IMP derivatives against PC-3. Cells were treated 
with (HrIMP), (HrIMB), (HIMP), and (HIMB) with 0.1 % DMSO as the delivery vehicle 
at 1, 10, and 100 μM with 72 hours of incubation. Error bars indicate the standard 
deviation. 
 
Similar to the time-based study, HrIMP and HIMP showed the most activity with 
cell survival being limited to fewer than 50% at 10 μM.  The other molecule HIMB and 
HrIMB required 10-fold increase in concentration to display any significant activity 
against the proliferation of PC-3 cellular lines.  
When comparing the structures between HIMP and HIMB (Figure 48), both are 
similar. However, the presence of a pyridine ring on C3 position for HIMP and phenyl 
ring on C3 is their difference, which could contribute to the difference in antiproliferation 
 



















properties amongst the molecules.  HIMP displaying the highest activity between the two 
molecules could be the contribution of the electron donor nature of the pyridine when it 
binds to its target protein. When comparing between HIMP and HrIMP (Figure 48), the 
saturated ring of HrIMP causes the lipophilicity of the molecule to increase, which may 
contribute to stronger binding in the hydrophobic binding site. The contribution of 
lipophilicity doesn’t affect the binding of the molecule to the binding site as much as the 
existence of a pyridine moiety when comparing HrIMB to HIMB. The activity of HrIMB 
is deficient (88% at 100 μM) as it doesn’t contain pyridine moiety.  
  5.1.2.2 Evaluation of Imidazopyridine Derivatives against PC-3, DU- 
  145, LNCaP and RWPE-1 
 To determine the antiproliferation activity of imidazopyridine derivatives, 
we used MTS assays at 72 hours of incubation for cellular lines PC-3, DU-145, LNCaP, 
and RWPE-1. The treatment of 10 μM of the 4 compounds  HIMP, HrIMP, HIMB, and 
HrIMB were used and shown (Figure 49) significant activity against highly aggressive 
molecules PC-3 and DU-145 and little to no activity against LNCaP and RWPE-1 
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Figure 49. Antiproliferation of Imidazopyridine derivatives against prostate cell lines. 
PC-3 and DU-145 cells are grown in 5% FBS supplemented MEM media. LNCaP cells 
are cultured in 5% FBS supplemented RPMI media. LNCaP C-81cells was prepared in 
steroid reduced media with 5% charcoal stripped FBS supplemented phenol red free 
RPMI media. RWPE-1 cells were prepared in 5% FBS supplemented KSFM media. 
Tested from quadruplicates and two experiments. Error bars are the standard deviation.  
 
For PC-3 cells, HIMP, HrIMP, HIMB, and HrIMB reduced cell proliferation on 
average 48%, 32%, 88% and 92%, respectively. As mentioned, HrIMP displays the 
highest toxicity to PC-3 cells.  In DU-145 cells, HIMP, HrIMP, HIMB, and HrIMB 
shows cell survival values averages of 45%, 52%, 68%, and 65%, respectively. The 




versus PC-3 cells with HIMP showing the highest activity. Less aggressive PCa, LNCaP, 
and LNCaP C-81 treated with imidazopyridine derivatives displayed even less 
antiproliferative activity with LNCaP C-81 showing the lesser activity amongst the two.  
HIMP showed the highest antiproliferative activity averages in both cellular lines 38% 
for LNCaP and 62% for LNCaP C-81. H-rIMP displayed the second largest 
antiproliferative properties averages of both cell lines at 64% for LNCaP and 85% for 
LNCaP C-81. The normal prostate epithelial cell line RWPE-1 shown little to no toxicity 
effects when using the imidazopyridine derivatives. HIMP, HrIMP, HIMB, and HrIMB 
displayed average cell survival values of 90%, 98%, 101% and 97%. Those values 
indicate none lethal effects of imidazopyridine derivatives at 10 μM treatments.   
  5.1.2.3 EC50 of Imidazopyridine Derivatives against PC-3 
  
 In Table 22, the researcher investigated many substituents attached to the 
4 para- position of the phenyl ring at position C1 of Phenyl-IMP. The addition, 
derivatives substantially increased the activity of the compound anti-proliferative 
property; 4-CH2(CH3)2 showed the lowest EC50 at ~1.96 μM, which could be the 
contribution of the aliphatic carbons that may play a role in the increased binding in the 
hydrophobic region of the target protein. The lowest active compound is the parent 
molecule phenyl-H-IMP at 88.54 μM. That molecule does not have any functional groups 
beyond the imidazopyridine moiety that may play a significant role the hydrophobic 
binding site. 3-NO2-4-OH showed moderate activity with hydrogen donating group and 





Table 22. Half Maximal Effective Concentration (EC50) of IMB Derivatives 
 
R-Group EC50  Imidazopyridine (µM) 
H 88.54 ± 5.29 
4-CH(CH3)2 1.963 ± 0.46 
4-OCH3 13.49 ± 6.29 
4-CH3 4.718 ± 1.95 
4-OH 5.221 ± 1.53 
4-F 12.33 ± 6.60 
4-NO2 5.46 ± 3.337 
3-NO2-4-OH 21.59 ± 4.12 
 
The hydrogen donating (hydroxyl-) group could be responsible for hydrogen 
bonding with essential amino acids within the target protein. Hydrogen bonding 
contributes to the strongest biochemical interaction that’s none covalent. The nitro group 
is identified as the electron withdrawing group, which pulls the electron density from the 
imidazopyridine group effecting Van der Waals interaction in the protein.  Halogens play 
an important role in pharmaceuticals, where in are compound we investigated fluorine 
bonded in the para- position which also displayed moderate EC50 of ~12.33 μM. When 




used as the delivery vehicle. Next, we investigated the same substituents on the other 
parent molecules IMP (Table 23), phenyl-rIMP (Table 24), and rIMP (Table 25). 
Table 23. Half Maximal Effective Concentration (EC50) of IMP Derivatives 
 
R-Group EC50  Imidazopyridine (µM) 
H ll.71 ± 2.01 
4-CH(CH3)2 4.07 ± 0.64 
4-OCH3 4.27 ± 0.97 
4-CH3 5.22 ± 0.97 
4-OH 11.17 ± 5.69 
4-F 1.367 ± 0.736 
4-NO2 37.23 ± 8.07 









Table 24. Half Maximal Effective Concentration (EC50) of rIMB Derivatives 
 
R-Group EC50  Imidazopyridine (µM) 
H 189.64 ± 2.76 
4-CH(CH3)2 41.69 ± 11.06 
4-OCH3 7.761 ± 3.654 
4-CH3 3.25 ± 1.46 
4-OH 76.04 ± 4.02 
4-F 15.30 ± 6.06 
4-NO2 1.129 ± 0.40 












Table 25. Half Maximal Effective Concentration (EC50) of rIMP Derivatives 
 
R-Group EC50  Imidazopyridine (µM) 
H 5.37 ± 1.02 
4-CH(CH3)2 37.77 ± 13 
4-OCH3 12.24 ± 5.82 
4-CH3 10.12 ± 1.51 
4-OH 19.28 ± 5.55 
4-F Poor Solubility 
4-NO2 7.11 ± 1.99 
3-NO2-4-OH 3.989 ± 1.40 
 
Derivatives of IMP, collectively, showed the highest EC50 for all the compounds 
which may be contributed to the presence of the pyridine group attached to the C3 
position.  Compared to Phenyl-IMP derivatives, IMP derivatives show a slightly different 
trend with halogen substituted derivative displaying the lowest EC50 at ~1.37 μM.  In 
addition, many of the derivatives displayed lowered EC50 with average values of 3-NO2-
4-OH at ~14.16 μM, H-IMP at ~11.71 μM, and 4-OCH3 at ~4.27 μM. The EC50 for the 




nitrophenyl-IMP which may indicate a decrease in Van der Waals interactions with an 
altered electron density around the imidazopyridine moiety. In treating, the cells with 
phenyl-rIMP, the results showed the highest EC50 amongst all the tested derivatives.  
4-NH2 showed the lowest EC50 at ~1.13 μM, which indicates that amine groups 
could play a major role in the antiproliferation of PC-3 cells.  Another amine containing 
derivative 3-NH2-4-OH displayed an extremely high EC50 at ~112.60 μM. The addition of 
the para- position of the hydroxyl and the meta- position of amine contributed to the high 
EC50 value. Similarly, the hydroxyl group in the para- position displays a high EC50 of 
~76.04 μM, which indicates the negative impact hydroxyl has at the para-position. The 
other derivatives phenyl-IMP, 4-CH(CH3)2 , 4-OCH3, 4-CH3, and  4-F follows the trend 
of phenyl-IMP derivatives, which are ~189.64 μM, ~41.69 μM, ~7.76 μM,  ~3.25 μM, 
and ~15.13 μM. The rIMP derivatives displayed the second lowest EC50 values 
collectively between all the tested derivatives.   
The molecule 3-NH2-4OH displayed the lowest EC50 at ~3.99 μM, which is the 
lowest value of all tested disubstituted derivatives. Moreover, rIMP showed a very low 
EC50 when compared to other parent molecules with the same substitution.  4-F wasn’t 
calculated in the MTS assay, because of its low aqueous solubility that attributed to the 
formation of crystals in 24 hours.  4-CH(CH3)2 , 4-OCH3, 4-CH3,  4-OH,  and 4-NH2 
showed moderate EC50 of ~37.77 μM, ~12.24 μM, ~10.12 μM,  ~19.28 μM, and ~7.11 





  5.1.2.4 Positional Relationship of Antiproliferative Property of   
  Imidazopyridine Derivatives  
 
 To further investigate the structural motifs that contribute to increased 
antiproliferative activity, we used the MTS assay to calculate the EC50 of IMP derivatives 
at different positions on the phenol group on carbon 1 (Table 26). The ortho-, para- and 
meta- positions were used to evaluate the potency of IMP derivative at those different 
positions.  




R-Group EC50  Imidazopyridine (µM) 
2-OH 56.33 ± 8.36 
3-OH 57.73 ± 6.19 
4-OH 11.17 ± 5.69 
 
The ortho-, meta-, and para- position displayed EC50 values of ~56.33 μM, 
~57.73 μM, and ~11.17 μM, respectively. The para- position displayed the lowest EC50, 
which may be a result of the compounds ability to have hydrogen bonding with 




moderately high EC50 values, which may result from the hydroxyl group ability to have 
an interaction with nitrogen group attached to the imidazopyridine moiety. Solubility 
issues of the molecules have also been proposed to prevent the molecules from 
interacting with cells within their aqueous solutions.  We developed compounds that 
contain a –OCH2CH2OH moiety that plays a role in slightly increasing aqueous 
solubility. In Table 27, the EC50 value of those newly developed glycol substituted IMPs 
at different positions on the phenyl ring attached at C1.   
Table 27. Half Maximal Effective Concentration (EC50) of Ethyl Alcohol Substituted 
IMP Derivatives 
 
R-Group EC50  Imidazopyridine (µM) 
2-OC2H20H 33.66 ± 7.50 
3-OC2H20H 28.29 ± 6.29 
4-OC2H20H 17.95 ± 5.06 
 
 
The ortho-, meta-, and para- position displayed EC50 values of ~33.66 μM, ~28.29 
μM, and ~17.95 μM, respectively. In comparisons to the hydroxyl- derivatives in Table 
26, the ortho- and meta- positions effectively decreased the EC50 values. The lowered 




interact with neighboring amino acids and not being limited to intermolecular 
interactions. Inversely, the para- position EC50 value increase slightly, which may be 
attributed to the increase in the size of molecule that negatively impacts the binding site.  
Overall, adding –(OCH2CH2)nOH units would increase the solubility of the molecules in 
aqueous media, but the size may prevent binding in the binding site based on the increase 
sized.  
 5.1.3  Conclusion 
 
 The antiproliferative study has shown that the novel imidazopyridine derivatives 
are potential therapeutic targets for prostate cancers. Initially, we demonstrated IMP 
derivatives ability to inhibit proliferation of PC3 in a dose dependent manner. 
Furthermore, we were able to show antiproliferative activity against PC3, DU145, 
LNCaP and LNCaP C-81 cellular lines.  Alternatively, our compounds showed minimal 
cytotoxicity effects against RWPE-1 cells, which are normal immortalized prostate cells. 
Amongst the four different IMP moieties, HIMP proved most toxic against all cellular 
lines, but HrIMP showed increased antiproliferative against PC3 when compared to the 
four compounds.  Using the IMP moieties, we changed the groups attached to the phenyl 
ring at carbon 1, and then we were able to identify the most toxic molecule to PC3 cells. 
4-NH2-phenyl-rIMP proved to be the most toxic molecule at 1.129 μM. Further studies 
indicated that substitution in the four position of the phenyl ring attached to carbon 1 is 




5.2  Protein Kinase Activity 
 Protein Kinases, PI3K α, β, γ, and δ, is used for this study, which was purchased 
from Millipore. The PI3Kinase Activity Assay is a competitive assay used for the fast 
and sensitive quantitation of activity of the four class I PI3 kinases (p110 α, β, γ, δ). The 
PI3 Kinase Activity/Inhibitor Assay works on the principle that PI3 Kinase 
phosphorylates PI(3,4)P2 (PIP2) converting it to PI(3,4,5)P3 (PIP3). The PH domain of the 
protein GRP-1 binds PIP3 with high affinity and specificity. The kit includes this 
recombinant protein that is used as the capture protein. This protein binds to the 
glutathione plate and captures either the PIP3 generated as part of the kinase reaction or 
the biotinylated-PIP3 tracer included in the kit. The captured biotinylated-PIP3 is detected 
using streptavidin-HRP conjugate and a colorimetric read out (OD 450).188 
 5.2.1  PI3 Kinase  
 
In Chapter 2 a discussion of detailed materials and methods are mentioned, which 
is used in this section to help determine the inhibition properties of IMP and rIMP against 
each of the four PI3K class I isoforms. PI3K is a family of lipid kinases that mediate 
many intracellular signaling responses in both physiological and pathophysiological 
states. The class I PI3 Kinases is made up of a p85 regulatory protein and a p110 catalytic 
domain. There are 4 isoforms of the class I p110 catalytic domains. Class I(A) includes 
the α, β, and δ isoforms and class I(B) includes the γ isoform. They are activated 
downstream via receptor tyrosine kinases or G-protein coupled receptors. Once activated, 
PI3K generates phosphatidylinositol 3,4,5-trisphosphate (PIP3) from PIP2.  PTEN, a lipid 




de-activating the effects of PI3K. Overpopulation of PIP3 leads to the activation of many 
key signaling regulators including Akt and PDK. So, the primary role of PI3K is to the 
regulation of cell growth and cell metabolism. 
  5.2.1.1 Determination of IMP Derivatives Inhibition Activity against  
  PI3K Isoforms  
 
 Inhibition of kinase activity was determined using PI3Kinase kit at various 
inhibitor concentrations, and the protein concentration held constant at 10μg/mL for PI3K 
α, 50 μg/mL for PI3K β, 20μg/mL for PI3K δ, and 50μg/mL for PI3K γ. Wortmannin is 
the negative control that acts as a pan inhibitor for all class I PI3K isoforms. B-PIP3 is a 
positive control, which indicates 100% of kinase activity. We decided to uses H-IMP and 
H-rIMP as our treatments as they contain the essential parent group that contributes to 
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Figure 50. PI3K kinase assay. Proteins were treated with HIMP (10 nM), HrIMP (100 
nM) and wortmannin (5 nM) for 30 minutes prior to the addition of PIP2.The experiment 
was run in triplicates at two experiments. Errors are the standard deviation. 
HIMP displayed comparable percent inhibition of PI3Kα activity to Wortmannin 




activity at ~86.16% inhibited activity. HrIMP showed the lowest inhibitory activity 
towards PI3Kα isoform at ~15.64 %. For PI3Kβ activity, wortmannin displayed a 54% 
inhibited activity, which was substantially increased with the treatment of both HIMP and 
HrIMP at ~85.84% and 72.38%, respectively. PI3Kδ activity was inhibited by 
wortmannin at ~75.29%, which compared to the inhibitory activity of both HIMP and 
HrIMP at ~83.02% and ~68.07%, respectively. Finally, PI3Kγ activity was significantly 
uninhibited by HIMP and HrIMP at ~43.56% and ~46.98%, respectively. Wortmannin 
displayed a high inhibitory activity toward PI3Kδ activity at ~84.48%. In comparison, the 
tested compounds showed the ability to preferably inhibit the activity of PI3Kα, β, and δ 
isoform for HIMP at 10 nM and PI3Kβ and δ for HrIMP.  
  5.2.1.2 Titration of IMP Derivatives Inhibition Activity against PI3K  
  Isoforms  
 Using the PI3K kinase kit supplied by Millipore, we did a titration to 
determine the IC50 of IMP towards the activity of each PI3K isoform (Figure 51). The 
concentrations at .1 nM, 1 nM, 10 nM, 100nM, and 1000 nM was used to obtain a 





Figure 51. Titration of PI3K Kinase activity. (A) Display of an overlay of all kinase 
activity titration curves. (B) PI3Kα titration curve with calculated IC50 of 2.54 nM ± 1.30. 
Error bars are the standard deviation. (C) PI3Kβ titration curve with uncalculated IC50. 
Errors bars are the standard deviation. (D) PI3Kδ titration curve with calculated IC50 of 
0.51 nM ± 0.61. Errors bars are the standard deviation. (E) PI3Kγ titration curve with 








Based on the titration curve, HIMP shows more selectivity to PI3Kδ versus 
PI3Kα, which were the only curves that allowed the calculation of IC50. PI3Kβ titration 
curve demonstrated a high inhibition activity percent all the way the titration curve limit 
of 0.1 nM, which indicate that PI3Kβ inhibitions will occur at a lower concentration of 
inhibitor. PI3Kγ showed little to no inhibitory activity where the curve didn’t display any 
response to the increase in inhibitor concentration. The inhibitor shows excellent 
selectivity toward PI3Kβ, which the mutation of that isoform is implicated in many 
prostate cancers mutation. 
 5.2.2  Conclusion 
 
 The in vitro assays involves both cellular and biochemical analysis that 
demonstrates the novel imidazopyridine ability to kill castration resistant or even 
aggressive stages of prostate cancer. The MTS assay showed the variety of derivatives 
that enhance antiproliferative properties of newly developed molecules. From the results, 
amine, hydrogen bonding, and the imidazo moiety are essential elements that make 
therapeutic drugs for prostate cancer. The protein kinase assay provides an insight into 
the mechanism in which imidazopyridine molecules prevent the proliferation of 
cancerous prostate cancer cells.  
5.3  High-Throughput Screening (HTS) of Imidazopyridine Derivatives    
  
High-throughput Screening (HTS) is used determine the essential functional group 
that binds to essential amino acids within the ATP binding site of PI3K isoforms. 




based on the interactions with the binding site. The PI3K isoforms were retrieved from 
the RSCB protein data bank, which PI3K α (4ZOP), β (4BFR), γ (4URK), and δ (4V0I) 
files were used. All proteins were prepared according to procedures in Chapter 2.  Using 
the compounds that we thoroughly subjected to in vitro analysis, we will be able to 
compare the EC50 to calculated binding energy to confirm the methodology of molecular 
docking using our compounds. Additionally, molecular docking will depict the locations 
and interaction of our small molecule to the PI3K isoforms.   
 5.3.1  3D Structural Depiction PI3 Kinase 
 
As mentioned in Chapter 3, the PI3K isoforms were prepared using LigX protein 
preparation of the MOE software.  The software prepares the proteins by assigning bond 
orders, formal charges, and the addition of hydrogens.  Following the addition of 
hydrogens, the software optimizes the hydrogen bonding network, which includes a 
reorientation of thiols and hydroxyl groups, prediction of protonation states, and 
minimization of protein using Amber 10 calculations.   
  5.3.1.1 Superimposition of PI3K Isoform 
 To investigate the 3-dimensional differences of the PI3K isoforms, the 
researcher superimposed the structures using MOE software. From the superimposed 
images it can be determined that the structure is pretty conserved on a 3-dimensional 
level. PI3Kα (green) was crystallized with additional nSH2/ iSH2 domain in which the 
iSH2 was removed using PyMol software. Indicated by the view in (A) it’s evident that 
pieces of the nSH2 domain remain intact. The nSH2/iSH2 is associated with the p85α 




binds the receptor tyrosine kinase (RTK) of the cellular membrane. That domain has an 
activated and inactivated state, which the inactivated form is shown in Figure 52A with 
the nSH2 domain is attached to the helical domain of the catalytic subunit (p110α).   
 
Figure 52. Superimposed images of PI3K isoforms. Green is the PI3Kα isoform. Red is 
the PI3Kβ isoform. Purple is the PI3Kδ isoform. Blue is the PI3Kγ isoform. (A) The view 
is of the binding site and piece of the iSH2 binding domain in green. (B) Top view of the 
isoforms showing binding site. (C) Back view of isoforms. (D) 180 degree turns view of 
























The activated form is attached to RTKs as described above. The responsibility of 
the iSH2 is serving as a linker between nSH2/cSH2 domains.  The other PI3K isoforms 
only show their respective catalytic subunit (p110α, β, δ, and p120γ). The binding site 
(Figure 53) shows a more distinct difference in the shape of the region with addition or 
subtraction of amino acids that affect binding of inhibitors.  
 
Figure 53. Surface depiction of binding site for PI3K isoforms. Surface map of ATP-
competitive binding Site of the catalytic domain. (A) PI3Kα, binding site (yellow). (B) 
PI3Kβ, binding site (blue) (C) PI3Kδ, binding site (red) (D) PI3Kγ, binding site (green).  
 
The binding pocket for PI3Kα consists of GLN859, VAL851, TYR836, ILE848, 
ILE932, and SER854 residues. ILE932, ILE848, TYR836 forms the hydrophobic, that’s 
identified as the hinge region. The other residues form hydrogen bonding that further 






TRP781, MET773, ASP807, TRY833, VAL848, and LYS771residues. VAL848 residue 
plays an important role in the ATP binding pocket for PI3Kβ as it’s located in the hinge 
region. TRY781 and LYS771 are major residues in the hydrophobic region.  Similar to 
PI3K isoforms the other resides influences hydrogen bonding. PI3Kδ is extremely 
conservative of the PI3Kβ isoform with similar acting residues in each of the binding site 
regions. The hydrophobic region of PI3Kδ consists of TYR813, ILE910, and ILE777 
residues.  PI3Kγ has a large hydrophobic pocket that contains residues ILE879, ILE963, 
ILE831, and MET804. The major interaction for PI3Kγ is from VAL882 backbone in the 
hinge region.  
 5.3.2  Visualization Novel Imidazopyridine to PI3K isoforms 
As mentioned in Chapter III, the PI3K isoforms were prepared using LigX protein 
preparation of the MOE software.  The novel imidazopyridines were prepared using 3D 
ChemDraw 12.0 with MMFF94x minimization calculations. Docking and scoring were 
completed using Gold software and PyRX using Autodock Vina163. Imaging of the 
docked ligands was handled by MOE software. To investigate the interaction of novel 
IMP to PI3K isoforms, we used co-crystallized structures PBD: 3ZIM, 4BFR, 4URK, and 
4V0I. HIMP, HIMB, HrIMP, and HrIMB are used to compare different interaction the 
parent IMP moieties have in the binding site of the PI3Kα binding site. 
  5.3.2.1 IMP Derivatives Docked to PI3Kα  
 
 Using PDB: 3ZIM, we initially analyzed the H-IMP interaction with 




HIMP has a binding affinity for PI3Kα with a calculated value of -7.86 kcal/mol using 
GOLD docking and -8.80 kcal/mol using Autodock Vina (see Figure 54). 
 
Figure 54. Docked H-IMP to PI3Kα. (Left) The 3D depiction of H-IMP docked to 
PI3Kα. Yellow is the molecule. Blue represents Nitrogen. Red represents Oxygen. Green 
is the binding site. (Right) The 2D depiction of H-IMP docked to PI3Kα. The legend 
under diagram depicts molecular interactions. 
 
Moreover, the molecular modeling studies indicated that imidazopyridine moiety 
of H-IMP interacted with TYR836 of the hydrophobic region of the protein (Figure 54).  
Further, analysis of the model, the benzyl ring and pyridine are exposed to the opening of 
the binding site. The opening of the binding site is composed of the polar region, which 




compound (H-rIMP) binding in the PI3Kα binding site. In Figure 55, H-rIMP shows 
bonding with essential MET922, SER774, and TYR836.   
 
 
Figure 55. Docked H-rIMP in PI3Kα. (Left) The 3D depiction of H-rIMP docked to 
PI3Kα. Yellow is the molecule. Blue represents Nitrogen. Red represents Oxygen. Green 
is the binding site. (Right) The 2D depiction of H-rIMP docked to PI3Kα. The legend 
under diagram depicts molecular interactions. 
 
H-rIMP does effectively bind deep in the hydrophobic pocket displaying a 
calculated binding energy of -8.32 kcal/mol using GOLD and – 8.9 kcal/mol using 
Autodock Vina. Visualized by the model, the reduced imidazopyridine moiety interacts 
with the side chain of residue MET922. Consistently, the compound shows hydrogen-π 
interaction with both phenyl and pyridine ring.  The pyridine and reduced ring constitute 




H-IMP displays hydrogen-π interaction with residue MET922 and TRP780 at the 
imidazopyridine moiety of the molecule. The MET992 residue is associated with P-loop 
region of ATP-binding site. The binding energy is -8.23 kcal/mol using GOLD docking 
and -8.6 kcal/mol using Autodock Vina (see Figure 56).   
 
Figure 56. Docked H-IMB in PI3Kα. (Left) The 3D depiction of H-IMB docked to 
PI3Kα. Yellow is the molecule. Blue represents Nitrogen. Red represents Oxygen. Green 
is the binding site. (Right) The 2D depiction of H-rIMP docked to PI3Kα. The legend 
under diagram depicts molecular interactions. 
 
The molecule is also placed within the hydrophobic region with the 
imidazopyridine and phenyl moieties are the leading into that region. Similarly, H-rIMB 
interacts with the same residue as its unreduced form phenyl-H-IMP, MET922. The 
compound also interacts with residues TYR836 and SER 774, which is similar to H-IMP. 




kcal/mol and -8.8 kcal/mol, respectively.  As shown in the next figure, H-rIMB is 
oriented in the binding pocket similar to H-rIMP with the phenyl ring located at the 3 
position and reduced moiety exposed outside of the protein (see Figure 57). 
 
Figure 57. Docked H-rIMB in PI3Kα. (Left) The 3D depiction of H-rIMB docked to 
PI3Kα. Yellow is the molecule. Blue represents Nitrogen. Red represents Oxygen. Green 
is the binding site. (Right) The 2D depiction of H-rIMP docked to PI3Kα. The legend 
under diagram depicts molecular interactions. 
5.3.2.2 IMP Derivatives Docked to PI3Kβ  
 
Using PDB: 4BFR, we visually analyzed imidazopyridine derivatives interaction 
with key amino acids in the ATP binding site of PI3Kβ. H-IMP is observed in Figure 58 
with binding energies at -8.0 kcal/mol and -7.31 kcal/mol using both Autodock Vina and 
GOLD, respectively. Shown, H-IMP displays several interactions with residues within 





Figure 58. Docked H-IMP to PI3Kβ. (Left) The 3D depiction of H-IMP docked to 
PI3Kβ. Light Blue is the molecule. Blue represents Nitrogen. Red represents Oxygen. 
Red is the binding site with labels of essential residues. (Right) The 2D depiction of H-
IMP docked to PI3Kβ. The legend under diagram depicts molecular interactions. 
 
Located in the hinge region of the ATP binding pocket, H-IMP interacts with 
specifically TRP781 and MET773 residues in that region. The residues show hydrogen 
bonding with the imidazopyridine region of the compound, which is the strongest 
interaction that locates the molecules in the binding site.  Other interaction includes 
cationic-π interaction with LYS771 and LYS799. LYS771 is located at the opening of the 
binding site that prevents other molecules from locating in the binding site.  H-IMP is the 
only tested molecule that displays those interactions. Next, we investigated H-rIMP 
interaction with the PI3Kβ binding site, which is shown in the finger. The compound had 
binding energies of -7.6 and -6.22 kcal/mol using Autodock Vina and GOLD software, 





Figure 59. Docked H-rIMP to PI3Kβ. (Left) 3D depiction of H-rIMP docked to PI3Kβ. 
Light Blue is the molecule. Blue represents Nitrogen. Red represents Oxygen. Red is the 
binding site with labels of essential residues. (Right) 2D depiction of H-rIMP docked to 
PI3Kβ. Legend under diagram depicts molecular interactions. 
 
The compound is turned 180⁰ degrees in the binding in relationship to H-IMP. 
The imidazopyridine moiety is now located at the front of the binding site faced away 
from the hinge region. Located in the hydrophobic region, the phenyl group located on 
carbon 1 of the imidazopyridine moiety displays little interaction with residues in that 
region. The imidazopyridine moiety is located at the opening of the protein and 
specifically interacts with LYS799 showing cationic-π interaction with imidazole moiety 
of the fused rings. Located closely to the hinge region of the binding site, the pyridine of 




displaying hydrogen –π bonding. Oriented in the binding pocket similarly as H-rIMP, 
phenyl-H-IMP is shown in Figure 60 with binding energies of -8.2 and -6.71 kcal/mol 
using Autodock Vina and GOLD software, respectively.  
 
Figure 60. Docked H-IMB to PI3Kβ. (Left) The 3D depiction of H-IMB docked to 
PI3Kβ. Light Blue is the molecule. Blue represents Nitrogen. Red represents Oxygen. 
Red is the binding site with labels of essential residues. (Right) The 2D depiction of H-
IMB docked to PI3Kβ. The legend under diagram depicts molecular interactions. 
 
  Phenyl-H-IMP, shown in Figure 601, is the imidazopyridine moiety of the 
compound displays cationic-π interaction with LYS799, which is similar to H-IMP, but 
alternatively, indicates that both the pyridine and imidazole groups of the fused 
imidazopyridine moiety have that interaction. Located in the hydrophobic region of the 





Figure 61. Docked H-rIMB to PI3Kβ. (Left) The 3D depiction of H-rIMB docked to 
PI3Kβ. Light Blue is the molecule. Blue represents Nitrogen. Red represents Oxygen. 
Red is the binding site with labels of essential residues. (Right) The 2D depiction of H-
rIMB docked to PI3Kβ. Legend under diagram depicts molecular interactions. 
 
 By the same token, the phenyl group located on carbon 3 shows hydrogen-π 
bonding with residue MET773, similar to the pyridine group on H-rIMP.  Displaying the 
same orientation in the binding site as H-rIMP, H-rIMB resulted in calculated energies -
8.2 and -7.02 kcal/mol using Autodock Vina and GOLD software, respectively.  
As displayed in Figure 61, the compound shows binding interaction with residues 
MET773 and LYS799. Similar to H-rIMP, the imidazole group of the fused reduced 
imidazopyridine moiety interacts with LYS799; also the phenyl group located on carbon 




  5.3.2.3 IMP Derivatives Docked to PI3Kδ  
  
 Using PDB: 4V0I, we visually analyzed imidazopyridine derivatives 
interaction with the essential amino acids in the ATP binding site of PI3Kδ. H-IMP is 
observed in the figure with calculated binding energies of -6.8 and -7.28 kcal/mol using 
Autodock Vina and GOLD software, respectively.  
 In Figure 62, 2D depiction shows H-IMP interacting with one residue, 
ASP911. The interaction is shown as a hydrogen-π interaction. In the 3D depiction of H-
IMP and PI3Kδ, an additional interaction is shown via dotted lines with MET752 and 
LYS779 residues interacting with the imidazopyridine moiety. The imidazopyridine 
moiety has hydrogen and cationic-π bonding with the residues with LY779 displaying the 
latter interaction.  The compound imidazopyridine region is faced towards the P-loop of 
the ATP-binding site with TRP760 the key residue located on the loop. The compound is 
situated within the hydrophobic region of the binding site with the pyridine group on 
carbon 3 leading into that region. Next, the researcher visualized H-rIMP within the 
binding site of PI3Kδ. The molecule has shown calculated binding energies of -7.7 and -






Figure 62. Docked H-IMP to PI3Kδ. (Left) 3D depiction of H-IMP docked to PI3Kδ. 
Red is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow represents 
Sulfur. Blue is the binding site with labels of essential residues. (Right) 2D depiction of 
H-IMP docked to PI3Kδ. Legend under diagram depicts molecular interactions. 
 
Oriented in the binding pocket, similar to H-IMP, H-rIMP has interaction with 
one residue ASP911, shown in Figure 63 2D depiction. The 3D depiction shows an 
additional interaction with TYR833. The residue and compound displays a hydrogen-π 
interaction with imidazole group of the reduced fused imidazopyridine moiety. Similarly, 
the reduced imidazopyridine moiety is faced towards the P-loop residue, TRP760. 
Maintaining similar orientation to H-IMP and H-rIMP, phenyl-H-IMP shown in Figure 
64 has calculated binding energies of -7.3 and -7.89 kcal/mol using Autodock Vina and 





Figure 63. Docked H-rIMP to PI3Kδ. (Left) 3D depiction of H-rIMP docked to PI3Kδ. 
Red is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow represents 
Sulfur. Blue is the binding site with labels of essential residues. (Right) 2D depiction of 





Figure 64. Docked H-IMB to PI3Kδ. (Left) 3D depiction of H-IMB docked to PI3Kδ. 
Red is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow represents 
Sulfur. Blue is the binding site with labels of essential residues. (Right) 2D depiction of 
H-IMB docked to PI3Kδ. Legend under diagram depicts molecular interactions. 
 
The compound displays interaction with residues LYS779 and ASP 911, which 
was also depicted in the 3D image of H-IMP. The LYS779 shows cationic-π interactions 
with the imidazopyridine moiety. The ASP911 shows a hydrogen-π interaction with the 
phenyl group located on carbon 1 of the imidazopyridine moiety. Lastly, we visually 
investigate H-rIMB interaction with PI3Kδ. In Figure 65, the compound displayed 
calculated binding energies of -7.4 and -8.33 kcal/mol using Autodock Vina and GOLD 





Figure 65. Docked phenyl-H-rIMP to PI3Kδ. (Left) 3D depiction of phenyl-H-rIMP 
docked to PI3Kδ. Red is the molecule. Blue represents Nitrogen. Red represents Oxygen. 
Yellow represents Sulfur. Blue is the binding site with labels of essential residues. 
(Right) 2D depiction of phenyl-H-rIMP docked to PI3Kδ. Legend under diagram depicts 
molecular interactions. 
 
  5.3.2.4  IMP Derivatives Docked to PI3Kγ  
 
 The molecule is also oriented within the binding pocket as H-IMP, H-
rIMP, and H-IMB with the reduced imidazopyridine moiety facing the P-loop residue, 
TRP760. Residue ASP911 is the only interaction shown in the 2D depiction of the 




TYR813. The two interactions are hydrogen-π and hydrogen bonding with residue 
ASP911 and TYR813, respectively.  
Using PDB: 4URK, we visually analyzed imidazopyridine derivatives interaction 
with key amino acids in the ATP binding site of PI3Kγ. H-IMP is observed in Figure 66 
with calculated binding energies of -8.5 and -7.32 kcal/mol using Autodock Vina and 
GOLD software, respectively.  The P-loop of the PI3Kγ binding site plays vital role in 
the inactivation of PI3K activity. Indicated in Figure 65 2D depiction, H-IMP interacts 
solely with TRP812 residue, which is a residue associated with the P-loop. The residue 
shares hydrogen-π bonding with the imidazopyridine moiety of the molecule.  
 
Figure 66. Docked H-IMP to PI3Kγ. (Left) 3D depiction of H-IMP docked to PI3Kγ. 
Green is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow 
represents Sulfur. Purple is the binding site with labels of essential residues. (Right) 2D 





The 3D depiction of H-IMP docked to PI3Kγ shows an additional interaction 
phenyl group attached to carbon 1 and the residue LYS890, which is located at the 
opening of the protein. The residue and molecule interacts by sharing cationic-π bonding.  
Next, we visualized the interaction of H-rIMP within the binding site of PI3Kγ, in Figure 
67. The calculated binding energies are -8.4 and -7.56 kcal/mol using Autodock Vina and 
GOLD software, respectively.  According to the 2D depiction, H-rIMP shows only an 
interaction with MET804 residue. The interaction involves the MET804 and the pyridine 
ring group located on carbon 3 of H-rIMP. The two molecules interact by sharing a 
hydrogen-π bonding. The MET804 residue is located within the hinge region of the ATP 





Figure 67. Docked H-rIMP to PI3Kγ. (Left) 3D depiction of H-rIMP docked to PI3Kγ. 
Green is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow 
represents Sulfur. Purple is the binding site with labels of essential residues. (Right) 2D 
depiction of H-rIMP docked to PI3Kγ. Legend under diagram depicts molecular 
interactions. 
 
The 3D depiction shows one more interaction involving H-rIMP and the residue 
MET804. The molecule is located near the opening of the PI3Kγ binding site. Displaying 
more interactions with residues located in the binding site of PI3Kγ, phenyl-H-IMP 
shows calculated binding energies of -8.9 and -6.95 kcal/mol using Autodock Vina and 
GOLD software, respectively. Phenyl-H-IMP interacts with residues MET804 and 
MET953. The 2D depiction shows MET953 residue acting as a hydrogen bond acceptor, 




MET804 displays a hydrogen-π interaction with the phenyl ring group located on carbon 
3 (see Figure 68).  
 
Figure 68. Docked H-IMB to PI3Kγ. (Left) 3D depiction of H-IMB docked to PI3Kγ. 
Green is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow 
represents Sulfur. Purple is the binding site with labels of essential residues. (Right) 2D 
depiction of H-IMB docked to PI3Kγ. Legend under diagram depicts molecular 
interactions. 
 
The 3D depiction, in Figure 68 shows an additional interaction with closely 
associated residue, TRP812. Associated with the P-loop of the ATP binding site of 
PI3Kγ, TRP812 interaction prevents movement of the P-loop region, which acts as the 
gate of the binding site. The TRP812 residue interacts with the imidazopyridine moiety of 




binding site, which displayed calculated binding energies of -8.7 and -7.39 kcal/mol 
using Autodock Vina and GOLD software, respectively.  In Figure 69, H-rIMB interacts 
with residues TRP812 and MET804.  
 
Figure 69. Docked H-rIMB to PI3Kγ. (Left) 3D depiction of H-rIMB docked to PI3Kγ. 
Green is the molecule. Blue represents Nitrogen. Red represents Oxygen. Yellow 
represents Sulfur. Purple is the binding site with labels of essential residues. (Right) 2D 
depiction of H-rIMB docked to PI3Kγ. Legend under diagram depicts molecular 
interactions. 
 
The two residues display hydrogen-π bonding. TRP812 residue shows hydrogen-π 
bonding with the imidazole group that’s located on the fused reduced imidazopyridine 
moiety. MET804 residue shows hydrogen-π bonding with the phenyl ring group located 




 5.3.3  Quantitative Structure-Activity Relationship 
 Using data obtain from the molecular docking software MOE; we investigated 
those binding energies, EC50 towards PC3 cell lines, and the calculated LogP and LogS 
values (Table 28).  The information is used to further compare structural motifs and 
biological activity.  
Table 28. Quantitative Structure Activity Relationship 


























































Table 28 Continued 















































4-OH-rIMP 3.92 -4.05 89.125094 19.28 
(-6.72 PI3Kα) 
(-6.21 PI3Kβ)  
(-6.04 PI3Kδ) 
































The LogP value describes the lipophilicity of the molecules, where the ratio 
consists of octanol and water. The lipophilicity of a molecule determines the molecule 
ability to permeate through the cell membrane. The results indicate that phenyl-H-rIMP is 
the most lipophilic molecule, but displays the lowest biological activity at EC50 of 189.64 
μM.  According to our observation, the ideal LogP value lies between the values 3.48 and 
4.42, in Table 28.The lowest LogP value of 3.4 from 4-glycol-IMP shows biological 
cytotoxicity of 17.95 μM. The results showed that the addition of the reduced 
imidazopyridine on our molecules structure increased the LogP value effectively. The 
pyridine group at carbon 3 versus phenyl group at carbon 3 decreased the LogP value. 
Other groups, such as the addition of a glycol unit (-OCH2CH2OH) or hydroxyl (OH) 
group decreases the LogP value making the molecules less lipophilic.  
The opposite trend of LogP, LogS is a calculated measurement of the aqueous 
solubility. The aqueous solubility determines the maximum concentration of the molecule 
that will be soluble in an aqueous solution. The LogS value affects biological assays 
because the majority of the compounds require genotoxic DMSO as the solvent to treat 
cultured cells. The highest calculated LogS value in Table 28 was -4.05 for the IMP 
derivatives, which was from 4-OH-rIMP. The biological activity of the compound was 
19.28 μM EC50 against PC3 cells. The lowest calculated Log S was -6.02, which was 
from phenyl-H-IMP. The biological activity of the compound was 88.54 μM against PC3 
cells. The high Log S value shows that at the same concentration for a compound with a 
low Log S will precipitate out in an aqueous media before being adsorbed through the 




binding energies in Table 28 to develop an isoform specific molecule. According to 
Figure 50, H-IMP shows similar pan-PI3K activity as Wortmannin, this was treated as 
our control in the protein kinase assay. The calculated binding energies for Wortmannin 
are -7.89 PI3Kα, -5.90 PI3Kβ, -6.68 PI3Kδ and -6.41 PI3Kγ kcal/mol. In comparison, the 
binding energies for H-IMP are -7.27 PI3Kα, -6.17 PI3Kβ, -6.40 PI3Kδ, and -6.33 PI3Kγ 
kcal/mol. The binding energy values in Table 28 describes the trend shown in Figure 50, 
where Wortmannin shows the ability to inhibit the kinase activity of PI3Kα and PI3Kγ 
higher than H-IMP. Also, the binding energy shows were the H-IMP displays higher 
inhibitory kinase activity than Wortmannin for PI3Kβ and δ. The data describes how we 
can use QSAR measurements to developPI3K isoform specific molecules for castration 
resistant prostate cancer and other ailments. 
 5.3.4  Conclusion 
The 3D visualization of the molecules helps validate key residues and shape 
molecules play in the cytotoxicity of androgen independent cancer cells. In PI3Kα, the 
key residues that interact with the imidazopyridine derivatives are MET922, TRY836, 
SER774, and TRP780. TRP780 contain an indole moiety that interacts directly with 
imidazopyridine moiety of all isoforms. The other residues interact directly with phenyl 
or pyridine group attached to carbon 1 and 3. PI3Kβ residues that interact with 
imidazopyridine derivatives are MET773, TRP78, and LYS799. Those residues show 
evidence to interact directly with the imidazopyridine moiety. In PI3Kδ, key residues that 
interact with imidazopyridine derivatives are ASP911, TYR833, LYS779, and TYR813. 




1 and 3. The other residues specifically interact with imidazopyridine moiety of the 
derivatives. PI3Kγ residues that interact with imidazopyridine derivatives are TRP812, 
MET804, and MET953. MET953 and TRP812 interact solely with imidazopyridine 
moiety of the molecules. Indicated in the study, TRP, LYS, and MET residues play an 
important role in imidazopyridine binding in the ATP-binding site. Mutation of the 
isoforms residues will cause the imidazopyridine derivatives to lose their key 
interactions. The QSAR shows how to develop molecules that display the proper physio-








 The microwave synthesis of phenylimidazo[1,5-a]pyridine (IMB) was successful 
at decreasing the reaction time and yield, by also lowering the amount reagents needed 
produce the derivatives. The one step procedure provided the precursor for the 
development of novel phenyltetrahydroimidazo[1,5-a]pyridine (rIMB) through the 
transfer hydrogenation of phenylimidazo[1,5-a]pyridine (IMB). The two-step procedure 
for the synthesis of IMB and rIMB is an extremely viable and efficient method. The first-
step of the procedure developed IMB through microwave irradiation. The reaction 
between 2-benzoylpyridine, substituted benzaldehyde, and ammonium formate in acetic 
acid in an open vessel in the microwave under air was a viable methodology for the 
synthesis of IMBs. The use of reaction conditions of 1:1.5:4 ratio of 2-benzoylpyrdine, 
substituted benzaldehyde and ammonium formate resulted in an excellent yield of IMB.  
 The transfer hydrogenation of IMB using recyclable and inexpensive Pd/C 
catalyst, hydrazine hydrate in ethanol under N2 was shown to be viable and efficient. The 
need of an expensive catalyst, pressurized controlled gas and its elaborate equipment 





 The optimized reaction condition for the synthesis of rIMB revealed was 1:15 
mol%:15 eq ratio of phenyl-IMP, Pd/C and hydrazine hydrate that leads to high yields. In 
addition, an optimal temperature of 90⁰C was established. The presence of hydroxyl, 
alkyl and methoxy groups was unaffected by these reaction conditions. Hydrogenolysis 
was observed for halogenated bromine- and chlorine-IMP to give non-functionalized 
rIMB. The halogenated fluorine moiety was not affected by the reaction condition and 
resulted in fluorine phenyl-rIMP 
 The Williamson etherification of benzaldehyde and IMP was investigated by 
using 2-chloroethanol in DMSO. The reaction involved K2CO3 as a base, KI as a catalyst, 
and benzyltriethylammonium chloride as a phase transfer catalyst, which resulted in 
positive results. The methodology was used for both benzaldehyde and IMP. The IMP 
served as the most efficient method. Following, the recovery from DMSO produced a 
high 95% isolated yield.  
 The biological assays, such MTS and protein kinase assay showed the structural 
motifs of imidazopyridines are more potent inhibiting the proliferation of LNCaP, 
LNCaP C-81, PC3, and DU145 cellular lines.  The results indicate that IMP is more 
potent in all prostate cancer cell lines tested besides PC3, whereas rIMP is more potent in 
LNCaP.  It has been determined that isopropyl-containing IMP or phenyl-IMP is the most 
cytotoxic molecule against the PC3 cellular line. After adding the isopropyl-group to 
rIMP and phenyl-rIMP, the cytotoxicity decreased against PC3 cells.  The protein kinase 




inhibited the activity in PI3Kβ at a higher percentage. H-rIMP was effective in inhibiting 
the activity of only β and δ isoforms of PI3K. 
The 3D visualization and QSAR studies have shown how molecular modeling can 
be used to evaluate derivatives before testing its biological activity. The results showed 
positive correlations between LogP and LogS versus its experimental EC50 calculations. 
Also, the binding energies showed how the change of functional groups affects binding 
and isoform selectivity. 
In the future, it will be important to evaluate imidazopyridine derivatives against 
other protein kinases as they play the vital role many cellular pathways.  Also, we plan to 
subject our derivatives in in vivo studies to determine their efficacy in a whole biological 
organism. Finally, we are currently developing drug delivery vehicle for the 
imidazopyridine derivatives as many have solubility issues in aqueous media. Many types 






General Aspects and Characterization Data of Compounds 
All the chemicals, proteins, and cells were used as received. Ten percent of 
palladium on activated carbon from Aldrich was used as the catalyst. Melting points were 
obtained in open capillary tubes with Barnstead Electrothermal Mel-Temp 1201D 
melting point apparatus and are uncorrected. 1H NMR (500 and 400 MHz), and 13C NMR 
(126 and 101 MHz) spectra were recorded with TMS as an internal standard on Bruker 
Ultrashield 500 and 400 plus, respectively. Deuterated solvents DMSO-d6 and CDCl3 
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